Document:

Exhibit 10.1

 

Execution Version

 

EXCHANGE AGREEMENT 

 

This EXCHANGE AGREEMENT
(including the schedules, annexes and exhibits hereto, this “Agreement”), dated as of June 24, 2020, is
entered into by and between AdaptHealth Corp., a Delaware corporation (the “Company”), and Deerfield Private
Design Fund IV, L.P., a Delaware limited partnership (the “Holder”).

 

RECITALS:

 

A.            The
Holder owns 17,179,888 shares (the “Owned Common Shares”) of Class A common stock, par value $0.0001 per
share (the “Class A Common Stock”), and warrants (the “Warrants”) to purchase an additional
2,474,314 shares of Class A Common Stock, in each case, which are held of record as of the date hereof set forth on Schedule
A hereto.

 

B.            As
an inducement to the Holder’s willingness to enter into the Voting Agreement (as defined in the Letter Agreement (as defined
below)), the Holder and the Company entered into a letter agreement, dated as of May 25, 2020 (the “Letter Agreement”),
pursuant to which the Holder and the Company agreed, among other things, to negotiate and enter into an agreement that provides
for the exchange of the Owned Common Shares other than a number of Owned Common Shares equal to 4.5% of the outstanding shares
of Class A Common Stock as of the date of the closing of such exchange, and after giving effect to the Exchange (as defined
below), for shares of a newly-designated class of the Company’s preferred stock.

 

C.            The
board of directors of the Company (the “Board of Directors”) has authorized the creation of a new series of
preferred stock denominated as Series B-1 Convertible Preferred Stock (the “Series B-1 Preferred Stock”)
with the preferences, rights and limitations described in the Certificate of Designation of Preferences, Rights and Limitations
of the Series B-1 Preferred Stock, in the form attached hereto as Exhibit A (the “Certificate of Designation”).

 

D.            As
contemplated by the Letter Agreement, pursuant to this Agreement (and subject to the terms and conditions hereof), the Holder will
exchange 15,810,547 of the Owned Common Shares (the “Exchanged Common Shares”) for an aggregate of 158,105.47
shares (the “Preferred Shares”) of Series B-1 Preferred Stock, which Preferred Shares shall be convertible
from time to time by the holder thereof into shares of Class A Common Stock (the “Conversion Shares”) in
accordance with the Certificate of Designation.

 

NOW, THEREFORE,
in consideration of the foregoing and the mutual covenants and agreements contained herein, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

 

Article I.

exchange; closing

 

Section 1.01.     Exchange.
Upon the terms, and subject to the satisfaction (or waiver) of the conditions set forth in Article IV, at the Closing, the
Holder and the Company hereby agree to exchange the Exchanged Common Shares for Preferred Shares (the “Exchange”).

 

     

     

    

 

Section 1.02.     Closing
and Settlement.

 

(a)            Subject
to the satisfaction (or waiver) of the conditions set forth in Article IV, the closing of the Exchange (the “Closing”)
shall occur on the date hereof. At the Closing,

 

(i)            the
Holder shall deliver or cause to be delivered to the Company the Exchanged Common Shares to the Company, free and clear of any
mortgage, lien, pledge, charge, security interest, encumbrance, title retention agreement, option, equity or other adverse claim,
limitation or restriction thereto (collectively, “Liens”) other than Permitted Liens (as defined below); and

 

(ii)            (A) the
Company shall issue to the Holder or its designee the Preferred Shares, and (B) the Company shall deliver to the Holder (or
its designee) stock certificates, duly executed on behalf of the Company, representing the Preferred Shares. In addition to any
contractual restrictions or lock-up agreements to which such Holder may be a party, the Preferred Shares will be subject to the
same restrictions on transferability, if any, as the Conversion Shares.

 

(b)            Effective
as of the date of the Closing (the “Closing Date”), (i) the Holder shall be deemed for all corporate purposes
to have become the legal, beneficial and record holder of the Preferred Shares entitled to exercise all rights (including conversion
rights) as a holder thereof and (ii) the Exchanged Common Shares shall be deemed cancelled and retired, in each case, without
any further action by any party.

 

(c)            Effective
upon the Closing, the Holder shall, automatically and irrevocably, without any further action by any party, surrender all
voting rights in respect of the Exchanged Common Shares (but not, for the avoidance of doubt, any other Owned Common Shares,
any Conversion Shares that are issued following the Closing upon conversion of any Preferred Shares or other securities held
by the Holder as of the Closing Date). From and after the Closing, (i) the Holder shall not vote, and shall not be
entitled to vote, any of the Exchanged Common Shares at any meeting of stockholders, or in connection with any written
consent of stockholders, with respect to any matter and (ii) the Exchanged Common Shares shall not be considered present
or entitled to vote or otherwise accounted for in connection with any meeting or vote that occurs following the Closing
(including for purposes of determining the presence or absence of a quorum or the minimum vote required to approve any
matter) regardless of whether the record date in respect of such meeting or written consent preceded the date of this
Agreement. Other than as set forth in the Company’s Definitive Proxy Statement on Schedule 14A filed with the
Securities and Exchange Commission (“SEC”) on April 29, 2020 with respect to the Company’s
annual meeting of stockholders (the “2020 Annual Meeting”), the Company acknowledges and confirms that it
has not set a record date for any special meeting or any other meeting of stockholders (or for purposes of determining
stockholders entitled to consent to any matter in writing), and covenants and agrees to use its commercially reasonable
efforts to re-set the record date for the 2020 Annual Meeting for a date that occurs after the Closing Date.

 

    2

     

    

 

Section 1.03.     Existing
Agreements.

 

(a)            Notwithstanding
anything to the contrary contained herein, the Preferred Shares issued in the Exchange, and the Conversion Shares issuable upon
the conversion thereof, shall be entitled to the rights, privileges and benefits, and shall remain subject to the limitations,
applicable to the Exchanged Common Shares pursuant to the Registration Rights Agreement (as defined below), as amended by the RRA
Amendment (as defined below). The Company acknowledges and agrees that the Registration Statement (as defined in the Registration
Rights Agreement) previously filed with, and declared effective by, the SEC, covering the resale of (among other shares) the Exchanged
Common Shares will cover the resale by the Holder of the Conversion Shares, and that the Company will take such actions, including
filing supplements to the prospectus included in such Registration Statement, as shall be necessary to ensure that such Registration
Statement remains effective and available for the resale of the Conversion Shares (for the avoidance of doubt, in addition to the
Retained Shares) in accordance with (and without limiting the Company’s obligations under) the Registration Rights Agreement
(as amended by the RRA Amendment). Without limiting the foregoing, the Company agrees to file with the SEC such a prospectus supplement
on or before 8:00 a.m. (New York City time) on June 29, 2020.

 

(b)            Consistent
with the Subscription Agreement (as defined below), the Holder acknowledges that, during the period commencing on the Closing Date
and ending on August 8, 2020, the Holder (i) will not Transfer (as defined in the Subscription Agreement), (ii) make
any short sale of, grant any option for the purchase of, or (iii) enter into any hedging or similar transaction with the same
economic effect as a Transfer with respect to, a number of Retained Shares, Preferred Shares and Conversion Shares in excess of
the Nine-Month Permitted Transfer Amount. “Nine-Month Permitted Transfer Amount” means an aggregate number of Retained
Shares, Conversion Shares and Preferred Shares (on an “as converted” basis, without giving effect to the 4.9% Cap)
equal to 7,179,888 shares of Class A Common Stock (subject to appropriate adjustment for any subdivision of outstanding shares
of Class A Common Stock (by any stock split, stock dividend, recapitalization or otherwise), combination of outstanding shares
of Common Stock (by consolidation, combination, reverse stock split or otherwise), reclassification or other similar transaction
of such character that outstanding shares of Class A Common Stock shall be changed into or become exchangeable for a larger
or smaller number of shares).

 

    3

     

    

 

Article II. 

REPRESENTATIONS
AND WARRANTIES

 

Section 2.01.     Representations
and Warranties of the Holder. The Holder hereby represents and warrants to the Company as of the date of this Agreement and
as of the Closing Date as follows:

 

(a)            Incorporation
and Authority. The Holder is duly organized, validly existing and in good standing under the Laws of its jurisdiction of organization.
The Holder has all requisite corporate or other applicable organizational power to (i) enter into, consummate the transactions
contemplated by, and carry out its obligations under this Agreement, and (ii) own, lease and operate its properties and carry
on its business as it is now being conducted and is duly qualified to do business and is in good standing in all jurisdictions
where its ownership or leasing of property or the conduct of its business requires it to be so qualified, except for any failure
under clause (ii) that would not, individually or in the aggregate, reasonably be expected to adversely affect the Holder’s
ability to perform its obligations under this Agreement or consummate the transactions contemplated hereby on a timely basis. The
execution and delivery by the Holder of this Agreement and the RRA Amendment and the consummation by the Holder of the transactions
contemplated by this Agreement and the RRA Amendment have been duly authorized by all requisite corporate or other similar organizational
action on the part of the Holder. This Agreement has been, and the RRA Amendment will be, duly executed and delivered by the Holder.
Assuming due authorization, execution and delivery by the other parties hereto, this Agreement constitutes, and the RRA Amendment
will constitute, the legal, valid and binding obligation of the Holder, enforceable against it in accordance with its terms, subject
in each case to the effect of any applicable bankruptcy, reorganization, insolvency, moratorium or similar Laws now or hereafter
in effect relating to or affecting creditors’ rights and remedies generally and subject, as to enforceability, to the effect
of general equitable principles (regardless of whether enforcement is sought in a proceeding in equity or at law).

 

(b)            Non-Contravention.

 

(i)            Neither
the execution, delivery and performance by the Holder of this Agreement or the RRA Amendment, nor the consummation of the transactions
contemplated hereby or thereby, nor compliance by the Holder with any of the provisions hereof or thereof, will (A) violate,
conflict with, or result in a breach of any provision of, or constitute a default (or an event which, with notice or lapse of time
or both, would constitute a default) under, or result in the termination of, or accelerate the performance required by, or result
in a right of termination or acceleration of, or result in the creation of any Lien upon any of the properties or assets of the
Holder under any of the terms, conditions or provisions of (i) its governing instruments or (ii) any note, bond, mortgage,
indenture, deed of trust, license, lease, agreement or other instrument or obligation to which the Holder is a party or by which
it may be bound, or to which the Holder or any of the properties or assets of the Holder may be subject, or (B) subject to
compliance with the statutes and regulations referred to in the next paragraph, violate any Law, statute, ordinance, rule or
regulation, permit, concession, grant, franchise or any judgment, ruling, order, writ, injunction or decree applicable to the Holder
or any of their respective properties or assets, except in the case of clauses (A)(ii) and (B) for such violations, conflicts
and breaches as would not reasonably be expected to materially and adversely affect the Holder’s ability to perform its respective
obligations under this Agreement or consummate the transactions contemplated hereby on a timely basis.

 

(ii)            Other
than filings with the SEC which may be required under Section 16, Section 13(d) or Section 13(f) of the
Securities and Exchange Act of 1934, as amended (the “Exchange Act”) on the part of the Holder and other persons
that may be deemed to beneficially own the Exchanged Common Shares or the Preferred Shares, no notice to, registration, declaration
or filing with, exemption or review by, or authorization, order, consent or approval of, any Governmental Entity (as defined below),
nor expiration or termination of any statutory waiting period, is necessary for the consummation by the Holder of the transactions
contemplated by this Agreement.

 

    4

     

    

 

(c)            Ownership
of the Exchanged Common Shares. The Holder owns beneficially (as such term is defined in Rule 13d-3 under the Exchange
Act) all of the Exchanged Common Shares free and clear of all Liens, other than Permitted Liens. The record holder of the Exchanged
Common Shares, which are held of record as of the date hereof as set forth on Schedule A hereto, and Warrants to purchase
an additional 2,474,314 shares of Class A Common Stock. Except pursuant to this Agreement and the Voting Agreement, there
are no options, warrants or other rights, agreements, arrangements or commitments of any character to which the Holder is a party
relating to the pledge, disposition or voting of any of the Exchanged Common Shares with respect to or otherwise affecting the
matters covered herein and there are no voting trusts or voting agreements with respect to the Exchanged Common Shares with respect
to or otherwise affecting the matters covered herein. Upon delivery of the Exchanged Common Shares to the Company, the Holder will
convey, or cause to be conveyed, to the Company good, valid and marketable title to the Exchanged Common Shares, free and clear
of all Liens other than Permitted Liens.

 

(d)            Securities
Law Matters.

 

(i)            The
Holder acknowledges that the Preferred Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”) or under any state securities Laws. The Holder (A) has such knowledge and experience in financial and business
matters and in investments of this type that it is capable of evaluating the merits and risks of its investment in the Preferred
Shares and of making an informed investment decision, (B) is an institutional “accredited investor” (as that term
is defined by Rule 501 of the Securities Act) or is a “qualified institutional buyer” (as that term is defined
in Rule 144A of the Securities Act) and (C) can bear the economic risk of (x) an investment in the Preferred Shares
indefinitely and (y) a total loss in respect of such investment.

 

(ii)            The
Holder acknowledges and agrees that the Holder has had the opportunity to review the all forms, reports, prospectuses, proxy statements
and documents (together with all amendments thereof and supplements thereto) required to be filed by it with the SEC since February 15,
2018 and the Holder has received such information as it deems necessary in order to make an investment decision with respect to
the Preferred Shares. The Holder represents and agrees that the Holder and the Holder’s professional advisor(s), if any,
have had the full opportunity to ask such questions, receive such answers and obtain such information as the Holder and the Holder’s
professional advisor(s), if any,

have deemed necessary to make
an investment decision with respect to the Preferred Shares. Notwithstanding anything to the contrary contained herein, neither
any such review nor any due diligence investigation conducted by the Holder or its advisors, if any, or its representatives shall
modify, amend or otherwise affect the Holder’s right to rely on the representations, warranties and covenants of the Company
contained in this Agreement.

 

(iii)            The
Holder understands that the Preferred Shares are being issued to it in reliance on specific exemptions from the registration requirements
of the United States federal and state securities Laws and that the Company is relying in part upon the truth and accuracy of,
and Holder’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Holder
set forth herein in order to determine the availability of such exemptions.

 

    5

     

    

 

(e)            Brokers
and Finders. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the consummation of the transactions contemplated by this Agreement based upon arrangements made by or on behalf
of the Holder.

 

Section 2.02.    Representations
and Warranties of the Company. The Company hereby represents and warrants to the Holder as of the date of this Agreement and
as of the Closing Date as follows:

 

(a)            Incorporation
and Authority.

 

(i)             The
Company is duly organized, validly existing and in good standing under the Laws of the State of Delaware. The Company has all requisite
corporate or other applicable organizational power to (i) enter into, consummate the transactions contemplated by, and carry
out its obligations under this Agreement, the Certificate of Designation, the RRA Amendment and each other agreement, document,
instrument, schedule or certificate contemplated by this Agreement to be executed by the Company in connection with or as a condition
to the Holder’s obligation to consummate the transactions contemplated hereunder (the “Ancillary Documents”),
and (ii) own, lease and operate its properties and carry on its business as presently conducted, and the Company is duly qualified
to do business and is in good standing in all jurisdictions where its ownership or leasing of property or the conduct of its business
requires it to be so qualified, except for any failure under clause (ii) that would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect (as defined below).

 

(ii)            The
execution and delivery by the Company of this Agreement and each Ancillary Document, and the consummation by the Company of
the transactions contemplated by this Agreement and the Ancillary Documents have been duly authorized by all requisite
corporate or other similar organizational action on the part of the Company. Without limiting the foregoing, no stockholder
approval is required in connection with the execution and delivery of this Agreement or any Ancillary Document, or the
consummation of the transactions contemplated hereby or thereby (including the issuance of the Preferred Shares and all of
the Conversion Shares issuable upon conversion thereof), including any stockholder approval that would be necessary to remain
in compliance with the rules of the Nasdaq Stock Market LLC (“Nasdaq”) or required under the
rules and regulations of the SEC or the General Corporation Law of the State of Delaware. This Agreement has been, and
each Ancillary Document will be, duly executed and delivered by the Company. Assuming due authorization, execution and
delivery by the other parties hereto, this Agreement constitutes, and each of the Ancillary Documents will constitute, the
legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective
terms, subject in each case to the effect of any applicable bankruptcy, reorganization, insolvency, moratorium or similar
Laws now or hereafter in effect relating to or affecting creditors’ rights and remedies generally and subject, as to
enforceability, to the effect of general equitable principles (regardless of whether enforcement is sought in a proceeding in
equity or at law).

 

    6

     

    

 

(iii)           Neither
the execution and delivery by the Company of this Agreement and each Ancillary Document, nor the consummation of the transactions
contemplated hereby or thereby, nor compliance by the Company with any of the provisions hereof or thereof will (a) violate
or conflict with the organizational documents of the Company, (b) conflict with or violate any Law applicable to the Company
or by which any of its properties or assets is bound or subject or (c) result in any breach of, or constitute a default (or
event which, with the giving of notice or lapse of time or both, would constitute a default) under, or give to any person any rights
of termination, acceleration or cancellation of or result in the creation of any lien on any of the assets or properties of the
Company, any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument or obligation to which
the Company or any of its subsidiaries is a party or by which any of them or any of their respective properties or assets is bound
or subject, except, in the case of clauses (b) and (c), for any such conflicts, violations, breaches, defaults, terminations,
accelerations, cancellations or creations as, individually or in the aggregate, would not reasonably be expected to have a Company
Material Adverse Effect. The execution and delivery of this Agreement and the issuance (directly or indirectly) of Preferred Shares
and the Conversion Shares is not, and will not be, subject to, or trigger, any preemptive rights, rights of first refusal, rights
of first offer, notice rights, approval/consent rights, voting rights, review rights or similar rights of any third party and will
not trigger any price reset or anti-dilution rights. No consent or approval of OEP AHCO Investment Holdings, LLC, One Equity Partners
VII, L.P. or any of their respective Affiliates is necessary for the consummation of the transaction contemplated by this Agreement
and the Ancillary Documents in accordance with the terms hereof and thereof, except to the extent that such consent has already
been obtained and has not been revoked.

 

(iv)            Except
for the filing of the Announcing Form 8-K (as defined below), compliance with any applicable state securities or blue
sky laws, the filing of the Certificate of Designation with the Secretary of State of the State of Delaware and the filings
required by the Registration Rights Agreement, no consent or approval of, or filing or registration with, any Governmental
Entity is necessary for the execution, delivery and performance by the Company of this Agreement or the Ancillary Documents,
other than such other consents, approvals, filings or registrations that, if not obtained, made or given, would not,
individually or in the aggregate, be material to the Company and its subsidiaries, taken as a whole.

 

(b)            Sale
of Securities. Based in part on the Holder’s representations in Section 2.01, the exchange of the Preferred Shares
for the Conversion Shares is exempt from the registration and prospectus delivery requirements of the Securities Act and the rules and
regulations promulgated thereunder. Without limiting the foregoing, neither the Company nor, to the Knowledge (as defined below)
of the Company, any other person authorized by the Company to act on its behalf, has engaged in a general solicitation or general
advertising (within the meaning of Regulation D of the Securities Act) of investors with respect to offer or sales of the Preferred
Shares or the Conversion Shares, and neither the Company nor, to the Knowledge of the Company, any person acting on its behalf,
has made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause
the offering or issuance of the Preferred Shares under this Agreement or the Conversion Shares under the Certificate of Designation
to be integrated with prior offerings by the Company, and the Company covenants and agrees that, following the date hereof, it
will not take any action or steps that would cause the offering or issuance of the Preferred Shares under this Agreement or the
Conversion Shares under the Certificate of Designation to be integrated with other offerings, in each case, for purposes of (i) the
Securities Act that would result in any applicable exemption from registration under the Securities Act not being available for
the offer, sale or issuance of the Preferred Shares or the Conversion Shares or (ii) the stockholder approval provisions of
Nasdaq. Neither the Company nor any other person acting on its behalf has paid any commission or remuneration that would render
the exemption from registration under Section 3(a)(9) under the Securities Act unavailable in connection with the issuance
of the Preferred Shares or any Conversion Shares. The Company acknowledges and agrees that, for purposes of Rule 144 under
the Securities Act, to the Company’s knowledge, the Holder’s holding period for the Preferred Shares and any Conversion
Shares shall be deemed to have commenced on the date the Holder acquired the Exchanged Common Shares from the Company or an affiliate
of the Company.

 

    7

     

    

 

(c)            Shares.
The Preferred Shares to be delivered to the Holder hereunder and the Conversion Shares have been duly authorized and, when
issued pursuant to this Agreement or the Certificate of Designation, as applicable, shall be validly issued, fully paid and
non-assessable and not subject to pre-emptive rights created by statute, the Amended and Restated Bylaws of the Company (as
amended or modified from time to time prior to the date hereof, the “Bylaws”) or the Second Amended and
Restated Certificate of Incorporation of the Company (as amended or modified from time to time prior to the date hereof, the
 “Certificate of Incorporation”) or any contract to which the Company is a party or is otherwise bound. As
of the Closing Date, the Company shall have the right, authority and power to sell, assign and transfer the Preferred Shares
and any Conversion Shares to the Holder. Upon delivery of such Preferred Shares and any Conversion Shares to the Holder, the
Holder shall acquire good, valid and marketable title to the Preferred Shares or Conversion Shares, as applicable, free and
clear of all Lien, other than Permitted Liens. The Company has reserved from its duly authorized capital stock 15,810,547
shares of Class A Common Stock for issuance hereafter upon conversion of the Preferred Shares.

 

(d)            Capitalization.

 

(i)            The
total number of shares of all classes of capital stock which the Company is authorized to issue is 250,000,000 shares, which consists
of (a) 245,000,000 shares of common stock, par value $0.0001 per share (“Common Stock”), which Common Stock
consists of (i) 210,000,000 shares of Class A Common Stock and (ii) 35,000,000 shares of Class B Common Stock,
par value $0.0001 per share (“Class B Common Stock”), and (b) 5,000,000 shares of preferred stock,
par value $0.0001 per share (“Preferred Stock”), of which 185,000 shares of Preferred Stock are authorized as
Series B-1 Preferred Stock. As of the close of business on June 15, 2020 (the “Capitalization Date”),
there were 46,217,170 shares of Class A Common Stock outstanding, 28,508,750 shares of Class B Common Stock outstanding
and no shares of Preferred Stock outstanding. As of the close of business on the Capitalization Date, (i) 2,905,179 shares
of Class A Common Stock remained available for issuance pursuant to the AdaptHealth Corp. 2019 Stock Incentive Plan (the “Stock
Plan”), (ii) options to purchase 3,464,001 shares of Class A Common Stock (“Company Stock Options”)
pursuant to the Stock Plan were outstanding, (iii) 1,572,203 unvested shares of Class A Common Stock granted pursuant
to the Stock Plan were outstanding (together with the Company Stock Options, the “Company Stock Awards”), (iv) 
1,000,000 shares of Class A Common Stock remained available for issuance pursuant to the AdaptHealth 2019 Employee Stock Purchase
Plan and (v) public and private Warrants to acquire 7,946,237 shares of Class A Common Stock were outstanding. All of
the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid, nonassessable
and free of preemptive or similar rights. From the Capitalization Date through and as of the date of this Agreement, no other shares
of Common Stock or Preferred Stock have been issued other than shares of Common Stock issued in respect of the exercise of Company
Stock Options or grant or payment of Company Stock Awards in the ordinary course of business. The Company does not have outstanding
stockholder purchase rights or “poison pill” or any similar arrangement in effect.

 

    8

     

    

 

(ii)            No
bonds, debentures, notes or other indebtedness having the right to vote (or convertible into or exchangeable for, securities
having the right to vote) on any matters on which the stockholders of the Company may vote (“Voting Debt”)
are issued and outstanding. Except (i) pursuant to any cashless exercise provisions of any Company Stock Options or
pursuant to the surrender of shares to the Company or the withholding of shares by the Company to cover tax withholding
obligations under Company Stock Options or Company Stock Awards, (ii) for the Warrants and (iii) as set forth in Section 2.02(d)(i),
the Company does not have and is not bound by any outstanding options, preemptive rights, rights of first offer, warrants,
calls, commitments or other rights or agreements calling for the purchase, sale or issuance of, or securities or rights
convertible into, or exchangeable for, any shares of Common Stock or any other equity securities of the Company or Voting
Debt or any securities representing the right to purchase or otherwise receive any shares of capital stock of the Company
(including any rights plan or agreement).

 

(e)            Brokers
and Finders. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the consummation of the transactions contemplated by this Agreement based upon arrangements made by or on behalf
of the Company or its Affiliates.

 

(f)            Anti-Takeover
Provisions. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any “control share acquisition”, “interested stockholder”, “business combination”, “fair
price”, “moratorium”, or other similar anti-takeover provision under the Certificate of Incorporation, Bylaws
or other organizational documents or the Laws of the State of Delaware which is applicable to the Holder as a result of the consummation
of the transactions contemplated by this Agreement and the Ancillary Documents in the manner contemplated hereby and thereby, including,
without limitation, the Company’s issuance of the Preferred Shares and the Conversion Shares and the Holder’s ownership
of the Preferred Shares and the Conversion Shares.

 

(g)            Investment
Company Status. Neither the Company nor any of its subsidiaries in an “investment company,” and, to the Company’s
Knowledge, neither the Company nor any of its subsidiaries is a company controlled by an “investment company” or an
 “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment
company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

    9

     

    

 

(h)            Certificate
of Designation. The Series B-1 Certificate of Designation has been filed with the Secretary of State of the State of Delaware,
has become effective and has not have been rescinded or revoked.

 

Article III.

COVENANTS

 

Section 3.01.     Reservation
of Shares. On and after the date hereof, the Company shall at all times reserve and keep available, free of preemptive or similar
rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue all of the Conversion Shares
pursuant to the Certificate of Designation (without regard to the 4.9% Cap (as defined in the Certificate of Designation)).

 

Section 3.02.     Certain
Stockholders’ Rights Plans. At any time that any Preferred Shares or Conversion Shares remain outstanding, the
Company shall not adopt any stockholder rights agreement, “poison pill” or similar anti-takeover agreement or
plan that is applicable to the Holder unless the Company has excluded the Holder from the definition of “acquiring
person” (or such similar term) as such term is defined in such anti-takeover agreement to the extent of the
Holder’s beneficial ownership of Preferred Stock or Common Stock owned as of the date any such agreement or plan is
adopted by the Company.

 

Section 3.03.     Blue
Sky Filings. The Company shall make all filings, if any, under applicable securities or “Blue Sky” Laws of the
states of the United States as shall be necessary in connection with the offering and sale of the Preferred Shares and the Conversion
Shares.

 

Section 3.04.     Listing.
At or prior to the Closing, the Company shall use its reasonable efforts to cause Nasdaq to have completed its review of a “Listing
of Additional Shares Notification Form” for listing of the Conversion Shares on the Nasdaq Capital Market (“Nasdaq
CM”). From time to time following the Closing Date, in the event the number of Conversion Shares into which the Preferred
Shares are convertible increases under the Certificate of Designation, the Company shall, as necessary to maintain the listing
of the Conversion Shares, apply to cause the number of Conversion Shares issuable upon conversion of the then outstanding Preferred
Shares to be listed on the Nasdaq CM.

 

Section 3.05.     Disclosure.
On or prior to June 26, 2020, the Company shall file with the SEC one or more Forms 8-K describing the terms of the transactions
contemplated by this Agreement and the Ancillary Documents, and including as exhibits to such Form(s) 8-K this Agreement,
the form of Series B-1 Certificate of Designation and the form of RRA Amendment, without redaction (including all schedules,
exhibits, appendices hereto and thereto) (such Form or Forms 8-K, collectively, the “Announcing Form 8-K”).

 

Section 3.06.     Undertaking. 
The Holder undertakes that it will only sell or otherwise transfer the Conversion Shares pursuant to either registration under
the Securities Act or an exemption therefrom, and that if the Conversion Shares are sold pursuant to a registration statement,
they will be sold in compliance with the plan of distribution set forth therein.  The Company acknowledges and agrees that
the foregoing undertaking constitutes the Undertaking (as defined in the Certificate of Designation) and that no additional Undertaking
by or on behalf of the Holder shall be required (i) to satisfy clause (A) of the definition of “Unrestricted Conditions”
under the Certificate of Designation or (ii) for purposes of Section 6(d)(iii) of the Certificate of Designation
so long as this Undertaking remains in effect.

 

    10

     

    

 

Article IV.

CONDITIONS PRECEDENT.

 

Section 4.01.     Conditions
to the Company’s and Holder’s Obligations. The obligations of the Holder, on the one hand, and the Company,
on the other hand, to consummate the Exchange and effect the Closing are subject to the satisfaction at the Closing of the
following condition: no temporary restraining order, preliminary or permanent injunction or other judgement or order issued
by any Governmental Entity shall have been issued, and no Law shall be in effect, restraining, enjoining, making illegal or
otherwise prohibiting the consummation of the transactions contemplated by this Agreement.

 

Section 4.02.     Conditions
to the Company’s Obligations. The obligation of the Company to consummate the Exchange and effect the Closing is subject
to the satisfaction at or prior to the Closing of the following conditions:

 

(a)            The
Holder shall have delivered to the Company at the Closing the deliverables set forth in Section 1.02(a)(i); and

 

(b)            The
representations and warranties of the Holder contained in Section 2.01 shall be true and correct as of the date when
made and as of the Closing Date as though made as of such date (except for representations and warranties that speak as of a specific
date, which shall be true and correct in all material respects as of such date), except where the failure of such representations
and warranties to be so true and correct would not, individually or in the aggregate, reasonably be expected to materially impair
or delay the Holder’s ability to perform or comply with its obligations under this Agreement or to consummate the transactions
contemplated hereby, and the Holder shall have in all material respects performed, satisfied and complied with the covenants, agreements
and conditions required hereunder to be performed, satisfied or complied with by the Holder at or prior to the Closing Date.

 

Section 4.03.     Conditions
to the Holder’s Obligations. The obligation of the Holder to consummate the Exchange and effect the Closing is subject
to the satisfaction at or prior to the Closing of the following conditions:

 

(a)            The
Company shall have delivered to the Holder at the Closing the deliverables set forth in Section 1.02(a)(ii);

 

(b)            The
representations and warranties of the Company contained in Section 2.02 (disregarding all qualifications as to materiality
set forth therein) shall be true and correct in all material respects as of the date when made and as of the Closing Date as though
made as of such date (except for representations and warranties that speak as of a specific date, which shall be true and correct
as of such date), and the Company shall have in all material respects performed, satisfied and complied with the covenants, agreements
and conditions required hereunder to be performed, satisfied or complied with by the Holder at or prior to the Closing Date;

 

    11

     

    

 

 

(c)            The
Company shall have delivered to the Holder a copy of the Certificate of Designations that has been filed with the Secretary of
State of the State of Delaware;

 

(d)            The
Holder (or their counsel) shall have received customary legal opinions from Willkie Farr & Gallagher LLP, as counsel to
the Company, containing the opinions substantially in the form set forth in Schedule B;

 

(e)            Nasdaq
shall have completed its review of a “Listing of Additional Shares Notification Form” for
listing of the Conversion Shares on the Nasdaq Capital Market; and

 

(f)            The
Registration Rights Agreement shall have been amended as set forth in Exhibit B (the “RRA Amendment”),
and the Holder shall have received evidence reasonably satisfactory to the Holder that RRA Amendment shall have been adopted by
the Company and the holders of a majority of the Registrable Securities (as defined in the Registration Rights Agreement).

 

Article V.

MISCELLANEOUS

 

Section 5.01.     Entire
Agreement. This Agreement constitutes the entire agreement, and supersedes all other prior and contemporaneous agreements
and understandings, both oral and written (including the Letter Agreement), among the Holder and the Company with respect to the
subject matter hereof.

 

Section 5.02.     Amendments
and Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed by the Company and
the Holder. No waiver of any breach or default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent breach or default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner
impair the exercise of any such right.

 

Section 5.03.     Successors
and Assigns. All of the covenants and provisions of this Agreement by or for the benefit of the Holder or the Company shall
bind and inure to the benefit of their respective successors and permitted assigns. No party hereunder may assign its rights or
obligations hereunder without the prior written consent of the other parties hereto, except that the Holder may assign its rights
hereunder to any Related Fund and/or to any assignee or transferee of Preferred Shares or Conversion Shares; provided, that
no such assignment shall relieve the Holder of its obligations hereunder. “Related Fund” means any investment
fund or managed account that is managed on a discretionary basis by the same investment manager as the Holder.

 

Section 5.04.     Counterparts;
Effectiveness. This Agreement and any amendment hereto may be executed and delivered in any number of counterparts, and by
the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of
which taken together shall constitute one and the same agreement. In the event that any signature to this Agreement or any amendment
hereto is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall
create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force
and effect as if such facsimile or “.pdf” signature page were an original thereof. No party hereto shall raise
the use of a facsimile machine or e-mail delivery of a “.pdf” format data file to deliver a signature to this Agreement
or any amendment hereto or the fact that such signature was transmitted or communicated through the use of a facsimile machine
or e-mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and
each party hereto forever waives any such defense.

 

Section 5.05.     Effect
of Headings. The section and subsection headings herein are for convenience only and not part of this Agreement and shall not
affect the interpretation thereof.

 

    12 

     

    

 

Section 5.06.     Further
Assurances. The parties hereby agree, from time to time, as and when reasonably requested by any other party hereto, to execute
and deliver or cause to be executed and delivered, all such documents, instruments and agreements, including secretary’s
certificates, stock powers and irrevocable transfer agent instructions, and to take or cause to be taken such further or other
action, as may be reasonably necessary or desirable in order to carry out the intent and purposes of this Agreement (including
to effectuate the surrender of voting rights as contemplated by Section 1.02(c)).

 

Section 5.07.     No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rule of strict construction will be applied against any party.

 

Section 5.08.     Reserved.

 

Section 5.09.     Governing
Law. This Agreement will be governed by and construed in accordance with the Laws of the State of Delaware. The parties hereby
irrevocably and unconditionally consent to submit to the exclusive jurisdiction of the state and federal courts located in the
State of Delaware for any actions, suits or proceedings arising out of or relating to this Agreement and the transactions contemplated
hereby. The parties hereby irrevocably and unconditionally consent to the jurisdiction of such courts (and of the appropriate appellate
courts therefrom) in any such action, suit or proceeding and irrevocably waive, to the fullest extent permitted by Law, any objection
that they may now or hereafter have to the laying of the venue of any such action, suit or proceeding in any such court or that
any such action, suit or proceeding which is brought in any such court has been brought in an inconvenient forum. Process in any
such action, suit or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of
any such court. Without limiting the foregoing, each party agrees that service of process on such party as provided in Section 5.11
shall be deemed effective service of process on such party.

 

Section 5.10.     WAIVER
OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

Section 5.11.     Notices.
Any notice, request, instruction or other document to be given hereunder by any party to the other will be in writing and will
be deemed to have been duly given (a) on the date of delivery if delivered personally or by electronic mail (so long as such
transmission does not generate an error message or notice of non-delivery), (b) on the first business day following the date
of dispatch if delivered by a recognized next-day courier service, or (c) on the third business day following the date of
mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall be
delivered as set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such
notice.

 

    13 

     

    

 

If to the Holder:

 

c/o Deerfield Management
Company L.P.

780 Third Avenue, 37th Floor

New York, NY 10017

Attn:     David J. Clark

Email:    dclark@deerfield.com

 

with a copy to:

 

Katten Muchin Rosenman
LLP 

525 W. Monroe Street

Chicago, Illinois 60661

Attn:     Mark D. Wood, Esq.

Email:    mark.wood@katten.com

 

If to the Company:

 

AdaptHealth Corp.

220 West Germantown Pike Suite 250

Plymouth Meeting, PA 19462

Attention: General Counsel

E-mail: cjoyce@adapthealth.com

 

with a copy to:

 

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, NY 10019

Attention: Steven J. Gartner

   Michael E. Brandt

   Danielle
Scalzo

E-mail: sgartner@willkie.com

      mbrandt@willkie.com

      dscalzo@willkie.com

Facsimile: 212-728-9962

 

    14 

     

    

 

Section 5.12.     Interpretation;
Other Definitions. Wherever required by the context of this Agreement, the singular shall include the plural and vice versa,
and the masculine gender shall include the feminine and neuter genders and vice versa, and references to any agreement, document
or instrument shall be deemed to refer to such agreement, document or instrument as amended, supplemented or modified from time
to time. All article, section, paragraph or clause references not attributed to a particular document shall be references to such
parts of this Agreement, and all exhibit, annex, letter and schedule references not attributed to a particular document shall be
references to such exhibits, annexes, letters and schedules to this Agreement. In addition, the following terms are ascribed the
following meanings:

  

(a)            the
word “or” is not exclusive;

 

(b)            the
words “including,” “includes,” “included” and “include”
are deemed to be followed by the words “without limitation”;

 

(c)            the
terms “herein,” “hereof” and “hereunder” and other words of similar import
refer to this Agreement as a whole and not to any particular section, paragraph or subdivision;

 

(d)            “beneficial
owner,” “beneficially own” or “beneficial ownership” has the meaning assigned to
such term in Rule 13d-3 under the Exchange Act, and a person or entity’s beneficial ownership of securities shall be
calculated in accordance with the provisions of such Rule (in each case, irrespective of whether or not such Rule is
actually applicable in such circumstance).

 

(e)            the
term “business day” means any day except Saturday, Sunday and any day which shall be a legal holiday
or a day on which banking institutions in the State of New York or State of Pennsylvania generally are authorized or required by
Law or other governmental action to close; and

 

(f)            the
term “person” has the meaning given to it in Section 3(a)(9) of the Exchange Act and as used
in Sections 13(d)(3) and 14(d)(2) of the Exchange Act.

 

(g)            “Affiliate”
means, with respect to any specified person, any other person that, at the time of determination, directly or indirectly through
one or more intermediaries, controls, is controlled by or is under common control with such specified person. Without limiting
the foregoing, with respect to the Holder, any investment fund or managed account that is managed on a discretionary basis by the
same investment manager as such Holder shall be deemed an Affiliate of such Holder.

 

    15 

     

    

 

(h)            “Company
Material Adverse Effect” means any change, effect, event, occurrence, condition, state of facts or development
that, either alone or in combination, has had, or would be reasonably expected to have, (a) a materially adverse effect
on the business, operations, assets, liabilities or condition (financial or otherwise) or results of operations of the Company,
taken as a whole; provided, however, that none of the following shall constitute or be deemed to contribute to
a Company Material Adverse Effect, or shall otherwise be taken into account in determining whether a Company Material Adverse
Effect has occurred or would be reasonably likely to occur: any adverse effect arising out of, resulting from or attributable
to (i) (A) the economy generally or credit, currency, oil, financial, banking, securities, capital markets or
financial markets generally (including any decline in the price of any security, commodity or
market index), including changes in interest or exchange rates, and (B) changes or conditions generally affecting the
industry or markets in which the Company participates, (ii) any changes or prospective changes in applicable Law, GAAP,
or the enforcement or interpretation thereof after the date hereof or any action required to be taken under any Law by which
the Company or any of its subsidiaries (or any of their respective assets or properties) is bound, (iii) any
international or national political, regulatory or social conditions, hostilities, cyber-attack, act of war, sabotage,
terrorism, declaration of national emergency or military actions, or any escalation or worsening of any such hostilities,
cyber-attack, act of war, sabotage, terrorism, declaration of national emergency or military actions, (iv) the failure
of the Company to meet or achieve the results set forth in any internal budget, plan, projection or forecast; provided
that this clause (iv) will not prevent a determination that any change, effect or other cause underlying such failure to
meet budgets, plans, projections or forecasts has resulted in or contributed to a Company Material Adverse Effect,
(v) actions of the Company expressly required by the terms of this Agreement or taken with the prior written consent of
the Holder, (vi) the negotiation or execution of this Agreement or any other Ancillary Document or announcement,
pendency or consummation of this Agreement or the transactions contemplated hereby or thereby or the identity, nature or
ownership of the Holder, including the impact thereof on the relationships, contractual or otherwise, of the Company or any
of its subsidiaries with any of its or their business relations or employees, (vii) epidemics, pandemics or disease or
virus outbreaks (including the COVID-19 virus) or (viii) hurricanes, earthquakes, tsunamis, tornados, mudslides, floods
or other natural disasters, weather conditions, explosions or fires or other force majeure events or acts of God, whether or
not caused by any person, or any national or international calamity or crisis; provided that the matters described in
clauses (i), (iii) and (viii) shall be included and taken into account in the term “Company Material Adverse
Effect” to the extent any such matter has a disproportionate adverse impact on the business, operations, assets,
liabilities or condition (financial or otherwise) or results of operations of the Company, taken as a whole, relative to the
other participants in the industries in which they operate; and (b) a material impairment on or material delay in the
ability of the Company to perform its material obligations under this Agreement or any Ancillary Document or to consummate
the transactions contemplated by this Agreement and/or the Ancillary Documents.

 

(i)            “Governmental
Entity” means any court, administrative or regulatory agency or commission or other governmental or arbitral body or
authority or instrumentality, including the SEC and any state-controlled or owned corporation or enterprise, in each case whether
federal, state, local or foreign, and any applicable industry self-regulatory organization (including Nasdaq).

 

(j)            “Knowledge
of the Company” means the actual knowledge after reasonable inquiry of one or more of Luke McGee, Joshua Parnes, Christopher
Joyce, Wendy Russalesi, Gregg Holst, John Gentile, Shaw Rietkerk or Andy Palan.

 

(k)            “Law”
means any federal, state, local or foreign law, statute or ordinance, or any rule, code, treaty, constitution, regulation, judgment,
order, writ, injunction, ruling, decree, administrative interpretation or agency requirement of any Governmental Entity.

 

(l)            “Permitted
Liens” means (i) Liens arising under this Agreement, the Registration Rights Agreement, the Voting Agreement, the
Subscription Agreement or any other agreement to which the Company is a party, (ii) Liens imposed by the Company and (iii) restrictions
on transfer arising under applicable securities laws.

 

    16 

     

    

 

(m)            “Registration
Rights Agreement” means that certain Registration Rights Agreement, dated as of November 8, 2019, by and among
AdaptHealth Holdings LLC and certain other parties thereto, as amended.

 

(n)            “Retained
Shares” means the 1,369,341 Owned Common Shares that are not being exchanged for Preferred Shares hereunder.

 

(o)            “Subscription
Agreement” means the Amended and Restated Subscription Agreement, dated October 15, 2019, by and between the Holder
and the Company (without expanding, limiting or otherwise modifying any provision thereof).

 

Section 5.13.     Captions.
The article, section, paragraph and clause captions herein are for convenience of reference only, do not constitute part of this
Agreement and will not be deemed to limit or otherwise affect any of the provisions hereof.

 

Section 5.14.     Severability.
If any provision of this Agreement or the application thereof to any person (including the officers and directors of the parties
hereto) or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining
provisions hereof, or the application of such provision to persons or circumstances other than those as to which it has been held
invalid or unenforceable, will remain in full force and effect and shall in no way be affected, impaired or invalidated thereby,
so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any party. Upon such determination, the parties shall negotiate in good faith in an effort to agree upon a suitable and equitable
substitute provision to effect the original intent of the parties.

 

Section 5.15.     No
Third Party Beneficiaries. Nothing contained in this Agreement, expressed or implied, is intended to confer upon any person
or entity other than the parties hereto (and their permitted assigns), any benefit, right or remedies.

 

Section 5.16.     Specific
Performance. The parties agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed
that, without the necessity of posting bond or other undertaking, the parties shall be entitled to specific
performance of the terms hereof, this being in addition to any other remedies to which they are entitled at law or equity,
and in the event that any action or suit is brought in equity to enforce the provisions of this Agreement, and no party will
allege, and each party hereby waives, the defense or counterclaim that there is an adequate remedy at law.

 

[The remainder of this page is
intentionally left blank—signature pages follow]

 

    17 

     

    

 

 

IN WITNESS WHEREOF,
each party hereto has caused this Agreement to be duly executed as of the date first written above.

 

	 	THE COMPANY:
	 	 
	 	ADAPTHEALTH CORP.
	 	 
	 	By:	/s/ Luke McGee
	 	Name:	Luke McGee
	 	Title:	Chief Executive Officer

 

[Signature page to Exchange Agreement]

 

     

     

    

 

	 	HOLDER:
	 	 
	 	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
	 	 
	 	By:  Deerfield Mgmt III, L.P., its General Partner
	 	By:  J.E. Flynn Capital III, LLC, its General Partner
	 	 
	 	By:	/s/ David J. Clark                
	 	Name: David J. Clark
	 	Title: Authorized Signatory

 

[Signature page to Exchange Agreement]Exhibit 10.2 

 

Execution
Version

 

INVESTMENT AGREEMENT

 

dated as of June 24, 2020

 

by and between

 

ADAPTHEALTH CORP.

 

and

 

DEERFIELD PARTNERS, L.P.

 

     

     

    

 

	Article I
    PURCHASE; CLOSING	 	     2
	1.1	Purchase	 	2
	1.2	Closing	 	2
	1.3	Closing Conditions.	 	3
	Article
    II REPRESENTATIONS AND WARRANTIES	 	5
	2.1	Representations and Warranties of the Company	 	5
	2.2	Representations and Warranties of the Purchaser	 	11
	Article
    III COVENANTS	 	15
	3.1	Confidentiality	 	15
	3.2	Listing	 	16
	3.3	Efforts	 	16
	3.4	Legend	 	16
	3.5	Back Leverage	 	16
	3.6	Corporate Actions	 	16
	3.7	Negative Covenants	 	17
	3.8	Tax Matters	 	17
	3.9	Stockholder Approval	 	18
	Article
    IV SURVIVAL	 	19
	4.1	Survival	 	20
	Article
    V SHAREHOLDER RIGHTS	 	20
	5.1	Information Rights	 	20
	5.2	Registration Rights	 	20
	5.3	Form 8-K	 	21
	Article
    VI MISCELLANEOUS	 	22
	6.1	Expenses	 	22
	6.2	Amendment; Waiver	 	23
	6.3	Counterparts; Electronic Transmission	 	23
	6.4	Governing Law	 	23
	6.5	WAIVER OF JURY TRIAL	 	24
	6.6	Notices	 	24
	6.7	Entire Agreement	 	25
	6.8	Assignment	 	25
	6.9	Interpretation; Other Definitions	 	25
	6.10	Captions	 	30
	6.11	Severability	 	31
	6.12	No Third Party Beneficiaries	 	31
	6.13	Public Announcements	 	31
	6.14	Specific Performance	 	31
	6.15	Termination	 	31
	6.16	Effects of Termination	 	32
	6.17	Non-Recourse	 	32

 

	Schedule A:	 	Legal Opinion
	 	 	 
	Schedule B:	 	Investor Requirements
	 	 	 
	Schedule C:	 	Competitors
	 	 	 
	ANNEXES
	 	 	 
	Annex I	–	Form of Series B-2 Certificate of Designations
	 	 	 
	Annex II	–	Form of Amended and Restated Registration Rights Agreement
	 	 	 

     ii

     

    

 

INDEX OF DEFINED TERMS

 

	Term	 	Location of Definition
	Affiliate	 	6.9(g)
	Agreement	 	Preamble
	Beneficial Owner/Beneficially Own/Beneficial Ownership	 	6.9(d)
	Board of Directors	 	2.1(a)(1)
	BSA/PATRIOT Act	 	2.2(c)(8)
	business day	 	6.9(e)
	Bylaws	 	2.1(d)
	Capitalization Date	 	2.1(b)(1)
	Certificate of Incorporation	 	2.1(d)
	Class A Common Stock	 	2.1(b)(1)
	Class B Common Stock	 	2.1(b)(1)
	Closing	 	1.2(a)
	Closing Date	 	1.2(a)
	Closing Notice	 	1.2(a)
	Common Stock	 	2.1(b)(1)
	Company	 	Preamble
	Company Material Adverse Effect	 	6.9(h)
	Company Stock Awards	 	2.1(b)(1)
	Company Stock Options	 	2.1(b)(1)
	Contract	 	6.9(i)
	DGCL	 	2.2(f
	Effect	 	6.9(k)
	Encumbrance	 	6.9(l)
	Equity Securities	 	6.9(m)
	Exchange Act	 	2.1
	GAAP	 	2.1(e)(2)
	Governmental Entity	 	6.9(n)
	herein/hereof/hereunder	 	6.9(c)
	including/includes/included/include	 	6.9(b)
	Information	 	3.1
	Knowledge of the Company	 	6.9(p)
	Law	 	6.9(q)
	Lien	 	6.9(r)
	Non-Recourse Party	 	6.17
	OFAC List	 	2.2(c)(8)
	or	 	6.9(a)
	person	 	6.9(f)
	Preferred Stock	 	2.1(b)(1)
	Purchaser	 	Preamble
	Reference Date	 	2.1
	Registration Rights Agreement	 	6.9(t)
	SEC	 	2.1(e)(1)
	SEC Reports	 	2.1(e)(1)
	Securities Act	 	2.1
	Series B-2 Certificate of Designations	 	Recitals
	Series B-1 Certificate of Designations	 	3.10
	Shares	 	1.1
	Stock Plan	 	2.1(b)(1)
	Subsidiary	 	6.9(u)
	Target Acquisition	 	6.9(v)
	Purchase Price	 	1.1(c)
	Transfer Agent	 	1.2(b)(1)
	Voting Debt	 	2.1(b)(2)
	Warrants	 	2.1(b)(1)

 

    iii

     

    

 

INVESTMENT AGREEMENT,
dated as of June 24, 2020 (this “Agreement”), by and between AdaptHealth Corp., a Delaware corporation
(the “Company”), and Deerfield Partners, L.P., a Delaware limited partnership (the “Purchaser”).

 

RECITALS:

 

WHEREAS, on May 25,
2020, the Company entered into an Investment Agreement (the “Third Party Investment Agreement”) with OEP AHCO
Investment Holdings, LLC, a Delaware limited liability company (the “OEP Purchaser”), and, solely for purposes
of Section 3.10 thereof, One Equity Partners VII, L.P., a Delaware limited partnership, pursuant to which the OEP Purchaser
has agreed to purchase $190,000,000 of the Company’s Series A Preferred Stock from the Company (subject to the terms
and conditions thereof);

 

WHEREAS, on May 25,
2020, the Company, the Purchaser and Deerfield Private Design Fund IV, L.P. (“DPD IV”) entered into a letter
agreement (the “Letter Agreement”), pursuant to which the Purchaser and the Company agreed, among other things,
to negotiate and enter into an agreement that provides for the purchase by the Purchaser from the Company, and the sale by the
Company to the Purchaser, of $35,000,000 of convertible preferred stock having terms that are substantially equivalent to the terms
of the Series A Preferred Stock sold pursuant to the Third Party Investment Agreement, subject to specified exceptions;

 

WHEREAS, consistent
with the Letter Agreement, the Company proposes to issue and sell to the Purchaser (including its permitted assignees pursuant
to Section 6.8) shares of Series B-2 Convertible Preferred Stock, par value $0.0001 per share, of the Company
(the “Series B-2 Preferred Stock”), having the designation, preferences, conversion or other rights, voting
powers, restrictions, limitations as to dividends, qualifications and terms and conditions, as specified in the form of Series B-2
Certificate of Designation, Preferences and Rights attached hereto as Annex I (the “Series B-2 Certificate
of Designations”);

 

WHEREAS, on May 25,
2020, the Company entered into that certain Stock Purchase Agreement and Agreement and Plan of Merger, by and among the Company,
Eleanor Merger Sub LLC, Solara Holdings, LLC and LCP Solara Blocker Seller, LLC, in its capacity as Blocker Seller and the Representative
(in each case as defined therein), regarding the Target Acquisition (the “Stock Purchase Agreement”); and

 

WHEREAS, capitalized
terms used in this Agreement have the meanings set forth in Section 6.9 or such other section indicated in the preceding
Index of Defined Terms.

 

NOW, THEREFORE, in
consideration of the premises, and of the representations, warranties, covenants and agreements set forth herein, the parties agree
as follows:

 

     1

     

    

 

Article I

 

PURCHASE; CLOSING

 

1.1            Purchase.

 

(a)            On
the terms and subject to the conditions herein and subject to the satisfaction (or waiver) of the conditions set forth in Section 1.3
below, on the Closing Date (as defined below), the Company agrees to sell and issue to the Purchaser, and the Purchaser agrees
to purchase from the Company, 35,000 shares of Series B-2 Preferred Stock (the “Shares”) for the total
price in cash of $35,000,000 (the “Purchase Price”).

 

(b)            The
Company will use the proceeds of the Purchase Price for (a) payment of fees and expenses incurred in connection with the transactions
contemplated by this Agreement, (b) other general corporate purposes, and (c) funding of the Target Acquisition.

 

1.2            Closing.

 

(a)            The
closing of the sale of Shares contemplated hereby (the “Closing”) shall occur on the date, and immediately prior
to the consummation of, the Target Acquisition (the consummation of the Target Acquisition, the “Target Acquisition Closing”).
Upon (a) satisfaction or waiver of the conditions set forth in Section 1.3 of this Agreement (other than those
conditions that by their nature are to be satisfied at the Closing, but subject to their satisfaction or waiver at or prior to
the Closing), and (b) written notice from (or on behalf of) the Company to the Purchaser (the “Closing Notice”)
that the Company reasonably expects all conditions to the Target Acquisition Closing to be satisfied on a date that is not less
than three (3) business days from the date of such Closing Notice, the Purchaser shall deliver to the Company, at least one
(1) business day prior to the proposed date of the Closing specified in the Closing Notice, an amount equal to the Purchase
Price, which shall be held in escrow by the Company until the Closing and immediately subsequent Target Acquisition Closing. In
the event the Target Acquisition Closing does not occur on the date specified in such Closing Notice, the Company shall promptly
(but not later than one (1) business day thereafter) return to the Purchaser the Purchase Price. The date that the Closing
occurs shall be referred to as the “Closing Date”.

 

(b)            At
the Closing:

 

(1)            (i) the
Company shall issue to the Purchaser or its designee the Shares and the Purchaser shall be deemed for all corporate purposes to
have become the legal and record holder of the Shares, entitled to exercise all rights (including conversion rights) as a holder
thereof, (ii) the Company shall deliver to the Purchaser (or its designee) stock certificates representing the Shares, and
(iii) the Company shall deliver to the Purchaser (A) an opinion of Willkie Farr & Gallagher LLP containing the
opinions substantially in the form set forth in Schedule A, (B) the executed Amended and Restated Registration Rights
Agreement, in the form of Annex II hereto, and (C) all other documents, instruments and writings required to be delivered
by the Company to the Purchaser pursuant to this Agreement or otherwise required in connection herewith.

 

(2)            the
Purchaser will deliver or cause to be delivered (i) to a bank account previously designated by the Company in writing, the
Purchase Price, by wire transfer of immediately available funds (provided, however, that the delivery of the Purchase Price in
escrow in accordance with Section 1.2 shall satisfy this obligation), (ii) the executed Amended and Restated Registration
Rights Agreement and (iii) all other documents, instruments and writings required to be delivered by the Purchaser to the
Company pursuant to this Agreement or otherwise required in connection herewith.

 

     2

     

    

 

1.3            Closing
Conditions.

 

(a)            The
obligations of the Purchaser, on the one hand, and the Company, on the other hand, to effect the Closing is subject to the satisfaction
by the Purchaser and the Company at the Closing of the following conditions:

 

(1)            no
temporary restraining order, preliminary or permanent injunction or other judgement or order issued by any Governmental Entity
shall have been issued, and no Law shall be in effect, restraining, enjoining, making illegal or otherwise prohibiting the consummation
of the transactions contemplated by this Agreement; and

 

(2)            all
conditions precedent to the Company’s obligation to consummate closing of the Target Acquisition shall have been satisfied
or, waived (other than those conditions which, by their nature, are to be satisfied at the closing of the Target Acquisition) and
the parties to the Target Acquisition are ready, willing and able to consummate the Target Acquisition immediately subsequent to
the Closing.

 

(b)            The
obligation of the Purchaser to effect the Closing is subject to the satisfaction by the Company at the Closing of the following
conditions:

 

(1)            (A) the
Fundamental Representations (other than Section 2.1(a)(1)(ii) and Section 2.1(a)(5)) (disregarding all
qualifications as to materiality or “Company Material Adverse Effect” set forth therein) shall be true and
correct in all material respects as of the Closing Date as if made on and as of the Closing Date (except to the extent any
such Fundamental Representation speaks as of the date of this Agreement or any other specific date, in which case such
representation or warranty shall be true and correct as of such date), (B) Section 2.1(a)(1)(ii) (for
the avoidance of doubt, without disregarding any qualifications as to materiality or “Company Material Adverse
Effect” set forth therein) shall be true and correct in all respects as of the Closing Date as if made on and as of the
Closing Date, (C) Section 2.1(a)(5) shall be true and correct as of the Closing Date as if made on and as of
the Closing Date and (D) the other representations and warranties of the Company set forth in Section 2.1
(disregarding all qualifications as to materiality or “Company Material Adverse Effect” set forth therein) shall
be true and correct as of the Closing Date as though made on and as of the Closing Date (except to the extent any such
representation or warranty speaks as of the date of this Agreement or any other specific date, in which case such
representation or warranty shall be true and correct as of such date), except, solely
with respect to this clause (D), where the failure of such representations and warranties to be so true and correct would
not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect;

 

(2)            the
Company shall have performed or complied with in all material respects all of the covenants and agreements required to be performed
or complied with by the Company under this Agreement on or prior to the Closing Date;

 

(3)            since
the date of this Agreement, there shall not have occurred and be continuing any Company Material Adverse Effect;

 

(4)            the
Purchaser shall have received a certificate, signed on behalf of the Company by an authorized officer thereof, certifying that
the conditions set forth in Sections 1.3(b)(1), 1.3(b)(2) and 1.3(b)(3) have been satisfied;

 

(5)            the
Company shall have delivered to the Purchaser a copy of the Series B-2 Certificate of Designations that has been filed with
the Secretary of State of the State of Delaware;

 

(6)            Nasdaq
shall have completed its review of a “Listing of Additional Shares Notification Form” for
listing of the any shares of Common Stock issuable upon conversion of the Series B-1 Preferred Stock into which the Series B-2
Preferred Stock is convertible at the applicable Conversion Rate specified in the applicable Certificate of Designations as in
effect on the date hereof on the Nasdaq CM;

 

     3

     

    

 

(7)            if
the Company Stockholder Approval has not been obtained prior to the Closing, (A) Voting Parties (other than the Purchasers
and their Affiliates) shall have entered into Voting Agreements or (B) other persons shall have entered into other voting
agreements in substantially the form of the Voting Agreements, which Voting Agreements and other such voting agreements collectively
represent, when taken together with the 1,369,341 shares of Class A Common Stock held by Deerfield Private Design Fund IV,
L.P., at least a majority of the outstanding voting power of the Company as of the earlier of (x) the record date of the first
Company Stockholders’ Meeting to be held after the Closing for the Company Stockholder Approval and (y) the Closing,
entitled to vote with respect to the Company Stockholder Approval and such Voting Agreements and other such voting agreements shall
be in full force and effect;

 

(8)            the
consents set forth on Schedule 2.1(a)(3) shall have been obtained and are in full force and effect; and

 

(9)            the
Company shall be consummating the closing of the purchase and sale of $190,000,000 of the Series A Preferred Stock pursuant
to the Third Party Investment Agreement substantially contemporaneously with the Closing.

 

(c)            The
obligation of the Company to effect the Closing is subject to the satisfaction by the Purchaser at the Closing of the following
conditions:

 

(1)            the
representations and warranties of the Purchaser set forth in Section 2.2 (disregarding all qualifications as to materiality
set forth therein) shall be true and correct as of the Closing Date as though made on the Closing Date (except to the extent any
such representation or warranty speaks as of the date of this Agreement or any other specific date, in which case such representation
or warranty shall be true and correct as of such date), except where the failure of such representations and warranties to be so
true and correct would not, individually or in the aggregate, reasonably be expected to materially impair or delay the Purchaser’s
ability to perform or comply with its obligations under this Agreement or to consummate the transactions contemplated hereby or
thereby;

 

(2)            the
Purchaser shall have performed or complied with in all material respects all covenants and agreements required to be performed
or complied with by the Purchaser under this Agreement on or prior to the Closing Date; and

 

(3)            the
Company shall have received a certificate, signed on behalf of the Purchaser by an authorized representative thereof, certifying
that the conditions set forth in Section 1.3(c)(1) and Section 1.3(c)(2) have been satisfied.

 

     4

     

    

 

Article II

 

REPRESENTATIONS AND WARRANTIES

 

2.1            Representations
and Warranties of the Company. Except as set forth (x) in publicly available SEC Reports filed by the Company with the
SEC following December 31, 2019 (the “Reference Date”), excluding any disclosures set forth in risk factors
or any “forward looking statements” within the meaning of the Securities Act of 1933 (the “Securities Act”)
or the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or (y) in a correspondingly identified
schedule attached hereto (provided that any such disclosure shall be deemed to be disclosed with respect to each other representation
and warranty to which the relevance of such exception is reasonably apparent on the face of such disclosure), the Company represents
and warrants to the Purchaser that:

 

(a)            Incorporation
and Authority.

 

(1)            The
Company is duly organized, validly existing and in good standing under the Laws of the State of Delaware. The Company has all
requisite corporate or other applicable organizational power to (i) enter into, consummate the transactions contemplated
by, and carry out its obligations under this Agreement, and (ii) own, lease and operate its properties and carry on its
business as presently conducted, and the Company is duly qualified to do business and is in good standing in all
jurisdictions where its ownership or leasing of property or the conduct of its business requires it to be so qualified,
except for any failure under clause (ii) that would not, individually or in the aggregate, reasonably be expected to
have a Company Material Adverse Effect. The execution and delivery by the Company of this Agreement, the Series B-2
Certificate of Designations and each other agreement, document, instrument, schedule or certificate contemplated by this
Agreement to be executed by the Company in connection with the transactions contemplated hereunder (the “Ancillary
Documents”) and the consummation by the Company of the transactions contemplated by this Agreement and the
Ancillary Documents have been or will be duly authorized by all requisite corporate or other similar organizational action on
the part of the Company. This Agreement has been, and the Ancillary Documents will be, duly executed and delivered by the
Company. Assuming due authorization, execution and delivery by the other parties hereto, this Agreement constitutes, and the
Ancillary Documents will constitute, the legal, valid and binding obligations of the Company, enforceable against it in
accordance with their respective terms, subject in each case to the effect of any applicable bankruptcy, reorganization,
insolvency, moratorium or similar Laws now or hereafter in effect relating to or affecting creditors’ rights and
remedies generally and subject, as to enforceability, to the effect of general equitable principles (regardless of whether
enforcement is sought in a proceeding in equity or at law). True and complete copies of the Second Amended and Restated
Certificate of Incorporation of the Company (as amended or modified from time to time prior to the date hereof, the
 “Certificate of Incorporation”)) and the Amended and Restated Bylaws of the Company (as amended or
modified from time to time prior to the date hereof, the “Bylaws”)), each as in effect, have been made
available to the Purchaser prior to the date hereof. The Board of Directors of the Company (the
 “Board of Directors”), at a meeting duly called and held or by written consent, adopted resolutions
(y) directing that the Company submit to the holders of Common Stock a proposal (the “Conversion
Proposal”) to approve the issuance of shares of Common Stock upon conversion of the Series B-1 Preferred Stock
that is issuable upon conversion of the Series B-2 Preferred Stock in excess of the number of shares permitted without
obtaining such approval under Nasdaq Rule 5635 and to otherwise approve the removal of the Conversion Restriction (as
such term is defined in the Series B-2 Certificate of Designations) at a meeting of the holders of Common Stock in
accordance with the terms of this Agreement and (z) recommending that the holders of the Common Stock approve the
Conversion Proposal (such recommendation, the “Company Board Recommendation”), which resolutions have not
been subsequently rescinded, modified or withdrawn. The affirmative vote (in person or by proxy) of the holders of a majority
of the shares of Common Stock (excluding shares of Common Stock issuable upon conversion of the Series B-1 Preferred
Stock that is issuable upon conversion of the Shares) voting for the approval of the Conversion Proposal is the only vote or
approval of the holders of any class or series of capital stock of the Company or any of its Subsidiaries that is required
(or necessary to remain in compliance with the rules of Nasdaq) under the rules and regulations of the SEC, the
General Corporation Law of the State of Delaware (the “DGCL”) or Nasdaq to approve the transactions
contemplated hereby and the consummation thereof, including the conversion of all the shares of Series B-1 Preferred
Stock that are issuable upon conversion of the Shares under Nasdaq listing rule 5635 into shares of Class A Common
Stock (without giving effect to the Conversion Restriction) (the “Company Stockholder
Approval”).

 

     5

     

    

 

(2)            Each
of the Company’s Significant Subsidiaries (as defined in Rule 1-02 of Regulation S-X of the SEC) (i) is duly organized
and validly existing under the Laws of its jurisdiction of organization, (ii) has all requisite corporate or other applicable
entity power and authority to own its properties and conduct its business as presently conducted, and (iii) is duly qualified
to do business and is in good standing in all jurisdictions where its ownership or leasing of property or the conduct of its business
requires it to be so qualified, except, in the case of this clause (iii), where failure to be so qualified or in good standing,
individually or in the aggregate, has not and would not reasonably be expected to have a Company Material Adverse Effect.

 

(3)            Neither
the execution and delivery by the Company of this Agreement or the Ancillary Documents, nor the consummation of the transactions
contemplated hereby or thereby, nor compliance by the Company with any of the provisions hereof or thereof will (a) violate
or conflict with the organizational documents of the Company, (b) conflict with or violate any Law applicable to the Company
or by which any of its properties or assets is bound or subject or (c) result in any breach of, or constitute a default (or
event which, with the giving of notice or lapse of time or both, would constitute a default) under, or give to any person any rights
of termination, acceleration or cancellation of or result in the creation of any Lien on any of the assets or properties of the
Company, any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument or obligation to which
the Company or any of its subsidiaries is a party or by which any of them or any of their respective properties or assets is bound
or subject, except, in the case of clauses (b) and (c), for any such conflicts, violations, breaches, defaults, terminations,
accelerations, cancellations or creations as, individually or in the aggregate, would not reasonably be expected to have a Company
Material Adverse Effect.

 

(4)            Except
for (a) the filing with the SEC of such current reports and other documents, if any, required to be filed with the SEC under
the Exchange Act or Securities Act in connection with the transactions contemplated hereunder, including the filing with the SEC
of a proxy statement relating to the Company Stockholders’ Meeting (the “Proxy Statement”), any filings
required by the Registration Rights Agreement or the Amended and Restated Registration Rights Agreement, as in effect at such time
the and Transaction 8-Ks, (b) compliance with any applicable state securities or blue sky laws, (c) pursuant to the terms
of any Contract by and between the Company or any of its Subsidiaries, on the one hand, and any Governmental Entity, on the other
hand, and (d) the filing of the Series B-2 Certificate of Designations with the Secretary of State of the State of Delaware,
no consent or approval of, or filing or registration with, any Governmental Entity is necessary for the execution, delivery and
performance by the Company of this Agreement and the Ancillary Documents, other than such other consents, approvals, filings or
registrations that, if not obtained, made or given, would not, individually or in the aggregate, reasonably be expected to have
a Company Material Adverse Effect.

 

(5)            As
of the date hereof, the persons set forth on Schedule 2.1(a)(5) (together with the Purchaser and its Affiliates and
any persons who execute and deliver a voting agreement following the date hereof in substantially the form of the Voting Agreements,
the “Voting Parties”) hold shares of Common Stock that (together with the Retained Shares), in the aggregate,
represent a majority of the voting power of the Company entitled to vote with respect to the Company Stockholder Approval. Each
of the Voting Parties set forth on Schedule 2.1(a)(5) has entered into a Voting Agreement as of the date hereof.

 

     6

     

    

 

(b)            Capitalization.

 

(1)            The
total number of shares of all classes of capital stock which the Company is authorized to issue is 250,000,000 shares, which consists
of (a) 245,000,000 shares of common stock, par value $0.0001 per share (“Common Stock”), which Common Stock
consists of (i) 210,000,000 shares of Class A Common Stock (“Class A Common Stock”) and (ii) 35,000,000
shares of Class B Common Stock (“Class B Common Stock”) and (b) 5,000,000 shares of preferred
stock, par value $0.0001 per share (“Preferred Stock”), of which 185,000 shares of Preferred Stock are authorized
as Series B-1 Preferred Stock and a certain number of shares of Preferred Stock will be authorized as Series A Preferred
Stock pursuant to the Third Party Investment Agreement. As of the close of business on June 15, 2020 (the “Capitalization
Date”), there were 46,217,170 shares of Class A Common Stock outstanding, 28,508,750 shares of Class B Common
Stock outstanding and no shares of Preferred Stock outstanding. As of the close of business on the Capitalization Date, (i) 2,905,179
shares of Class A Common Stock remained available for issuance pursuant to the AdaptHealth Corp. 2019 Stock Incentive Plan
(the ”Stock Plan”), (ii) options to purchase 3,464,001 shares of Class A Common Stock (“Company Stock
Options”) pursuant to the Stock Plan were outstanding, (iii) 1,572,203 unvested shares of Class A Common Stock
granted pursuant to the Stock Plan were outstanding (together with the Company Stock Options, the “Company Stock Awards”),
(iv) 1,000,000 shares of Class A Common Stock remained available for issuance pursuant to the AdaptHealth 2019 Employee
Stock Purchase Plan and (v) public and private warrants to acquire 7,946,237 shares of Class A Common Stock were outstanding
(the “Warrants”). The Series B-1 Certificate of Designations has been filed with the Secretary of State of the
State of Delaware. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are
fully paid, nonassessable and free of preemptive or similar rights. From the Capitalization Date through and as of the date of
this Agreement, no other shares of Common Stock or Preferred Stock have been issued other than shares of Common Stock issued in
respect of the exercise of Company Stock Options or grant or payment of Company Stock Awards in the ordinary course of business.
The Company does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect.

  

(2)            No
bonds, debentures, notes or other indebtedness having the right to vote (or convertible into or exchangeable for, securities having
the right to vote) on any matters on which the stockholders of the Company may vote (“Voting Debt”) are issued
and outstanding. Except (i) pursuant to any cashless exercise provisions of any Company Stock Options or pursuant to the surrender
of shares to the Company or the withholding of shares by the Company to cover tax withholding obligations under Company Stock Options
or Company Stock Awards, (ii) for the Warrants and (iii) as set forth in Section 2.1(b)(1), the Company does
not have and is not bound by any outstanding options, preemptive rights, rights of first offer, warrants, calls, commitments or
other rights or agreements calling for the purchase, sale or issuance of, or securities or rights convertible into, or exchangeable
for, any shares of Common Stock or any other equity securities of the Company or Voting Debt or any securities representing the
right to purchase or otherwise receive any shares of capital stock of the Company (including any rights plan or agreement).

 

(c)            Sale
of Securities. Based in part on the Purchaser’s representations in Section 2.2, the offer and sale of the
Securities is exempt from the registration and prospectus delivery requirements of the Securities Act and the rules and regulations
promulgated thereunder. Without limiting the foregoing, neither the Company nor, to the Knowledge of the Company, any other person
authorized by the Company to act on its behalf, has engaged in a general solicitation or general advertising (within the meaning
of Regulation D of the Securities Act) of investors with respect to offer or sales of the Securities and neither the Company nor,
to the Knowledge of the Company, any person acting on its behalf, has made any offers or sales of any security or solicited any
offers to buy any security, under circumstances that would cause the offering or issuance of the Securities under this Agreement
or the Certificates of Designations to be integrated with prior offerings by the Company for purposes of the Securities Act that
would result in Regulation D or any other applicable exemption from registration under the Securities Act not being available,
nor will the Company take any action or steps that would cause the offering or issuance of the Securities under this Agreement
or the Certificates of Designations to be integrated with other offerings.

 

     7

     

    

 

(d)            Shares.
The Securities to be delivered to the Purchaser hereunder, under the Series B-2 Certificate of Designations and under
the Series B-1 Certificate of Designations upon conversion fo the Series B-2 Preferred Stock have been duly
authorized and, when issued and paid for pursuant to this Agreement or issued pursuant to the Series B-2 Certificate of
Designations or the Series B-1 Certificate of Designations, as applicable, shall be validly issued, fully paid and
non-assessable and not subject to pre-emptive rights created by statute, the Company’s Bylaws or Certificate of
Incorporation or any contract to which the Company is a party or is otherwise bound. As of the Closing, the Company shall
have the right, authority and power to sell, assign and transfer the Securities to the Purchaser. Upon delivery of such
Securities to the Purchaser, the Purchaser shall acquire good, valid and marketable title to such Securities, free and clear
of all Liens other than restrictions on transfer imposed by applicable securities Laws or in this Agreement, the Registration
Rights Agreement or the Amended and Restated Registration Rights Agreement, as in effect at such time, or in the Certificates
of Designations. The Securities to be issued hereunder and that are or may become issuable under the Series B-1
Certificate of Designations have been duly authorized and reserved for such issuance.

 

(e)            SEC
Reports; Financial Statements.

 

(1)            The
Company has filed, on a timely basis, all forms, reports, prospectuses, proxy statements and documents (together with all amendments
thereof and supplements thereto) required to be filed by it with the Securities and Exchange Commission (the “SEC”)
since February 15, 2018 (together with all exhibits and schedules thereto and all information incorporated therein by reference,
the “SEC Reports”). The SEC Reports (as of the date filed with the SEC and, in the case of registration statements,
prospectuses and proxy statements, on the dates of effectiveness and the dates of mailing, respectively, and, in the case of any
SEC Reports amended or superseded by a filing prior to the date hereof, then on the date of such amending or superseding filing)
(i) have complied in all material respects in accordance with either the applicable requirements of the Securities Act or
the Exchange Act, as the case may be, and the applicable rules and regulations promulgated by the SEC thereunder and (ii) did
not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(2)            As
of the date hereof, (A) none of the Company’s Subsidiaries is required to file any documents with the SEC, (B) there
are no outstanding or unresolved comments in comment letters from the SEC staff with respect to any of the SEC Reports, and (C) to
the Company’s knowledge, none of the SEC Reports is the subject of ongoing SEC review, outstanding SEC comment or outstanding
SEC investigation. Each of the certifications and statements relating to the SEC Reports required by: (x) Rule 13a-14
or Rule 15d-14 under the Exchange Act; (y) 18 U.S.C. §1350 (Section 906 of the Sarbanes-Oxley Act); or (z) any
other rule or regulation promulgated by the SEC or applicable to the SEC Reports is accurate and complete, and complies as
to form and content, in all material respects with all applicable Laws.

 

     8

     

    

 

 

(3)            The
consolidated financial statements of the Company, and the related notes thereto, included or incorporated by reference in the
SEC Reports, as of the date filed with the SEC (and, in the case of registration statements, prospectuses and proxy
statements, on the dates of effectiveness and the dates of mailing, respectively, and, in the case of any SEC Report amended
or superseded by a filing prior to the date hereof, then on the date of such amending or superseding filing), have complied
as to form in all material respects with applicable accounting requirements and with the published rules and regulations
of the SEC with respect thereto, were prepared in accordance with generally accepted accounting principles in the United
States (“GAAP”) applied on a consistent basis during the periods indicated (except as may be indicated in
the notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q of the SEC), and fairly presented,
in all material respects (subject, in the case of the unaudited statements, to normal year-end adjustments and the absence of
footnote disclosure, none of which, individually or in the aggregate, are material to the Company and its Subsidiaries taken
as a whole), the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates of
such financial statements and the consolidated results of their operations and cash flows for each of the periods
specified.

 

(4)            The
Company (a) has implemented and maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under
the Exchange Act) that are reasonably designed to provide assurance that material information relating to the Company, including
its consolidated Subsidiaries, is made known to the individuals responsible for the preparation of the Company’s filings
with the SEC, and (b) has disclosed, based on its most recent evaluation prior to the date of this Agreement, to the Company’s
outside auditors and the Board of Director’s audit committee (i) any significant deficiencies and material weaknesses
in the design or operation of internal controls over financial reporting (as defined in Rule 13a-15(f) under the Exchange
Act) that are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report material
financial information, and (ii) any fraud involving the Company, whether or not material, by management or other employees
who have a significant role in the Company’s internal controls over financial reporting. As of the date of this Agreement,
to the Knowledge of the Company, the outside auditors and its chief executive officer and chief financial officer will be able
to give the certifications and attestations required pursuant to the rules and regulations adopted pursuant to Section 404
of the Sarbanes-Oxley Act of 2002, without qualification, when next due.

 

(5)            There
is no transaction, arrangement or other relationship between the Company and/or any of its Subsidiaries and an unconsolidated or
other off-balance sheet entity that is required to be disclosed by the Company in its SEC Reports and is not so disclosed.

 

(6)            The
Proxy Statement (including any amendment or supplement thereto) will comply as to form in all material respects with the requirements
of the Exchange Act and will not, at the time it or any amendment or supplement thereto is filed with the SEC or at the time first
published, sent or given to the stockholders of the Company, or at the time of the Company Stockholders’ Meeting, contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they are made, not misleading. Notwithstanding the foregoing,
the Company makes no representation or warranty with respect to statements made or incorporated by reference therein based on information
supplied by or on behalf of the Purchaser or any Affiliates thereof for inclusion or incorporation by reference in the Proxy Statement.

 

    9 

     

    

 

(f)            Brokers
and Finders. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or
commission in connection with the consummation of the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of the Company or its Affiliates.

 

(g)            Litigation.
There are no actions or proceedings or, to the Knowledge of the Company, investigations pending or, to the Knowledge of the Company,
any actions, proceedings, or investigations threatened in writing against the Company or any of its Affiliates or any of their
respective assets, properties or businesses that (i) question the legality of the transactions contemplated by this Agreement
or (ii) individually or in the aggregate would reasonably be expected to have a Company Material Adverse Effect. Except as
has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
neither the Company nor any of its Subsidiaries is subject to any judgment, order or decree of any Governmental Entity.

 

(h)            Compliance
with Laws. Neither the Company nor any of its Subsidiaries is, or since February 15, 2018 has been, in violation of any
applicable Law, except where such violation would not, individually or in the aggregate, reasonably be expected to have, or has
not had, a Company Material Adverse Effect. To the Knowledge of the Company as of the date of this Agreement, neither the Company
nor any of its Subsidiaries is being investigated with respect to any applicable Law, except for such of the foregoing as would
not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.

 

(i)            Absence
of Changes. Since December 31, 2019, there has not been any Company Material Adverse Effect or any event, change or occurrence
that would, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.

 

(j)            Listing
and Maintenance Requirements. The shares of Class A Common Stock are registered pursuant to Section 12(b) of
the Exchange Act and listed on the Nasdaq Capital Market (“Nasdaq”), and the Company has taken no action designed
to, or which to the Knowledge of the Company is reasonably likely to, have the effect of, terminating the registration of the shares
of Class A Common Stock under the Exchange Act or delisting the Class A Common Stock from the Nasdaq nor has the Company
received as of the date of this Agreement any notification that the SEC or the Nasdaq is contemplating terminating such registration
or de-listing.

 

(k)            Indebtedness.
Neither the Company nor any of its Subsidiaries is, immediately prior to the execution and delivery of this Agreement, in default
in the payment of any material indebtedness or in material default under any agreement relating to its material indebtedness.

 

(l)            Anti-Takeover
Provisions. Assuming the accuracy of the representations in Section 2.2(f), the Company and the Board of Directors
have taken all necessary action, if any, in order to render inapplicable any “control share acquisition”, “interested
stockholder”, “business combination”, “fair price”, “moratorium”, or other similar anti-takeover
provision under the Certificate of Incorporation, Bylaws or other organizational documents or the Laws of the State of Delaware
which is applicable to the Purchaser as a result of the consummation of the transactions contemplated by this Agreement and the
Ancillary Documents in the manner contemplated hereby and thereby, including, without limitation, the Company’s issuance
of the Shares and the Purchaser’s ownership of the Shares and the shares of Common Stock issuable upon conversion of the
Shares.

 

    10 

     

    

 

(m)            Investment
Company Status. Neither the Company nor any Subsidiary is an “investment company,” and, to the Company’s
knowledge, neither the Company nor any Subsidiary is a company controlled by an “investment company” or an “affiliated
person” of, or “promoter” or “principal underwriter” for, an “investment company” as
such terms are defined in the Investment Company Act of 1940, as amended.

 

(n)            No
Disqualification Events. With respect to the issuance of the Securities, none of the Company, any of its predecessors, any
Affiliated issuer, any director, executive officer, other officer of the Company, any beneficial owner of 20% or more of the Company’s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405
under the Securities Act) connected with the Company in any capacity at the time of sale is subject to any of the “Bad Actor”
disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act except for items covered by
Rule 506(d)(2) or (d)(3).

 

(o)            No
Plan Assets. Neither the Company nor any of its Subsidiaries holds “plan assets” within the meaning of the Department
of Labor regulations located at 29 C.F.R. Section 2510.3-101, as modified by Section 3(42) of the Employee Retirement
Income Security Act of 1974, as amended (“Plan Assets”).

 

(p)            No
Additional Representations. Except for the representations and warranties made by the Company in this Section 2.1,
none of the Company or any of its Affiliates or representatives makes any other representation or warranty of any kind or nature
whatsoever, oral or written, express or implied, with respect to itself, its Affiliates, their respective businesses, this Agreement
or the transactions contemplated by the Agreement.

 

2.2            Representations
and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company that:

 

(a)            Incorporation
and Authority. The Purchaser is duly organized, validly existing and in good standing under the Laws of its jurisdiction
of organization. The Purchaser has all requisite corporate or other applicable organizational power to (i) enter into,
consummate the transactions contemplated by, and carry out its obligations under this Agreement, and (ii) own, lease and
operate its properties and carry on its business as it is now being conducted and is duly qualified to do business and is in
good standing in all jurisdictions where its ownership or leasing of property or the conduct of its business requires it to
be so qualified, except for any failure under clause (ii) that would not, individually or in the aggregate, reasonably
be expected to adversely affect the Purchaser’s ability to perform its obligations under this Agreement or the
Ancillary Documents or consummate the transactions contemplated hereby or thereby on a timely basis. The execution and
delivery by the Purchaser of this Agreement and the Ancillary Documents to which the Purchaser is or will be a party and the
consummation by the Purchaser of the transactions contemplated by this Agreement and the Ancillary Documents to which the
Purchaser is or will be a party have been or will be duly authorized by all requisite corporate or other similar
organizational action on the part of the Purchaser. This Agreement has been, and the other Ancillary Documents to which the
Purchaser is or will be a party will be, duly executed and delivered by the Purchaser. Assuming due authorization,
execution and delivery by the other parties hereto, this Agreement constitutes, and the other Ancillary Documents to which
the Purchaser is or will be a party will constitute, the legal, valid and binding obligation of the Purchaser, enforceable
against it in accordance with their respective terms, subject in each case to the effect of any applicable bankruptcy,
reorganization, insolvency, moratorium or similar Laws now or hereafter in effect relating to or affecting creditors’
rights and remedies generally and subject, as to enforceability, to the effect of general equitable principles (regardless of
whether enforcement is sought in a proceeding in equity or at law).

 

    11 

     

    

 

(b)            Non-Contravention.

 

(1)            Neither
the execution, delivery and performance by the Purchaser of this Agreement or the Ancillary Documents to which the Purchaser is
or will be a party, nor the consummation of the transactions contemplated hereby or thereby, nor compliance by the Purchaser with
any of the provisions hereof or thereof, will (A) violate, conflict with, or result in a breach of any provision of, or constitute
a default (or an event which, with notice or lapse of time or both, would constitute a default) under, or result in the termination
of, or accelerate the performance required by, or result in a right of termination or acceleration of, or result in the creation
of any Lien upon any of the properties or assets of the Purchaser under any of the terms, conditions or provisions of (i) its
governing instruments or (ii) any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument
or obligation to which the Purchaser is a party or by which it may be bound, or to which the Purchaser or any of the properties
or assets of the Purchaser may be subject, or (B) subject to compliance with the statutes and regulations referred to in the
next paragraph, violate any law, statute, ordinance, rule or regulation, permit, concession, grant, franchise or any judgment,
ruling, order, writ, injunction or decree applicable to the Purchaser or any of its properties or assets except in the case of
clauses (A)(ii) and (B) for such violations, conflicts and breaches as would not reasonably be expected to materially
and adversely affect the Purchaser’s ability to perform its respective obligations under this Agreement or consummate the
transactions contemplated hereby on a timely basis.

 

(2)            Other
than (A) the securities or blue sky laws of the various states, (B) filings with the SEC pursuant to Section 13(d),
Section 13(f) or Section 16 of the Exchange Act, if applicable, on the part of the Purchaser and (C) the filing
by the Company of the Series B-2 Certificate of Designations with the Delaware Secretary of State, no notice to, registration,
declaration or filing with, exemption or review by, or authorization, order, consent or approval of, any Governmental Entity, nor
expiration or termination of any statutory waiting period, is necessary for the consummation by the Purchaser of the transactions
contemplated by this Agreement or the Ancillary Documents.

 

    12 

     

    

 

(c)            Securities
Law Matters.

 

(1)            The
Purchaser acknowledges that the Shares have not been registered under the Securities Act or under any state securities laws. The
Purchaser (A) acknowledges that it is acquiring the Shares pursuant to an exemption from registration under the Securities
Act with no present intention to distribute any of the Shares to any person or entity in violation of applicable securities Laws,
(B) is acquiring the Shares only for its own account and not for the account of others, and not on behalf of any other account,
person or entity, (C) will not sell, transfer, pledge or otherwise dispose of any Shares, except in compliance with the registration
requirements or exemption provisions of the Securities Act or any other applicable securities Laws, (D) has such knowledge
and experience in financial and business matters and in investments of this type that it is capable of evaluating the merits and
risks of its investment in the Shares and of making an informed investment decision, (E) is an institutional “accredited
investor” (as that term is defined by Rule 501 of the Securities Act) or is a “qualified institutional buyer”
(as that term is defined in Rule 144A of the Securities Act), in each case of this clause (B), satisfying the requirements
set forth on Schedule B, and (F) can bear the economic risk of (x) an investment in the Shares indefinitely and
(y) a total loss in respect of such investment.

 

(2)            In
making its decision to purchase the Shares, the Purchaser has relied solely upon independent investigation made by the Purchaser
and the representations, warranties, covenants and agreements of the Company made (or that will be made) herein and in the Ancillary
Documents, as well as the representations, warranties, covenants and agreements made (or that will be made) by each other party
to the Ancillary Documents (including, for the avoidance of doubt, the parties to the Voting Agreements). The Purchaser acknowledges
and agrees that it has had the opportunity to review the SEC Reports and it has received such information as it deems necessary
in order to make an investment decision with respect to the Shares. The Purchaser represents and agrees that it and its professional
advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such information as it
and its professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares. Notwithstanding
anything to the contrary contained herein, neither any such review nor any due diligence investigation conducted by the Purchaser
or its advisors, if any, or its representatives shall modify, amend or otherwise affect the Purchaser’s right to rely on
the representations and warranties of the Company contained in this Agreement.

 

(3)            The
Purchaser became aware of this offering of the Shares solely by means of direct contact between it and the Company or a representative
of the Company, and the Shares were offered to the Purchaser solely by direct contact between it and the Company or a representative
of the Company. The Purchaser did not become aware of this offering of the Shares, nor were the Shares offered to the Purchaser,
by any other means. The Purchaser acknowledges that it was not induced to acquire the Shares through any form of general solicitation
or general advertising.

 

    13 

     

    

 

(4)            The
Purchaser is not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons
administered by the U.S. Treasury Department’s Office of Foreign Assets Control or in any Executive Order issued
by the President of the United States and administered by OFAC (“OFAC List”), or a person or entity
prohibited by any OFAC sanctions program, (ii) a Designated National as defined in the Cuban Assets Control Regulations,
31 C.F.R. Part 515, or (iii) a non-U.S. shell bank or providing banking services indirectly to a non-U.S. shell
bank. The Purchaser agrees to provide law enforcement agencies, if requested thereby, such records as required by applicable
law, provided that the Purchaser is permitted to do so under applicable law. If the Purchaser is a financial institution
subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.), as amended by the USA PATRIOT Act of 2001, and its
implementing regulations (collectively, the “BSA/PATRIOT Act”), the Purchaser maintains policies and
procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. To the extent required, the
Purchaser maintains policies and procedures reasonably designed for the screening of its investors against the OFAC sanctions
programs, including the OFAC List. To the extent required, the Purchaser maintains policies and procedures reasonably
designed to ensure that the funds held by it and used to purchase the Shares allocated to it were legally derived.

 

(5)            None
of (i) the Purchaser, (ii) any of its directors, executive officers, other officers that may serve as a director or officer
of any company in which it invests, general partners or managing members, nor (iii) any beneficial owner of the Company’s
voting equity securities (in accordance with Rule 506(d) of the Securities Act) held by the Purchaser is subject to any
of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act
(a “Disqualification Event”), except for Disqualification Events covered by Rule 506(d)(2)(ii) or
(iii) or (d)(3) under the Securities Act and disclosed reasonably in advance of the Closing in writing in reasonable
detail to the Company.

 

(6)            The
Purchaser does not hold Plan Assets.

 

(7)            The
Purchaser understands that the Shares are being offered and sold to it in reliance on specific exemptions from the registration
requirements of the United States federal and state securities laws and that the Company is relying in part upon the truth and
accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of the Purchaser set forth herein in order to determine the availability of such exemptions.

 

(d)            Financial
Capability. The Purchaser at the Closing will have available funds necessary for it to consummate the Closing on the
terms and conditions contemplated by this Agreement. The Purchaser is not aware as of the date hereof of any reason why the
funds sufficient to fulfill its obligations under Article I will not be available at the Closing. The Purchase
Price to be paid by the Purchaser, together with the purchase price for any shares of Class A Common Stock held by the
Purchaser prior to the Closing, is less than the maximum amount that the Purchaser is permitted to invest in any one
portfolio investment pursuant to the terms of its organizational or governing documents or otherwise. The Purchaser has
uncalled capital commitments or otherwise has available funds in excess of its portion of the Purchase Price and all
other unfunded contractually binding equity commitments of the Purchaser that are currently outstanding.

 

(e)            Brokers
and Finders. Neither the Purchaser nor its Affiliates or any of their respective officers, directors, employees or agents has
employed any broker or finder for which the Company will incur any liability for any financial advisory fees, brokerage fees, commissions
or finder’s fees.

 

    14 

     

    

 

 

(f)            Ownership
of Common Stock. As of the date of this Agreement, except as publicly disclosed by the Purchaser prior to the date hereof,
neither the Purchaser nor any of its Affiliates owns (directly or indirectly, beneficially or of record) any shares of Common Stock
and neither the Purchaser nor any of its Affiliates holds any rights to acquire or vote any shares of Common Stock except pursuant
to this Agreement. Except as publicly disclosed prior to the date hereof, as of the date hereof, there are no Contracts between
the Purchaser, on the one hand, and any member of the Company’s management or directors, on the other hand, that relate in
any way to the transactions contemplated hereby.

 

(g)            No
Additional Representations. Except for the representations and warranties made by the Company in this Section 2.2,
none of the Purchaser or any of its Affiliates or representatives makes any other representation or warranty of any kind or nature
whatsoever, oral or written, express or implied, with respect to itself, its Affiliates, their respective businesses, this Agreement,
any Ancillary Document or the transactions contemplated by the Agreement.

 

Article III

 

COVENANTS

 

3.1            Confidentiality.
Subject to Section 5.3, each party to this Agreement will hold, and will cause its respective Affiliates and
their respective directors, managers, officers, employees, agents, consultants and advisors to hold, in strict confidence,
unless disclosure to a regulatory authority is reasonably necessary in connection with any reasonably necessary regulatory
approval, examination or inspection or unless disclosure is required by judicial or administrative process or by other
requirement of law or the applicable requirements or request of any regulatory agency or relevant stock exchange (in which
case, other than in connection with a disclosure in connection with a routine audit or examination by, or document request
from, a regulatory or self-regulatory authority, bank examiner or auditor, the party disclosing such Information shall, to
the extent permissible under applicable law, rule or regulation, provide the other party with prior written notice of
such permitted disclosure), all non-public records, books, contracts, instruments, computer data and other data and
information (collectively, “Information”) concerning the other party hereto furnished to it by or on
behalf of such other party or its representatives pursuant to this Agreement (except to the extent that such information can
be shown to have been (1) previously known by such party from other sources, provided that such source was not known,
after reasonable inquiry and investigation, by such party to be bound by a contractual, legal or fiduciary obligation
of confidentiality to the other party, (2) in the public domain through no violation of this Section 3.1 by
such party or (3) later lawfully acquired from other sources by the party to which it was furnished), and neither party
hereto shall release or disclose such Information to any other person, except its auditors, investment managers, attorneys,
financial advisors, financing sources and other consultants and advisors (including, in each case, their respective employees
and representatives).

 

    15 

     

    

 

3.2            Listing.
At or prior to the Closing, the Company shall use its reasonable best efforts to cause Nasdaq to have completed its review of a
“Listing of Additional Shares Notification Form” for listing of the
shares of Class A Common Stock issuable upon the conversion of the Series B-1 Preferred Stock into which the Series B-2
Preferred Stock issued to the Purchaser pursuant to this Agreement is convertible on the Nasdaq Capital Market (“Nasdaq
CM”). From time to time following the Closing Date, in the event the number of shares of Class A Common Stock into
which such shares of Series B-1 Preferred Stock is convertible increases under the Certificates of Designations, the Company
shall, as necessary to maintain the listing of the Conversion Shares, apply to cause the number of shares of Class A Common
Stock issuable upon conversion of the then outstanding shares of Series B-1 Preferred Stock and, if applicable, Series B-2
Preferred Stock to be listed on the Nasdaq CM.

 

3.3            Efforts.
Subject to the other terms and conditions of this Agreement, each of the parties hereto shall use its respective reasonable best
efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary, proper or advisable
under this Agreement and applicable Law to, as promptly as reasonably practicable following the date of this Agreement, consummate
the Closing.

 

3.4            Reserved.

 

3.5            Reserved.

 

3.6            Corporate
Actions.

 

(a)            At
any time that any Series B-2 Preferred Stock is outstanding, the Company shall from time to time take all lawful action within
its control to cause the authorized capital stock of the Company to include a sufficient number of authorized but unissued shares
of Series B-1 Preferred Stock and Class A Common Stock to satisfy the direct and indirect conversion requirements of
all shares of the Series B-2 Preferred Stock then outstanding (including the requirement to issue shares of Class A Common
Stock upon the conversion of Series B-1 Preferred Stock into which shares of Series B-2 Preferred Stock may be converted),
based solely on the conversion rate then in effect (and without regard to any limitation on the conversion thereof, including the
4.9% Cap (as defined in the Series B-1 Certificate of Designations) and the Share Cap (as defined in the Series B-2 Certificate
of Designations).

 

(b)            Prior
to or upon the Closing, the Company shall file with the Secretary of State of the State of Delaware the Series B-2 Certificate
of Designations, in the form attached hereto as Annex I.

 

(c)            If
any occurrence since the date of this Agreement until the Closing would have resulted in an adjustment to the Conversion Rate pursuant
to any Certificate of Designations (including Sections 10 and 11 of the Series B-2 Certificate of Designation) if the series
of Preferred Stock subject to such Certificate of Designations had been issued and outstanding since the date of this Agreement,
and such series of Preferred Stock is not issued and outstanding as of the date of such occurrence, the Company shall adjust the
Conversion Rate with respect to such series of Preferred Stock, effective as of the Closing, in the same manner as would have been
required by the applicable Certificate of Designations if such series of Preferred Stock had been issued and outstanding since
the date of this Agreement.

 

    16 

     

    

 

(d)            At
any time that any Series B-2 Preferred Stock or any Series B-1 Preferred Stock is outstanding, the Company shall not
adopt any stockholder rights agreement, “poison pill” or similar anti-takeover agreement or plan that is applicable
to the Purchaser unless the Company has excluded the Purchaser from the definition of “acquiring person” (or such similar
term) as such term is defined in such anti-takeover agreement to the extent of the Purchaser’s beneficial ownership of Preferred
Stock or Common Stock owned as of the date any such agreement or plan is adopted by the Company.

 

3.7            Negative
Covenants. Except as required by applicable Law or to comply with any notice from a Governmental Entity, as expressly contemplated,
required or permitted by this Agreement or as described in Section 3.7 of the Company Disclosure Schedule, during the
period from the date of this Agreement until (x) in the case of clauses (b) through (d) below, the Closing Date
(or such earlier date on which this Agreement may be terminated pursuant to Section 6.15) and (y) in the case
of clause (a) below, the date on which the first Company Stockholders’ Meeting is held at which the Conversion Proposal
is submitted to the holders of Common Stock for purposes of obtaining the Company Stockholder Approval (or such earlier date on
which this Agreement may be terminated pursuant to Section 6.15), unless the Purchaser otherwise consents in writing
(such consent not to be unreasonably withheld, conditioned or delayed), the Company shall not:

 

(a)            other
than the authorization and issuance of the Series B-2 Preferred Stock to the Purchaser and the consummation of the other transactions
contemplated hereunder and under the Acquisition Agreement, issue, sell or grant any shares of its capital stock or other equity
or voting interests, or any securities or rights convertible into, exchangeable or exercisable for, or evidencing the right to
subscribe for any shares of its capital stock or other equity or voting interests, or any rights, warrants or options to purchase
any shares of its capital stock or other equity or voting interests, in each case, following which the Voting Parties would beneficially
own less than a majority of the outstanding equity interests eligible to vote for the Company Stockholder Approval;

 

(b)            establish
a record date for, declare, set aside for payment or pay any dividend on, or make any other distribution in respect of, any shares
of its capital stock or other equity or voting interests;

 

(c)            amend,
alter, repeal or otherwise modify (whether by merger, consolidation or otherwise) any provision of the Certificate of Incorporation
in a manner that would adversely affect the powers, preferences, rights or privileges of the Series B-2 Preferred Stock or
the Purchaser’s investment therein; or

 

(d)            agree
or commit to do any of the foregoing.

 

3.8            Tax
Matters. The Purchaser and the Company agree (i) not to treat the Series B-2 Preferred Stock (based on its terms
as set forth in the Series B-2 Certificate of Designations) as “preferred stock” within the meaning of Section 305
of the Code and Treasury Regulation Section 1.305-5 and (ii) to not take a reporting position that the holders of Series B-2
Preferred Stock are required to include as dividend income any amounts in respect of the Series B-2 Preferred Stock unless
and until dividends on the Series B-2 Preferred Stock are paid in cash or other property, in each case, for United States
federal income tax and withholding tax purposes.

 

    17 

     

    

 

3.9            Stockholder
Approval.

 

(a)            As
promptly as reasonably practicable after the execution of this Agreement, and in any event no later than the first to occur
of (x) the thirtieth (30th) day following the date on which the Company receives the Target Financial
Statements, and (y) the fifteenth (15th) day following the Closing Date, the Company shall prepare the Proxy
Statement in preliminary form and file it with the SEC. The Board of Directors shall recommend to the Company’s
stockholders that the holders of the Common Stock approve the transactions contemplated hereunder and shall include such
recommendation in the Proxy Statement. The Purchaser shall provide to the Company all information concerning the Purchaser
and its Affiliates as may be reasonably requested by the Company in connection with the Proxy Statement and shall otherwise
assist and cooperate with the Company in the preparation of the Proxy Statement and the resolution of any comments thereto
received from the SEC. Each of the Company and the Purchaser shall promptly correct any information provided by it for use in
the Proxy Statement if and to the extent such information shall have become false or misleading in any material
respect. Subject to Sections 5.3, the Company shall notify the Purchaser promptly upon the receipt of any comments from
the SEC and of any request by the SEC for amendments or supplements to the Proxy Statement and shall supply the Purchaser
with copies of all written correspondence between the Company or any of its representatives, on the one hand, and the SEC, on
the other hand, with respect to the Proxy Statement. The Company shall use its reasonable best efforts to respond as
promptly as reasonably practicable to any comments received from the SEC concerning the Proxy Statement and to resolve such
comments with the SEC, and shall use its reasonable best efforts to cause the Proxy Statement to be disseminated to its
stockholders as promptly as reasonably practicable after the resolution of any such comments. Prior to the filing of the
Proxy Statement (or any amendment or supplement thereto) or any dissemination thereof to the stockholders of the Company, or
responding to any comments from the SEC with respect thereto, the Company shall provide the Purchaser with a
reasonable opportunity to review and to propose comments on such document or response, which the Company shall consider in
good faith. The Company shall inform Legal Counsel promptly (and in any event within two business days) of the receipt of the
Target Financial Statements (or the purported delivery of the Target Financial Statements by Solara Holdings, LLC).

 

(b)            Subject
to Section 3.9(a), the Company shall take all necessary actions in accordance with applicable Law, the organizational
documents of the Company and the rules of Nasdaq to duly call, give notice of, convene and hold a meeting of its stockholders
(including any adjournment, recess or postponement thereof, the “Company Stockholders’ Meeting”) for the
purpose of obtaining the Company Stockholder Approval as soon as reasonably practicable after the SEC confirms that it has no further
comments on the Proxy Statement. The Company shall not submit any Additional Transaction for approval or adoption by the stockholders
of the Company prior to (x) (but the Company may submit an Additional Transaction contemporaneously with) the first Company
Stockholders’ Meeting at which the Conversion Proposal is submitted to the holders of Common Stock for purposes of obtaining
the Company Stockholder Approval or (y) if earlier, the termination of this Agreement in accordance with its terms if termination
occurs prior to the Closing; provided, however, that for the avoidance of doubt, any Additional Transaction shall not include any
of the matters set forth on the Company’s proxy statement filed with the SEC on April 29, 2020. The Company shall use
its reasonable best efforts to obtain the Company Stockholder Approval. Notwithstanding anything to the contrary contained in this
Agreement, the Company may, in its sole discretion, adjourn, recess, or postpone the Company Stockholders’ Meeting (i) after
consultation with the Purchaser, to the extent necessary to ensure that any required supplement or amendment to the Proxy Statement
is provided to the stockholders of the Company within a reasonable amount of time in advance of the Company Stockholders’
Meeting, (ii) if as of the time for which the Company Stockholders’ Meeting is originally scheduled (as set forth in
the Proxy Statement) there are insufficient shares of Common Stock represented (either in person or by proxy) to constitute a quorum
necessary to conduct the business of the Company Stockholders’ Meeting or (iii) to solicit additional proxies if the
Company reasonably believes it may be necessary to obtain the Company Stockholder Approval.

 

    18 

     

    

 

(c)            Each
Purchaser agrees during the term of this Agreement to vote the Common Stock of the Company held by such Purchaser, and to
cause any Affiliate of such Purchaser to which such Purchaser Transfers Common Stock of the Company to agree to vote such
Common Stock: (i) in favor of the Conversion Proposal at every meeting of the stockholders of the Company at which such
matters are considered and at every adjournment or postponement thereof; and (ii) against (1) any action, proposal,
transaction or agreement which would result in a breach of any covenant, representation or warranty or any other obligation
or agreement of the Purchasers under this Section 3.9(c) and (2) any action, proposal, transaction or
agreement that would reasonably be expected to impede, interfere with, delay, discourage, adversely affect or inhibit the
Company Stockholder Approval, including any change in any manner to the voting rights of any class of shares of the Company
(including any amendments to the certificate of incorporation or bylaws of the Company) (provided, however, that the dilution
of voting rights through the authorization or issuance of additional shares of capital stock of the Company not
otherwise in breach of the restrictions set forth in Section 3.7 shall not be deemed a change in any manner to the
voting rights).

 

(d)            The
Company shall use its reasonable best efforts to enforce the obligations of each of the stockholders of the Company party to a
Voting Agreement, including through the exercise of proxies provided thereunder, to the extent necessary or appropriate to cause
each such stockholder to (i) appear at the Company Stockholders Meeting or otherwise cause the shares of Common Stock outstanding
and beneficially owned by such stockholder to be counted as present thereat for purposes of calculating a quorum, and (ii) vote,
or cause to be voted, all of the shares of Common Stock outstanding and beneficially owned by such stockholder in favor of the
removal of the Conversion Restriction (as such term is defined in the Series B-2 Certificate of Designations) at the Company
Stockholders Meeting. Without limiting the foregoing, from the date hereof through the date of the first Company Stockholders’
Meeting to be held after the Closing for the Company Stockholder Approval, the Company hereby covenants and agrees that it will
not, by amendment of the Certificate of Incorporation or the By-laws or otherwise, take any action that has the purpose or effect
of (y) materially reducing the likelihood of obtaining, or causing a material delay in obtaining, the Company Stockholder
Approval, or (z) enabling the parties to the Voting Agreements to circumvent their obligations thereunder.

 

3.10            [Reserved].

 

Article IV

 

SURVIVAL

 

    19 

     

    

 

4.1            Survival.
The representations and warranties of the parties contained in this Agreement shall survive for twelve (12) months following the
Closing. All of the covenants or other agreements of the parties contained in this Agreement to be performed prior to the Closing
shall terminate at the Closing. All covenants or agreements of the parties contained in this Agreement to be performed following
the Closing shall survive until fully performed or fulfilled, unless and to the extent that non-compliance with such covenants
or agreements is waived in writing by the party entitled to such performance.

 

Article V

 

SHAREHOLDER RIGHTS

 

5.1            Information
Rights. From and after the date hereof and for so long as the Purchaser and its Affiliates hold at least 25% of the Shares,
on an as-converted basis, issued to the Purchaser hereunder, the Company will permit the Purchaser and its representatives, at
the Purchaser’s expense, to reasonable and customary rights to the information of the Company and access to management of
the Company as reasonably requested by the Purchaser, all at such reasonable times and as often as may be reasonably requested.

 

(a)            [Reserved].

 

(b)            [Reserved].

 

5.2            Transfer
Restrictions.

 

(a)            Other
than Permitted Transfers, the Purchaser agrees that it shall not Transfer any Shares, or the other Securities into which the Shares
are converted (together, the “Prohibited Shares”) during the period commencing on the Closing Date and continuing
until the sixtieth (60th) day after the Closing Date (such date, the “Restricted Period Termination Date”).

 

(b)            “Permitted
Transfer” means, in each case so long as such Transfer is in accordance with applicable Law:

 

(1)            a
Transfer of Prohibited Shares to Affiliates of the Purchaser, so long as such transferee, to the extent it has not already done
so, executes a customary joinder to this Section 5.3, in form and substance reasonably acceptable to the Company, in which
such transferee agrees to be subject to the restrictions on Transfer in this Section 5.3;

 

(2)            a
Transfer of Prohibited Shares as a distribution in-kind to the Purchaser’s investors, and to their subsequent investors,
including limited partners, so long as all such transferees, to the extent it has not already done so, executes a customary joinder
to this Section 5.3, in form and substance reasonably acceptable to the Company, in which such transferee agrees to be subject
to the restrictions on Transfer in this Section 5.3;

 

(3)            a
Transfer of Prohibited Shares in connection with the exercise of piggyback registration rights set forth in the Amended and Restated
Registration Rights Agreement;

 

    20 

     

    

 

 

(4)            a
Transfer of Prohibited Shares in connection with a sale of the Company approved by the Board of Directors or in connection with
a tender offer into which a majority of the Unaffiliated Shareholders of the Company have tendered their respective Shares;

 

(5)            a
Transfer of Prohibited Shares to the Company; and

 

(6)            a
Transfer of Prohibited Shares following a voluntary filing by the Company of a petition for relief under the United States Bankruptcy
Code.

 

(c)            Notwithstanding
anything to the contrary contained herein, including the occurrence of the Restricted Period Termination Date, the Purchaser
acknowledges that the Prohibited Shares may not be Transferred other than pursuant to a registered offering or in accordance
with an exemption from registration. No Transfers of Prohibited Shares shall be made to a person that, to Purchaser’s
knowledge, is a competitor of the Company set forth on Schedule C attached hereto or becomes a competitor of the
Company after the date hereof, as set forth on a quarterly or annual report filed by the Company with the SEC;
provided, however, that nothing contained in this Section 5.3(c) shall prohibit any Transfer of Prohibited Shares
on an exchange or otherwise in open market transactions or non-privately negotiated transactions or to a hedge fund or other
institutional investor, other than a hedge fund or other institutional investor that is known by the Purchaser after
reasonable inquiry to hold more than five percent (5%) of the outstanding securities of any such competitor.

 

5.3            Form 8-K;
Material Non-public Information.

 

(a)            On
or prior to June 26, 2020, the Company shall file with the SEC one or more Forms 8-K describing the terms of the transactions
contemplated by this Agreement and the Ancillary Documents and including as exhibits to such Form(s) 8-K this Agreement, the
form of Amended and Restated Registration Rights Agreement, the form of Voting Agreement and the form of Series B-2 Certificate
of Designations, in each case, without redaction (such Form or Forms 8-K, collectively, the “Announcing Form 8-K”).
At or prior to 8:00 a.m. (New York City time) on the first business day following the Closing Date, the Company shall file
a Form 8-K with the SEC disclosing the occurrence of the Closing and the Target Acquisition Closing and any other material
transactions occurring in connection therewith (the “Closing Form 8-K” and, together with the Announcing
Form 8-K, the “Transaction 8-Ks”).

 

(b)            The
Company shall not, and shall cause each of its employees, officers, directors (or equivalent persons), Affiliates, attorneys, agents
and representatives on its behalf to not, provide the Purchaser or any of its Affiliates, attorneys, agents or representatives
on its behalf with any material nonpublic information regarding the Company, any Subsidiary of the Company, their respective securities,
any of their respective Affiliates or any other person or entity (including the Target Acquisition) from and after the filing of
the Announcing Form 8-K with the SEC without the express prior written consent of the Purchaser, other than prior to the Closing
as necessary to consummate the transactions contemplated hereby.

 

    21 

     

    

 

(c)            Notwithstanding
anything to the contrary herein, in the event that the Company believes that a notice or communication to the Purchaser or
any of its Affiliates, attorneys, agents or representatives contains material, nonpublic information relating to the Company,
its Subsidiaries, any of their respective securities, any of their respective Affiliates or any other person, the Company
shall so indicate to the Purchaser prior to delivery of such notice or communication, and such indication shall provide the
Purchaser the means to refuse to receive such notice or communication (and in the absence of any such indication, the
Purchaser and its Affiliates, agents and representatives shall be allowed to presume that all matters relating to such notice
or communication do not constitute material, nonpublic information relating to the Company, its Subsidiaries, any of their
respective securities, any of their Affiliates or any other person) and provide such notice or communication to Legal
Counsel. Notwithstanding the foregoing, to the extent the Company reasonably and in good faith determines that it is
necessary to disclose material non-public information to the Purchaser for purposes relating to this Agreement or any of the
Ancillary Documents (a “Necessary Disclosure”) or that the Company believes that indication referred to in
the foregoing sentence would itself constitute material, nonpublic information relating to the Company (in which case the
Company shall not be deemed to be in breach of any obligation to provide notice to Purchaser or any of its Affiliates subject
to its compliance with the terms of this Section 5.3(c)), the Company shall inform Legal Counsel of such
determination without disclosing the applicable material non-public information, and the Company and such counsel on behalf
of the applicable Purchaser shall endeavor to agree upon a process for making such Necessary Disclosure to the applicable
Purchaser or its representatives that is mutually acceptable to the Purchaser and the Company (an “Agreed Disclosure
Process”). Thereafter, the Company shall be permitted to make such Necessary Disclosure (only) in accordance with
the Agreed Disclosure Process.

 

(d)            The
Company hereby acknowledges and agrees that, notwithstanding the provisions of Section 3.1 or any other contrary provision
contained herein, neither the Purchaser nor any of the Purchaser’s Affiliates, attorneys, agents or representatives shall
have any duty of trust or confidence (including any obligation under any confidentiality or non-disclosure agreement entered into
by the Purchaser) with respect to, or any obligation not to trade in any securities of the Company (or any other person or entity)
while aware of, any material nonpublic information (i) provided by, or on behalf of, the Company, any Subsidiary of the Company,
any of their respective Affiliates or any of their respective officers, directors (or equivalent persons), employees, attorneys,
agents or representatives in violation of any of the representations, covenants, provisions or agreements set forth in Sections
5.3 (a), (b) and (c) or (ii) otherwise possessed (or continued to be possessed) by the Purchaser (or any Affiliate,
agent or representative thereof) as a result of any breach or violation of any representation, covenant, provision or agreement
set forth in Section 5.3 (a), (b) or (c).

 

Article VI

 

MISCELLANEOUS

 

6.1            Expenses.
The Company shall, regardless of whether any transaction contemplated hereby is consummated, reimburse the Purchaser for its reasonable
and documented out-of-pocket third-party costs and expenses (including legal fees) incurred in connection with due diligence, the
negotiation and preparation of the Letter Agreement, the agreements and instruments contemplated thereby,, including this Agreement,
and including the negotiation and preparation of a draft investment agreement and certificates of designation in connection with
the Purchaser’s and any of its Affiliates’ proposed investment in Series A Preferred Stock prior to the date of
the Letter Agreement, and any other agreement or transaction contemplated hereby or thereby and undertaking of the transactions
contemplated pursuant to this Agreement; provided, that such reimbursement obligation shall not exceed $250,000 in the aggregate.
Any such reimbursement shall be made promptly following submission of invoices in respect of the costs and expenses at or following
the first to occur of (x) the closing of the transactions contemplated by this Agreement, the (y) consummation of the
transactions contemplated by the Stock Purchase Agreement and (z) the termination of the Stock Purchase Agreement. The Company
will bear and pay all costs and expenses incurred by it or on its behalf in connection with the transactions contemplated pursuant
to this Agreement, including the fees and expenses of attorneys, accountants, investment bankers and consultants.

 

    22 

     

    

 

6.2            Amendment;
Waiver. No amendment or waiver of any provision of this Agreement will be effective with respect to any party unless made in
writing and signed by an officer of a duly authorized representative of such party. No failure or delay by any party in exercising
any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude
any other or further exercise thereof or the exercise of any other right, power or privilege. The conditions to each party’s
obligation to consummate the Closing are for the sole benefit of such party and may be waived by such party in whole or in part
to the extent permitted by applicable law. No waiver of any party to this Agreement will be effective unless it is in a writing
signed by a duly authorized officer of the waiving party that makes express reference to the provision or provisions subject to
such waiver. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by
law.

 

6.3            Counterparts;
Electronic Transmission. For the convenience of the parties hereto, this Agreement may be executed in any number of separate
counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts will together constitute
the same agreement. Executed signature pages to this Agreement may be delivered by facsimile or other means of electronic
transmission and such facsimiles or other means of electronic transmission will be deemed as sufficient as if actual signature
pages had been delivered.

 

6.4            Governing
Law. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware. The parties hereby
irrevocably and unconditionally consent to submit to the exclusive jurisdiction of the state and federal courts located in the
State of Delaware for any actions, suits or proceedings arising out of or relating to this Agreement and the transactions contemplated
hereby. The parties hereby irrevocably and unconditionally consent to the jurisdiction of such courts (and of the appropriate appellate
courts therefrom) in any such action, suit or proceeding and irrevocably waive, to the fullest extent permitted by law, any objection
that they may now or hereafter have to the laying of the venue of any such action, suit or proceeding in any such court or that
any such action, suit or proceeding which is brought in any such court has been brought in an inconvenient forum. Process in any
such action, suit or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of
any such court. Without limiting the foregoing, each party agrees that service of process on such party as provided in Section 6.6
shall be deemed effective service of process on such party.

 

    23 

     

    

 

6.5            WAIVER
OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

6.6            Notices.
Any notice, request, instruction or other document to be given hereunder by any party to the other will be in writing and
will be deemed to have been duly given (a) on the date of delivery if delivered personally or by telecopy,
facsimile or electronic mail (so long as such transmission does not generate an error message
or notice of non-delivery), (b) on the first business day following the date of dispatch if delivered by a recognized
next-day courier service, or (c) on the third business day following the date of mailing if delivered by registered or
certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered as set forth below, or
pursuant to such other instructions as may be designated in writing by the party to receive such notice.

 

If to the Purchaser:

 

c/o Deerfield Management
Company L.P.

780 Third Avenue, 37th Floor

New York, NY 10017

Attn:     David J. Clark

Email:    dclark@deerfield.com

 

with a copy to:

 

Katten Muchin Rosenman
LLP 

525 W. Monroe Street

Chicago, Illinois 60661

Attn:     Mark D. Wood, Esq.

Email:    mark.wood@katten.com

 

If to the Company:

 

AdaptHealth Corp.

220 West Germantown Pike Suite 250

Plymouth Meeting, PA
19462

Attention: General Counsel

E-mail: cjoyce@adapthealth.com

 

with a copy to:

 

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, NY 10019

Attention: Steven J. Gartner

Michael E. Brandt

Danielle Scalzo

E-mail: sgartner@willkie.com

mbrandt@willkie.com

dscalzo@willkie.com

Facsimile: 212-728-9962

 

    24 

     

    

 

6.7            Entire
Agreement. This Agreement (including the Schedules hereto and the documents and instruments referred to in this Agreement)
constitutes the entire agreement among the parties and supersedes all other prior agreements and understandings, both written and
oral, between the parties with respect to the subject matter hereof and transactions contemplated hereby. For the avoidance of
doubt, the provisions of this Agreement shall only supersede the Letter Agreement with respect to the subject matter hereof, and
shall not supersede the Letter Agreement with respect to any other matters set forth therein.

 

6.8            Assignment.
Neither this Agreement, nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto
(whether by operation of Law or otherwise) without the prior written consent of the other party; provided, however, that (a) prior
to the Closing, the Purchaser may assign its rights, interests and obligations under this Agreement, in whole or in part, to one
or more of its Affiliates and/or Related Funds, and (b) from and after the Closing, the Purchaser may assign its rights, interests
and obligations under this Agreement, in whole or in part, to any assignee of any Securities, and in the event of any such assignment,
the assignee shall agree in writing to be bound by the provisions of this Agreement, including the rights, interests and obligations
so assigned; provided that no such assignment will relieve the Purchaser of its obligations hereunder.

 

6.9            Interpretation;
Other Definitions. Wherever required by the context of this Agreement, the singular shall include the plural and vice versa,
and the masculine gender shall include the feminine and neuter genders and vice versa, and references to any agreement, document
or instrument shall be deemed to refer to such agreement, document or instrument as amended, supplemented or modified from time
to time. All article, section, paragraph or clause references not attributed to a particular document shall be references to such
parts of this Agreement, and all exhibit, annex, letter and schedule references not attributed to a particular document shall be
references to such exhibits, annexes, letters and schedules to this Agreement. In addition, the following terms are ascribed the
following meanings:

 

(a)            the
word “or” is not exclusive;

 

(b)            the
words “including,” “includes,” “included” and “include”
are deemed to be followed by the words “without limitation”;

 

(c)            the
terms “herein,” “hereof” and “hereunder” and other words of similar import
refer to this Agreement as a whole and not to any particular section, paragraph or subdivision;

 

    25 

     

    

 

(d)            “beneficial
owner,” “beneficially own” or “beneficial ownership” has the meaning assigned
to such term in Rule 13d-3 under the Exchange Act, and a person or entity’s beneficial ownership of
securities shall be calculated in accordance with the provisions of such Rule (in each case, irrespective of whether or
not such Rule is actually applicable in such circumstance).

 

(e)            the
term “business day” means any day except Saturday, Sunday and any day which shall be a legal holiday or a day
on which banking institutions in the State of New York or State of Pennsylvania generally are authorized or required by law or
other governmental action to close; and

 

(f)            the
term “person” has the meaning given to it in Section 3(a)(9) of the Exchange Act and as used in Sections
13(d)(3) and 14(d)(2) of the Exchange Act.

 

(g)            “Affiliate”
means, with respect to any specified person, any other person that, at the time of determination, directly or indirectly through
one or more intermediaries, controls, is controlled by or is under common control with such specified person. Without limiting
the foregoing, with respect to the Purchaser, any investment fund or managed account that is managed on a discretionary basis by
the same investment manager as the Purchaser shall be deemed an Affiliate of the Purchaser.

 

(h)            “Additional
Transaction” means, in each case involving any person other than the Purchaser or one of its Affiliates, any (i) sale,
lease, assignment, exchange or other transfer or disposition directly or indirectly by merger, consolidation, business combination,
share exchange, joint venture or otherwise of assets of the Company or any Subsidiary; (ii) issuance, sale or other disposition,
directly or indirectly (including, without limitation, by way of merger, consolidation, business combination, share exchange, joint
venture or any similar transaction), of securities (or options, rights, or warrants to purchase, or securities convertible into
or exchangeable for, such securities), including without limitation capital stock, partnership interests, membership interests
or other instruments directly or indirectly convertible into, exchangeable or exercisable for, or the value of which is determined
with reference to, Equity Securities of the Company or any of its Subsidiaries; (iii) tender offer or exchange offer as defined
pursuant to the Exchange Act that, if consummated, would result in any person beneficially owning any class or series (or the voting
power of any class or series) of Equity Securities of the Company or any of its Subsidiaries or any other transaction in which
any person shall acquire beneficial ownership or the right to acquire beneficial ownership, of any class or series (or the voting
power of any class or series) of Equity Securities; or (iv) combination of the foregoing (in each case, other than the arrangements
contemplated hereunder).

 

(i)            “Amended
and Restated Registration Rights Agreement” means the Amended and Restated Registration Rights Agreement in the form
attached hereto as Annex II; provided, that the Company and the holders of a majority of Registrable Securities (as defined
in the form of Amended and Restated Registration Rights Agreement) shall be entitled to make amendments to the form of Amended
and Restated Registration Rights Agreement to the extent that such amendments could be made following the effectiveness thereof
after giving effect to the acquisition by Purchaser of the Shares contemplated hereby;

 

    26 

     

    

 

(j)            “as-converted
basis” means with respect to the outstanding shares of Common Stock as of any date, all outstanding shares of Common
Stock calculated on a basis in which all shares of Common Stock issuable upon conversion of the outstanding shares of Series B-1
Preferred Stock (including the shares of Series B-1 Preferred Stock issuable upon conversion of Series B-2 Preferred
Stock, as applicable) at the Conversion Rate in effect on such date as set forth in the applicable Certificate of Designations),
are assumed to be outstanding as of such date, disregarding any restrictions or limitations upon the conversion of such Series B-2
Preferred Stock or Series B-1 Preferred Stock, as applicable.

 

(k)            “Certificates
of Designations” means the Series B-2 Certificate of Designation and the Series B-1 Certificate of Designations.

 

(l)            “Company
Material Adverse Effect” means any change, effect, event, occurrence, condition, state of facts or development
that, either alone or in combination, has had, or would be reasonably expected to have, (a) a materially adverse effect
on the business, operations, assets, liabilities or condition (financial or otherwise) or results of operations of the
Company, taken as a whole; provided, however, that none of the following shall constitute or be deemed to
contribute to a Company Material Adverse Effect, or shall otherwise be taken into account in determining whether a Company
Material Adverse Effect has occurred or would be reasonably likely to occur: any adverse effect arising out of, resulting
from or attributable to (i) (A) the economy generally or credit, currency, oil, financial, banking, securities,
capital markets or financial markets generally (including increased cost, or decreased availability, of capital or pricing or
terms related to any financing for the transactions contemplated hereunder or any disruption thereof and any decline in the
price of any security, commodity or market index), including changes in interest or exchange rates, and (B) changes or
conditions generally affecting the industry or markets in which the Company participates, (ii) any changes or
prospective changes in applicable Law, GAAP, or the enforcement or interpretation thereof after the date hereof or any action
required to be taken under any Law by which the Company or its Subsidiaries (or any of their respective assets or properties)
is bound, (iii) any international or national political, regulatory or social conditions, hostilities, cyber-attack, act
of war, sabotage, terrorism, declaration of national emergency or military actions, or any escalation or worsening of any
such hostilities, cyber-attack, act of war, sabotage, terrorism, declaration of national emergency or military actions,
(iv) the failure of the Company to meet or achieve the results set forth in any internal budget, plan, projection or
forecast; provided that this clause (iv) will not prevent a determination that any change, effect or other cause
underlying such failure to meet budgets, plans, projections or forecasts has resulted in or contributed to a Company Material
Adverse Effect, (v) actions of the Company expressly required by the terms of this Agreement or taken with the prior
written consent of the Purchaser, (vi) the negotiation or execution of this Agreement or any other Ancillary Document or
announcement, pendency or consummation of this Agreement or the transactions contemplated hereby or thereby or the identity,
nature or ownership of the Purchaser, including the impact thereof on the relationships, contractual or otherwise, of the
Company or any of its Subsidiaries with any of its or their business relations or employees, (vii) epidemics, pandemics
or disease or virus outbreaks (including the COVID-19 virus) or (viii) hurricanes, earthquakes, tsunamis,
tornados, mudslides, floods or other natural disasters, weather conditions, explosions or fires or other force majeure events
or acts of God, whether or not caused by any person, or any national or international calamity or crisis; provided
that the matters described in clauses (i), (iii) and (viii) shall be included and taken into account in the term
 “Company Material Adverse Effect” to the extent any such matter has a disproportionate adverse impact on the
business, operations, assets, liabilities or condition (financial or otherwise) or results of operations of the Company,
taken as a whole, relative to the other participants in the industries in which they operate; and (b) a material
impairment on or material delay in the ability of the Company to perform its material obligations under this Agreement or any
Ancillary Document or to consummate the transactions contemplated by this Agreement and/or the Ancillary Documents.

 

    27 

     

    

 

(m)            “Contract”
means any contract, agreement, instrument, undertaking, indenture, commitment, loan, license, settlement, consent, note or other
legally binding obligation (whether or not in writing).

 

(n)            “Conversion
Rate” has the meaning set forth in the applicable Certificate of Designations.

 

(o)            “Derivative
Instruments” means any and all derivative securities (as defined under Rule 16a-1 under the Exchange Act) that
increase in value as the value of any Equity Securities of the Company increases, including a long convertible security, a long
call option and a short put option position, in each case, regardless of whether (i) such derivative security conveys any
voting rights in any Equity Security, (ii) such derivative security is required to be, or is capable of being, settled through
delivery of any Equity Security or (iii) other transactions that hedge the value of such derivative security.

 

(p)            “Effect”
means any change, event, effect, development or circumstance.

 

(q)            “Encumbrance”
means any mortgage, commitment, transfer restriction, deed of trust, pledge, option, power of sale, retention of title, right of
pre-emption, right of first refusal, executorial attachment, hypothecation, security interest, encumbrance, claim, lien or charge
of any kind, or an agreement, arrangement or obligation to create any of the foregoing.

 

(r)            “End
Date” means the date that is 150 days after the date hereof.

 

(s)            “Equity
Securities” means any and all (i) shares, interests, participations or other equivalents (however
designated) of capital stock or other voting securities of a corporation, any and all equivalent or analogous ownership
(or profit) or voting interests in a person (other than a corporation), (ii) securities convertible into or
exchangeable for shares, interests, participations or other equivalents (however designated) of capital stock or voting
securities of a corporation, and securities convertible into or exchangeable for any equivalent or analogous ownership (or
profit) or voting interests in a person (other than a corporation), and (iii) any and all warrants, rights or
options to purchase any of the foregoing, whether voting or nonvoting, and, in each case, whether or not such shares,
interests, participations, equivalents, securities, warrants, options, rights or other interests are authorized or
otherwise existing on any date of determination; provided that Equity Securities shall not include preferred stock that is
not convertible or exchangeable for common stock in a corporation.

 

(t)            “Fundamental
Representations” means the representations and warranties set forth in Sections 2.1(a)(1), (b)(1), (c),
(d) and (f).

 

    28 

     

    

 

(u)            “Governmental
Entity” means any court, administrative or regulatory agency or commission or other governmental or arbitral body or
authority or instrumentality, including the SEC and any state-controlled or owned corporation or enterprise, in each case whether
federal, state, local or foreign, and any applicable industry self-regulatory organization (including Nasdaq).

 

(v)            “Knowledge
of the Company” means the actual knowledge after reasonable inquiry of one or more of Luke McGee, Joshua Parnes, Christopher
Joyce, Wendy Russalesi, Gregg Holst, John Gentile, Shaw Rietkerk or Andy Palan.

 

(w)            “Law”
means any federal, state, local or foreign law, statute or ordinance, or any rule, code, treaty, constitution, regulation, judgment,
order, writ, injunction, ruling, decree, administrative interpretation or agency requirement of any Governmental Entity.

 

(x)            “Legal
Counsel” shall mean Katten Muchin Rosenman LLP (Attn: Mark D. Wood) or such other legal counsel as shall have been designated
in writing by the Purchaser.

 

(y)            “Lien”
means any mortgage, deed of trust, pledge, hypothecation, security interest, encumbrance, claim, escheat, encroachment, lien, charge
of any kind, option, easement, purchase right, right of first refusal, right of pre-emption, conditional sale agreement, covenant,
condition or other similar restriction (including restrictions on transfer) or any agreement to create any of the foregoing.

 

(z)             “Registration
Rights Agreement” means that certain Registration Rights Agreement, dated as of November 8, 2019, by and among AdaptHealth
Holdings LLC and certain other parties thereto, as amended.

 

(aa)           “Related
Fund” means any investment fund or managed account that is managed on a discretionary basis by the same investment manager
as the Purchaser.

 

(bb)          “Securities”
means the Shares, the shares of Series B-1 Preferred Stock issuable upon conversion of the Shares and the shares of Class A
Common Stock issuable upon conversion of such shares of Series B-1 Preferred Stock, collectively.

 

(cc)           “Series A
Preferred Stock” means the Series A Convertible Preferred Stock of the Company established pursuant to the Certificate
of Designation, Preferences and Rights of Series A Convertible Preferred Stock of the Company, in substantially the form attached
as Annex I to the Third Party Investment Agreement (without giving effect to any amendment or modification thereof).

 

(dd)     “Series B-1
Certificate of Designations” means that certificate of designation, preferences and rights with respect to the Series B-1
Preferred Stock of the Company, filed with the Secretary of State for the State of Delaware on June 24, 2020.

 

(ee)           “Series B-1
Preferred Stock” means the Series B-1 Convertible Preferred Stock of the Company established pursuant to the Series B-1
Certificate of Designations.

 

    29 

     

    

 

(ff)            “Subsidiary”
means, with respect to any person, (a) any corporation of which a majority of the total voting power of shares of capital
entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof
is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of such person
or a combination thereof, or (b) any partnership, limited liability company, association or other business entity of which
a majority of the partnership, limited liability company or other similar ownership interest is at the time owned or controlled,
directly or indirectly, by such person or one or more Subsidiaries of such person or a combination thereof. For purposes of this
definition, a person is deemed to have a majority ownership interest in a partnership, limited liability company, association or
other business entity if such person is allocated a majority of the gains or losses of such partnership, limited liability company,
association or other business entity or is or controls the managing member or general partner or similar position of such partnership,
limited liability company, association or other business entity.

 

(gg)          “Target
Acquisition” means the acquisition by the Company or one of its Subsidiaries of Solara Holdings, LLC.

 

(hh)          “Target
Financial Statements” means for purposes of Section 3.9, the 2019 Audited Financials (as defined in the Stock Purchase
Agreement as in effect on the date hereof).

 

(ii)            “Transfer”
means (i) any direct or indirect sale, lease, assignment, Encumbrance, disposition or other transfer (by operation of law
or otherwise), either voluntary or involuntary, or entry into any Contract, option or other arrangement or understanding with respect
to any sale, lease, assignment, Encumbrance, disposition or other transfer (by operation of law or otherwise), of any Equity Security
or (ii) to enter into any Derivative Instrument, swap or any other Contract, agreement, transaction or series of transactions
that hedges or transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of any Equity Security,
whether any such Derivative Instrument, swap, Contract, agreement, transaction or series of transactions is to be settled by delivery
of securities, in cash or otherwise; provided, however, that, notwithstanding anything to the contrary in this Agreement,
a Transfer shall not include the conversion of one or more shares of Series B-2 Preferred Stock into shares of Series B-1
Preferred Stock or the subsequent conversion of such shares of Series B-1 Preferred Stock into Class A Common Stock pursuant
to the Series B-1 Certificate of Designations.

 

(jj)             “Unaffiliated
Shareholders” means the shareholders of the Company, other than (1) the Purchaser, (2) any Affiliates or
representatives of the Purchaser or any person acting for or on behalf of the Purchaser or (3) any shareholder
that is a member of a “group” (within the meaning of Section 13(d) of the Exchange Act and the
rules and regulations promulgated thereunder) with the Purchaser.

 

(kk)           “Voting
Agreements” means those certain Voting Agreements, dated as of the date hereof, by and between the Company and each of
the Voting Parties.

 

6.10           Captions.
The article, section, paragraph and clause captions herein are for convenience of reference only, do not constitute part of this
Agreement and will not be deemed to limit or otherwise affect any of the provisions hereof.

 

    30 

     

    

 

6.11           Severability.
If any provision of this Agreement or the application thereof to any person (including the officers and directors of the parties
hereto) or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining
provisions hereof, or the application of such provision to persons or circumstances other than those as to which it has been held
invalid or unenforceable, will remain in full force and effect and shall in no way be affected, impaired or invalidated thereby,
so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any party. Upon such determination, the parties shall negotiate in good faith in an effort to agree upon a suitable and equitable
substitute provision to effect the original intent of the parties.

 

6.12           No
Third Party Beneficiaries. Nothing contained in this Agreement, expressed or implied, is intended to confer upon any person
or entity (including, for the avoidance of doubt, Solara Holdings, LLC) other than the parties hereto (and their permitted assigns),
any benefit, right or remedies.

 

6.13           Public
Announcements. Subject to Section 5.3 and each party’s disclosure obligations imposed by Law or regulation
or the rules of any stock exchange upon which its securities are listed, each of the parties hereto will cooperate with each
other in the development and distribution of all news releases and other public information disclosures with respect to this Agreement
and any of the transactions contemplated by this Agreement, and neither the Company nor the Purchaser will make any such news release
or public disclosure without first consulting with the other, and, in each case, also receiving the other’s consent (which
shall not be unreasonably withheld, conditioned or delayed) and each party shall coordinate with the party whose consent is required
with respect to any such news release or public disclosure.

 

6.14           Specific
Performance. The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that, without the
necessity of posting bond or other undertaking, the parties shall be entitled to specific performance of the terms hereof, this
being in addition to any other remedies to which they are entitled at law or equity, and in the event that any action or suit is
brought in equity to enforce the provisions of this Agreement, and no party will allege, and each party hereby waives, the defense
or counterclaim that there is an adequate remedy at law.

 

6.15          Termination.
Prior to the Closing, this Agreement may only be terminated:

 

(a)             by
mutual written agreement of the Company and the Purchaser;

 

(b)             by
the Company or the Purchaser, upon written notice to the other party, if the Closing has not occurred by the End Date (the “Outside
Date”); provided, however that the right to terminate this Agreement pursuant to this Section 6.15(b) shall
not be available to any party whose failure to materially comply with any of its obligations under this Agreement shall have been
the cause of, or shall have resulted in, the failure of the Closing to occur on or prior to such date;

 

(c)             by
the Company if (i) the Purchaser shall have breached any representation, warranty, covenant or agreement of the Purchaser
set forth in this Agreement, (ii) such breach or misrepresentation is not cured or capable of being cured by the Outside Date,
and (iii) such breach or misrepresentation would cause any of the conditions set forth in Sections 1.3(c)(1) or
1.3(c)(2) not to be satisfied; provided that the Company is not then in breach of this Agreement so as to cause
the conditions to the Closing set forth in either Section 1.3(a) or Section 1.3(b) to not (in
the absence of a waiver) be satisfied as of the Closing Date; or

 

    31 

     

    

 

(d)             by
the Purchaser if (i) the Company shall have breached any representation, warranty, covenant or agreement of the Company set
forth in this Agreement, (ii) such breach or misrepresentation is not cured or capable of being cured by the Outside Date,
and (iii) such breach or misrepresentation would cause any of the conditions set forth in Sections 1.3(b)(1) or
1.3(b)(2) not to be satisfied; provided that the Purchaser is not then in breach of this Agreement so as to
cause the conditions to the Closing set forth in either Section 1.3(a) or Section 1.3(c) to not
(in the absence of a waiver) be satisfied as of the Closing Date.

 

6.16          Effects
of Termination. In the event of any termination of this Agreement in accordance with Section 6.15, neither party
(or any of its Affiliates) shall have any liability or obligation to the other (or any of its Affiliates) under or in respect of
this Agreement, except to the extent of (A) any liability arising from any willful and material breach by such party of its
obligations of this Agreement arising prior to such termination and (B) any fraud or intentional or willful breach of this
Agreement. In the event of any such termination, this Agreement shall become void and have no effect, and the transactions contemplated
hereby shall be abandoned without further action by the parties hereto, in each case, except (x) as set forth in the preceding
sentence and (y) that the provisions of Sections 3.1 (Confidentiality), 6.2 to 6.14 (Amendment;
Waiver; Counterparts; Electronic Transmission; Governing Law; Waiver of Jury Trial; Notices;
Entire Agreement; Assignment; Interpretation; Other Definitions; Captions; Severability;
No Third Party Beneficiaries; Public Announcements; and Specific Performance), this Section 6.16
(Effects of Termination) and Section 6.17 (Non-Recourse) shall survive the termination of this Agreement.
In the event that this Agreement is validly terminated in accordance with its terms, the Company shall file with the SEC a Form 8-K
disclosing such termination no later than 8:00 a.m. (New York City time on the Trading Day immediately following such termination.

 

6.17          Non-Recourse.
This Agreement may only be enforced against, and any claims or causes of action that may be based upon, arise out of or relate
to this Agreement, or the negotiation, execution or performance of this Agreement may only be made against the entities that are
expressly identified as parties hereto, including entities that become parties hereto after the date hereof, including permitted
assignees and successors, or that agree in writing for the benefit of the Company to be bound by the terms of this Agreement applicable
to the Purchaser, and no former, current or future equityholders, controlling persons, directors, officers, employees, agents or
Affiliates of any party hereto or any former, current or future equityholder, controlling person, director, officer, employee,
general or limited partner, member, manager, advisor, agent or Affiliate of any of the foregoing (each, a “Non-Recourse
Party”) shall have any liability for any obligations or liabilities of the parties to this Agreement or for any claim
(whether in tort, contract or otherwise) based on, in respect of, or by reason of, the transactions contemplated hereby or in respect
of any representations made or alleged to be made in connection herewith. Without limiting the rights of any party against the
other parties hereto, in no event shall any party or any of its Affiliates seek to enforce this Agreement against, make any claims
for breach of this Agreement against, or seek to recover monetary damages from, any Non-Recourse Party.

 

    32 

     

    

 

6.18          No
Fiduciary Relationship. The Company acknowledges and agrees that (a) the Purchaser is acting at arm’s length from
the Company with respect to this Agreement and the other Ancillary Documents and the transactions contemplated hereby and thereby;
(b) the Purchaser will not, solely by virtue of this Agreement or any of the other Ancillary Documents or any transaction
contemplated hereby or thereby, become an Affiliate of, or have any agency, tenancy or joint venture relationship with, the Company;
(c) the Purchaser has not acted, and is not and will not be acting, as a financial advisor to, or fiduciary (or in any similar
capacity) of, or have any fiduciary or similar duty to, the Company with respect to, or in connection with, this Agreement and
the other Ancillary Documents and the transactions contemplated hereby and thereby, and the Company agrees not to assert, and hereby
waives, any claim the Purchaser has any fiduciary duty to the Company; (d) any advice given by the Purchaser or any of its
representatives or agents in connection with this Agreement and the other Ancillary Documents and the transactions contemplated
hereby and thereby is merely incidental to the Purchaser’s performance of its obligations hereunder and thereunder (including,
in the case of the Purchaser, its acquisition of the Securities); and (e) the Company’s decision to enter into this
Agreement and the other Ancillary Documents to which it is or will be a party has been based solely on the independent evaluation
by the Company and its representatives.

 

    33 

     

    

 

IN WITNESS WHEREOF, this Agreement
has been duly executed and delivered by the duly authorized officers of the parties hereto as of the date first herein above written.

 

	 	COMPANY:
	 
	 	ADAPTHEALTH CORP.
	 
	 	By:	/s/ Luke McGee
	 	Name:	Luke McGee
	 	Title:	Chief Executive Officer
	 
	 	PURCHASER:
	 
	 	DEERFIELD PARTNERS, L.P.
	 
	 	By: Deerfield Mgmt, L.P., its General Partner
	 	By: J.E. Flynn Capital, LLC, its General Partner
	 
	 	By:	/s/ David Clark
	 	Name:	David Clark
	 	Title:	Authorized Signatory

 

[Signature
Page to Investment Agreement]

 

    

     

    

Annex I

 

Form of Series B-2 Certificate
of Designations

 

     

     

    

 

[Form of]

 

certificate of
designation, preferences and rights

 

OF

 

Series B-2 CONVERTIBLE
PREFERRED STOCK

 

PAR VALUE $0.0001

 

OF

 

ADAPTHEALTH CORP.

 

On June 12, 2020, the Board of Directors of
AdaptHealth Corp., a Delaware corporation (the “Company”), adopted
the following resolution designating and creating, out of the authorized and unissued shares of preferred stock of the Company,
35,000 authorized shares of a series of preferred stock of the Company titled the “Series B-2 Convertible Preferred Stock”:

 

RESOLVED, that, pursuant to the authority
granted to and vested in the Board in accordance with the provisions of the Company’s Second Amended and Restated Articles
of Incorporation, the Board hereby authorizes a series of preferred stock, par value $0.0001 per share, of the Company, classified
as “Series B-2 Convertible Preferred Stock” consisting of such number of shares as may be determined by the authorized
officers to allow for the Deerfield investment, and with such voting powers and preferences and relative, participating, optional
or other special rights, and such qualifications, limitations or restrictions thereof, as set forth below:

 

Section
1.      Classification and Number of Shares. The shares of such series of Preferred Stock
shall be classified as “Series B-2 Convertible Preferred Stock” (the “Series
B-2 Preferred Stock”). The number of authorized shares constituting the Series B-2 Preferred Stock shall be 35,000.
That number from time to time may be increased or decreased (but not below the number of shares of Series B-2 Preferred Stock then
outstanding) by (a) further resolution duly adopted by the Board and (b) the filing of a certificate of increase or decrease with
the Secretary of State of the State of Delaware. The Company shall not have the authority to issue fractional shares of Series
B-2 Preferred Stock.

 

Section
2.      Ranking. The Series B-2 Preferred Stock will rank, with respect to rights on the
distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company:

 

(a)              
on a parity basis with the Series A Preferred Stock and each other class or series of Capital Stock of the Company now existing
or hereafter authorized, classified or reclassified, the terms of which expressly provide that such class or series ranks on a
parity basis with the Series B-2 Preferred Stock as to rights on the distribution of assets on any voluntary or involuntary liquidation,
dissolution or winding up of the affairs of the Company (such Capital Stock, “Parity
Stock”);

 

     

     

    

 

(b)              
junior to each other class or series of Capital Stock of the Company now existing or hereafter authorized, classified or
reclassified, the terms of which expressly provide that such class or series ranks senior to the Series B-2 Preferred Stock as
to rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of
the Company (such Capital Stock, “Senior Stock”); and

 

(c)              
senior to the Common Stock and each other class or series of Capital Stock of the Company now existing or hereafter authorized,
classified or reclassified, other than Parity Stock and Senior Stock (such Capital Stock, “Junior
Stock”).

 

Section
3.      Definitions. As used herein with respect to Series B-2 Preferred Stock:

 

“Affiliate”
means, as to any Person, any other Person that, directly or indirectly, controls, or is controlled by, or is under common control
with, such Person; provided, however, (a) that the Company and its Subsidiaries shall not be deemed to be Affiliates
of the Investor or any of its Affiliates and (b) portfolio companies in which any Person or any of its Affiliates has an investment
shall not be deemed an Affiliate of such Person. For this purpose, “control”
(including, with its correlative meanings, “controlled by” and “under
common control with”) shall mean the possession, directly or indirectly, of the power to direct or cause the direction
of management or policies of a Person, whether through the ownership of securities or partnership or other ownership interests,
by contract or otherwise. With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis
by the same investment manager as such Holder shall, for purposes hereof, be deemed to be an Affiliate of such Holder.

 

Any Person shall
be deemed to “beneficially own,” to have “beneficial ownership”
of, or to be “beneficially owning” any securities (which securities shall also be deemed “beneficially
owned” by such Person) that such Person is deemed to “beneficially own” within the meaning of Rules 13d-3
and 13d-5 under the Exchange Act.

 

“Board”
means the Board of Directors of the Company or any committee thereof duly authorized to act on behalf of such Board of Directors
for the purposes in question.

 

“Business
Day” means any weekday that is not a day on which banking institutions in New York, New York or the State of Pennsylvania
are authorized or required by law, regulation or executive order to be closed.

 

“By-Laws”
means the Amended and Restated By Laws of the Company, as may be amended from time to time.

 

“Capital
Stock” means, with respect to any Person, any and all shares of, interests in, rights to purchase, warrants to
purchase, options for, participations in or other equivalents of or interests in (however designated) stock issued by such Person.

 

“Cash Payment” has the
meaning set forth in Section 8(f).

 

    2

     

    

 

“Cash Payment Deadline”
has the meaning set forth in Section 8(f).

 

“Certificate
of Designations” means this Certificate of Designation, Preferences and Rights, as may be amended from time to
time.

 

“Certificate
of Incorporation” means the Second Amended and Restated Certificate of Incorporation of the Company, as modified
by the Certificate of Correction to the Second Amended and Restated Certificate of Incorporation of the Company, and as may be
amended from time to time.

 

“Change
of Control” means the occurrence, directly or indirectly, of one of the following, whether in a single transaction
or a series of transactions:

 

(a) any “person”
or “group” (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act), is or becomes the “beneficial
owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of a majority of the total voting
power of the Voting Stock of the Company, other than as a result of any such transaction in which the holders of securities that
represented 100% of the Voting Stock of the Company immediately prior to such transaction are substantially the same as the holders
of securities that represent a majority of the total voting power of all classes of Voting Stock of the surviving Person or any
parent entity that wholly owns such surviving Person immediately after such transaction; or

 

(b) the merger or
consolidation of the Company with or into another Person or the merger of another Person with or into the Company, or the sale,
lease or transfer of all or substantially all of the assets of the Company (determined on a consolidated basis) to another Person,
or any recapitalization, reclassification or other transaction in which all or substantially all of the Class A Common Stock is
exchanged for or converted into cash, securities or other property, other than (i) a transaction following which holders of securities
that represented 100% of the Voting Stock of the Company immediately prior to such transaction own, directly or indirectly (in
substantially the same proportion to each other as immediately prior to such transaction, other than changes in proportionality
as a result of any cash/stock election provided under the terms of the definitive agreement regarding such transaction), at least
a majority of the voting power of the Voting Stock of the surviving Person in such merger or consolidation transaction immediately
after such transaction or (ii) a sale, lease or transfer to a Subsidiary or a Person that becomes a Subsidiary of the Company.

 

“Class A Common Stock”
means the Common Stock of the Company designated as Class A common stock, $0.0001 par value per share.

 

“Class B Common Stock”
means the Common Stock of the Company designated as Class B common stock, $0.0001 par value per share.

 

“close
of business” means 5:00 p.m. (New York City time).

 

    3

     

    

 

“Closing
Price” of the Class A Common Stock on any date of determination means the closing sale price or, if no closing
sale price is reported, the last reported sale price of the shares of the Class A Common Stock on the NASDAQ on such date. If the
Class A Common Stock is not traded on the NASDAQ on any date of determination, the Closing Price of the Class A Common Stock on
such date of determination means the closing sale price as reported in the composite transactions for the principal United States
securities exchange or automated quotation system on which the Class A Common Stock is so listed or quoted, or, if no closing sale
price is reported, the last reported sale price on the principal United States securities exchange or automated quotation system
on which the Class A Common Stock is so listed or quoted, or if the Class A Common Stock is not so listed or quoted on a United
States securities exchange or automated quotation system, the last quoted bid price for the Class A Common Stock in the over-the-counter
market as reported by OTC Markets Group Inc. or any similar organization, or, if that bid price is not available, the market price
of the Class A Common Stock on that date as mutually agreed between the Company and the Holders of a majority of the Series B-2
Preferred Stock or, in the absence of such agreement, as determined by an Independent Financial Advisor retained by the Company
for such purpose.

 

“Common
Stock” means (i) the common stock, $0.0001 par value per share, of the Company, consisting of Class A Common Stock
and Class B Common Stock and (ii) any capital stock into which such common stock shall have been changed or any share capital resulting
from a reclassification of such common stock.

 

“Company”
has the meaning set forth in the recitals above.

 

“Constituent
Person” has the meaning set forth in Section 11(a)(iii).

 

“Conversion
Date” has the meaning set forth in Section 8.

 

“Conversion
Notice” has the meaning set forth in Section 8(a)(i).

 

“Conversion
Price” means, for each share of Series B-2 Preferred Stock, a dollar amount equal to $1,000 divided by
the Conversion Rate.

 

“Conversion
Rate” means, for each share of Series B-2 Preferred Stock, 72.727273 shares of Class A Common Stock, subject to
adjustment as set forth herein.

 

“Current
Market Price” per share of Class A Common Stock, as of any date of determination, means the arithmetic average
of the VWAP per share of Class A Common Stock for each of the ten (10) consecutive full Trading Days ending on, and including,
the Trading Day immediately preceding such day, appropriately adjusted to take into account the occurrence during such period
of any event described in Section 10.

 

“Default Cash Dividends”
has the meaning set forth in Section 8(f).

 

“Distributed
Property” has the meaning set forth in Section 10(a)(iii).

 

“Distribution
Transaction” means any dividend or other distribution of equity securities of a Subsidiary of the Company to holders
of Class A Common Stock in which such Person ceases to be a Subsidiary of the Company by reason of such dividend or distribution
of equity securities, whether by means of a spin-off, split-off, redemption, reclassification, exchange, stock dividend, share
distribution, rights offering or similar transaction.

 

    4

     

    

  

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Exchange
Property” has the meaning set forth in Section 11(a).

 

“Exchange
Property Unit” has the meaning set forth in Section 11(a).

 

“Fair
Market Value” means, with respect to any security or other property, the fair market value of such security or
other property as reasonably determined by a majority of the Board acting in good faith, or as mutually agreed between the Company
and the Holders of a majority of the Series B-2 Preferred Stock or, in the absence of such agreement, (a) after consultation with
an Independent Financial Advisor, as to any security or other property with a Fair Market Value of less than $25,000,000, or (b)
otherwise using an Independent Financial Advisor to provide a valuation opinion.

 

“Holder”
means a Person in whose name any Series B-2 Preferred Stock is registered in the Register.

 

“Independent
Financial Advisor” means an accounting, appraisal, investment banking firm or consultant of nationally recognized
standing; provided, however, that such firm or consultant shall not be an Affiliate of the Company and shall be reasonably
acceptable to the Holders of at least a majority of the shares of Series B-2 Preferred Stock outstanding at such time.

 

“Investment
Agreement” means that certain Investment Agreement between the Company and the Investor, dated as of June [__],
2020, as it may be amended, supplemented or otherwise modified from time to time, with respect to certain terms and conditions
concerning, among other things, the rights of and restrictions on the Holders.

 

“Investor”
means Deerfield Partners, L.P.

 

“Issuance
Date” means, with respect to any share of Series B-2 Preferred Stock, the date of issuance of such share.

 

“Junior
Stock” has the meaning set forth in Section 2(c). 

 

“Liquidation
Preference” means, with respect to any share of Series B-2 Preferred Stock, as of any date, $0.0001 per share.

 

“Mandatory
Conversion” has the meaning set forth in Section 7.

 

“Mandatory
Conversion Date” has the meaning set forth in Section 7.

 

“Market
Disruption Event” means, with respect to any date, the occurrence or existence, during the one-half hour period
ending at the scheduled close of trading on such date on the principal U.S. national or regional securities exchange or other market
on which the Class A Common Stock is listed for trading or trades (or for purposes of determining the VWAP per share of Class A
Common Stock, any period or periods aggregating one half-hour or longer during the regular trading session on the relevant day),
of any material suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the
relevant exchange or otherwise) in the Class A Common Stock or in any options contracts or futures contracts relating to the Class
A Common Stock.

 

    5

     

    

 

“NASDAQ”
means the NASDAQ Stock Market (or its successor).

 

“Notice
of Mandatory Conversion” has the meaning set forth in Section 7(b).

 

“Optional
Conversion” has the meaning set forth in Section 6(a).

 

“Original
Issuance Date” means the date of closing pursuant to the Investment Agreement.

 

“Original Issue Price”
means, with respect to any share of Series B-2 Preferred Stock, as of any date, $1,000.00 per share.

 

“Parity
Stock” has the meaning set forth in Section 2(a).

 

“Participating
Dividends” has the meaning set forth in Section 4(b).

 

“Participating
Dividend Record Date” has the meaning set forth in Section 4(d).

 

“Person”
means any individual, corporation, estate, partnership, joint venture, association, joint-stock company, limited liability company,
trust, unincorporated organization or any other entity.

 

“Preferred Conversion Shares”
means shares of Series B-1 Preferred Stock issued or issuable upon conversion of Series B-2 Preferred Stock.

 

“Preferred
Stock” means the preferred stock, $0.0001 par value per share, of the Company.

 

“Preferred Stock Conversion Price”
means, as of any date of determination, a dollar amount equal to the Conversion Price as in effect on such date, multiplied by the Series B-1 Preferred Conversion Rate as in effect on such date.

 

“Record
Date” means, with respect to any dividend, distribution or other transaction or event in which the holders of
the Class A Common Stock have the right to receive any cash, securities or other property or in which the Class A Common Stock
is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders
of the Class A Common Stock entitled to receive such cash, securities or other property (whether such date is fixed by the Board
or by statute, contract or otherwise).

 

“Register”
means the securities register maintained in respect of the Series B-2 Preferred Stock by the Company, or, to the extent the Company
has engaged a transfer agent, such transfer agent.

 

“Reorganization
Event” has the meaning set forth in Section 11(a)(iii).

 

    6

     

    

 

“Requisite
Stockholder Approval” means the stockholder approval contemplated by NASDAQ listing rule 5635 (or its successor) with
respect to the issuance of shares of Common Stock upon conversion of Preferred Conversion Shares in excess of the limitations imposed
by such rule.

 

“Senior
Stock” has the meaning set forth in Section 2(b).

 

“Series
A Preferred Stock” means the Series A Convertible Preferred Stock, par value $0.0001 per share, of the Company, as designated
in the Certificate of Designation, Preferences and Rights filed with the Secretary of State as of the date hereof.

 

“Series
B-1 Certificate of Designation” means the Certificate of Designation of Preferences, Rights and Limitations of the Series
B-1 Preferred Stock.

 

“Series
B-1 Preferred Stock” means a series of the Company’s preferred stock designated as “Series B-1 Preferred
Stock” having the rights, privileges and benefits, and subject to the limitations, set forth in the Series B-1 Certificate
of Designation.

 

“Series
B-1 Preferred Conversion Rate” means, as of any date of determination, the Conversion Rate (as defined in the Series
B-1 Certificate of Designation) of the Series B-1 Preferred Stock as in effect on such date.

 

“Series
B-2 Preferred Stock” has the meaning set forth in Section 1.

 

“Share Cap” means zero
(0) shares of Series B-1 Preferred Stock.

 

“Standard Settlement Period”
means the standard settlement period for equity trades effected by U.S. broker-dealers, expressed in a number of Trading Days,
as in effect on the date the applicable Conversion Notice is received or deemed received by the Company.

 

A “Subsidiary”
of any Person means any corporation, limited liability company, partnership, association, trust or other entity of which securities
or other ownership interests representing more than 50% of the ordinary voting power (or, in the case of a partnership, more than
50% of the general partnership interests) are owned by such Person or one or more Subsidiaries of such Person or by such Person
and one or more Subsidiaries of such Person.

 

“Trading
Day” means a day on which the NASDAQ is open for the transaction of business and on which there has not occurred
a Market Disruption Event.

 

“Trigger
Event” has the meaning set forth in Section 10(a)(v).

 

“Voting
Stock” means (a) with respect to the Company, the Common Stock and any other Capital Stock of the Company
having the right to vote generally in any election of directors of the Board and (b) with respect to any other Person, all Capital
Stock of such Person having the right to vote generally in any election of directors of the board of directors of such Person or
other similar governing body.

 

    7

     

    

 

“VWAP”
per share of Class A Common Stock on any Trading Day means the per share volume-weighted average price as displayed under the heading
Bloomberg VWAP on Bloomberg (or, if Bloomberg ceases to publish such price, any successor service reasonably chosen by the Company)
page “AHCO <equity> AQR” (or its equivalent successor if such page is not available) in respect of the period
from the open of trading on the relevant Trading Day until the close of trading on such Trading Day (or if such volume-weighted
average price is unavailable, the market price of one (1) share of Class A Common Stock on such Trading Day determined, using a
volume-weighted average method, as mutually agreed between the Company and the Holders of a majority of the Series B-2 Preferred
Stock or, in the absence of such agreement, as determined by an Independent Financial Advisor retained by the Company for such
purpose).

 

Section
4.      Dividends. (a) Holders shall be entitled to receive dividends of the type and in
the amount determined as set forth in this Section 4.

 

(b)              
Participating Dividends. Holders shall be entitled to participate equally and ratably with the holders of shares
of Class A Common Stock in all cash dividends paid on the shares of Class A Common Stock as if immediately prior to each Participating
Dividend Record Date, all shares of Series B-2 Preferred Stock then outstanding were converted into shares of Series B-1 Preferred
Stock in accordance with Section 6 (without regard to the Conversion Restriction) and such shares of Series B-1 Preferred
Stock were converted into shares of Class A Common Stock in accordance with the Series B-1 Certificate of Designation (without
regard to the 4.9% Cap (as defined in the Series B-1 Certificate of Designation)). Dividends payable pursuant to this Section
4(b) (the “Participating Dividends”) shall be payable on the same
date that such dividends are payable to holders of shares of Class A Common Stock, and no dividends shall be payable to holders
of shares of Class A Common Stock, unless the full dividends contemplated by this Section 4(b) are paid substantially at
the same time to Holders.

 

(c)              
[Reserved]

 

(d)              
Record Date for Participating Dividends. Each Participating Dividend shall be paid pro rata to the Holders of shares
of Preferred Stock entitled thereto. Each Participating Dividend shall be payable to the Holders of Preferred Stock as they appear
on the Register at the close of business on the record date designated by the Board for such dividends (each such date, a “Participating
Dividend Record Date”) which shall be the same day as the record date for the
payment of dividends to the holders of shares of Class A Common Stock.

 

(e)              
Conversion Following a Participating Dividend Record Date. If the Conversion Date for any shares of Series B-2 Preferred
Stock is prior to the close of business on a Participating Dividend Record Date, the Holder of such shares will not be entitled
to any dividend in respect of such shares of Series B-2 Preferred Stock as to Participating Dividend Record Date. If the Conversion
Date for any shares of Series B-2 Preferred Stock is after the close of business on a Participating Dividend Record Date but prior
to the corresponding payment date for such dividend, the Holder of such shares as of such Participating Dividend Record Date shall
be entitled to receive such dividend in respect of such shares of Series B-2 Preferred Stock, notwithstanding the conversion of
such shares prior to the applicable dividend payment date.

 

    8

     

    

 

Section
5.      Liquidation Rights.   (a) Liquidation. In the event of any voluntary
or involuntary liquidation, dissolution or winding up of the affairs of the Company, the Holders shall be entitled, out of assets
legally available therefor, before any distribution or payment out of the assets of the Company may be made to or set aside for
the holders of any Junior Stock and subject to the rights of the holders of any Senior Stock or Parity Stock and the rights of
the Company’s existing and future creditors, to receive in full a liquidating distribution in cash and in the amount per
share of Series B-2 Preferred Stock equal to the greater of (i) the Liquidation Preference and (ii) the amount such Holders would
have received had such Holders, immediately prior to such voluntary or involuntary liquidation, dissolution or winding up of the
affairs of the Company, converted such shares of Series B-2 Preferred Stock into shares of Series B-1 Preferred Stock in accordance
with Section 6 (without regard to the Conversion Restriction) and converted such shares of Series B-1 Preferred Stock into
shares of Class A Common Stock in accordance with the Series B-1 Certificate of Designation (without regard to the 4.9% Cap).
Holders shall not be entitled to any further payments in the event of any such voluntary or involuntary liquidation, dissolution
or winding up of the affairs of the Company other than what is expressly provided for in this Section 5 and will have
no right or claim to any of the Company’s remaining assets.

 

(b)              
Partial Payment. If in connection with any distribution described in Section 5(a) above, the assets of the
Company or proceeds therefrom are not sufficient to pay in full the aggregate liquidating distributions required to be paid pursuant
to Section 5(a) above to all Holders and the liquidating distributions payable to all holders of any Parity Stock, the
amounts distributed to the Holders and to the holders of all such Parity Stock shall be paid pro rata in accordance with the respective
aggregate liquidating distributions to which they would otherwise be entitled if all amounts payable thereon were paid in full.

 

(c)              
Merger, Consolidation and Sale of Assets Not Liquidation. For purposes of this Section 5, the sale,
conveyance, exchange or transfer (for cash, shares of stock, securities or other consideration) of all or substantially all of
the property and assets of the Company shall not be deemed a voluntary or involuntary liquidation, dissolution or winding up of
the affairs of the Company, nor shall the merger, consolidation, statutory exchange or any other business combination transaction
of the Company into or with any other Person or the merger, consolidation, statutory exchange or any other business combination
transaction of any other Person into or with the Company be deemed to be a voluntary or involuntary liquidation, dissolution or
winding up of the affairs of the Company.

 

Section
6.      Right of the Holders to Convert.

 

(a)              
Subject to the terms of Section 8(f), each Holder shall have the right, at such Holder’s option, subject to the conversion
procedures set forth in Section 8, to convert (an “Optional Conversion”)
each share of such Holder’s Series B-2 Preferred Stock at any time into the number of shares of Series B-1 Preferred Stock
equal to the quotient of (A) the Original Issue Price divided by (B) the Preferred Stock Conversion Price as of the applicable
Conversion Date. The right of Optional Conversion may be exercised as to all or any portion of such Holder’s Series B-2
Preferred Stock from time to time; provided, however, that, in each case, no right of Optional Conversion may be exercised by
a Holder in respect of fewer than 10,000 shares of Series B-2 Preferred Stock (unless such conversion relates to all shares of
Series B-2 Preferred Stock held by such Holder or all shares of Series B-2 Preferred Stock that may be converted in compliance
with Section 8(f)).

 

    9

     

    

 

(b)              
The Company shall at all times reserve and keep available (i) out of its authorized and unissued Preferred Stock and Series
B-1 Preferred Stock, solely for issuance upon conversion of Series B-2 Preferred Stock, such number of shares of Series B-1 Preferred
Stock as shall from time to time be issuable upon the conversion of all the shares of Series B-2 Preferred Stock pursuant to Section
6 and (ii) out of its authorized and unissued Common Stock and Class A Common Stock, solely for issuance upon the conversion
of Preferred Conversion Shares, such number of shares of Class A Common Stock as shall from time to time be issuable upon the conversion
of all the shares of Series B-2 Preferred Stock pursuant to Section 6 and the subsequent conversion of Preferred Conversion
Shares in accordance with the Series B-1 Certificate of Designation. Any shares of Series B-1 Preferred Stock issued upon conversion
of Series B-2 Preferred Stock shall be duly authorized, validly issued, fully paid and nonassessable and will not be subject to
preemptive rights or subscription rights of any other stockholder of the Company.

 

Section
7.      Mandatory Conversion by the Company. (a) Following the day upon which the Requisite
Stockholder Approval is obtained, the Company may elect to convert up to 100% of the outstanding shares of Series B-2 Preferred
Stock (to the extent not previously redeemed by the Company) into shares of Series B-1 Preferred Stock (the election to convert
shares of Series B-2 Preferred Stock pursuant to this Section 7, a “Mandatory Conversion”, and the date
selected by the Company for any Mandatory Conversion pursuant to this Section 7, the “Mandatory
Conversion Date”). In the case of a Mandatory Conversion, each share of Series B-2 Preferred Stock then outstanding
that is to be converted pursuant to such Mandatory Conversion shall be converted into the number of shares of Series B-1 Preferred
Stock equal to the quotient of (1) the Original Issue Price with respect to such share of Series B-2 Preferred Stock as of the
Mandatory Conversion Date divided by (2) the Preferred Stock Conversion Price of such share in effect as of the Mandatory
Conversion Date.

 

(b)              
Notice of Mandatory Conversion. If the Company elects to effect a Mandatory Conversion, the Company shall provide
notice of a Mandatory Conversion to each Holder (such notice, a “Notice of Mandatory
Conversion”). The Mandatory Conversion Date selected by the Company shall be no less than five (5) Business Days
and no more than twenty (20) Business Days after the date on which the Company provides the Notice of Mandatory Conversion to the
Holders. The Notice of Mandatory Conversion shall state, as appropriate:

 

(i)             
the number of shares of Series B-2 Preferred Stock held by such Holder that are subject to the Mandatory Conversion;

 

(ii)            
the Mandatory Conversion Date selected by the Company; and

 

(iii)           
the Conversion Rate and the Preferred Stock Conversion Price, in each case, as in effect on the Mandatory Conversion Date
and the number of shares of Series B-1 Preferred Stock to be issued to such Holder upon conversion of each share of Series B-2
Preferred Stock held by such Holder.

 

    10

     

    

 

Section
8.      Conversion Procedures and Effect of Conversion. (a) Conversion Procedure.
A Holder must do each of the following in order to receive shares Series B-1 Preferred Stock upon conversion of shares of Series
B-2 Preferred Stock pursuant to this Section 8:

 

(i)               
in the case of an Optional Conversion, complete the conversion notice in the form attached hereto as Exhibit I (the
 “Conversion Notice”), and deliver such notice to the Company; provided,
however, that a Conversion Notice may be conditional on the completion of a Change of Control or other corporate transaction
as such Holder may specify;

 

(ii)             
if required, furnish appropriate endorsements and transfer documents; and

 

(iii)           
if required, pay any stock transfer, documentary, stamp or similar taxes not payable by the Company pursuant to Section
17.

 

The foregoing
clauses (ii) and (iii) shall be conditions to the issuance of shares of Series B-1 Preferred Stock to the Holders in the event
of a Mandatory Conversion pursuant to Section 7 (but, for the avoidance of doubt, not the Mandatory Conversion
of the shares of Series B-2 Preferred Stock on the Mandatory Conversion Date). Notwithstanding the foregoing, no Holder shall
be required to physically surrender any certificate(s) representing the Series B-2 Preferred Stock to the Company until all shares
of Series B-2 Preferred Stock represented by such certificate(s) have been converted in full (the “Final Conversion”),
in which case the applicable Holder shall surrender such certificate(s) to the Company for cancellation within three (3) Trading
Days following the final Conversion Date (it being acknowledged and agreed that such surrender shall not be a condition to the
Holder’s right to receive shares of Series B-1 Preferred Stock upon, or the effectiveness of, such conversion; provided,
however, that the Company shall not be obligated to deliver a stock certificate representing shares of Series B-1 Preferred Stock
issued upon the Final Conversion until the certificate(s) representing the shares of Series B-2 Preferred Stock so converted by
the Holder shall have been surrendered). Delivery of a Conversion Notice with respect to a partial conversion shall have the same
effect as cancellation of the original certificate(s) representing such shares of Series B-2 Preferred Stock and issuance of a
certificate representing the remaining shares of Series B-2 Preferred Stock. In accordance with the preceding sentence, upon the
written request of the applicable Holder and the surrender of certificate(s) representing shares of Series B-2 Preferred Stock,
the Company shall, within three (3) Trading Days of such request, deliver to such Holder certificate(s) (as specified by such
Holder in such request) representing such remaining shares of Series B-2 Preferred Stock.

 

The “Conversion Date” means (A)
with respect to an Optional Conversion pursuant to Section 6(a), the date on which such Holder complies with the procedures in
this Section 8 (including the satisfaction of any conditions to conversion set forth in the Conversion Notice) and (B) with respect
to Mandatory Conversion pursuant to Section 7, the Mandatory Conversion Date.

 

(b)              
Effect of Conversion. Effective immediately prior to the close of business on the Conversion Date applicable to any
shares of Series B-2 Preferred Stock, Participating Dividends shall no longer accrue or be declared on any such shares of Series
B-2 Preferred Stock, and on conversion, such shares of Series B-2 Preferred Stock shall cease to be outstanding.

 

    11

     

    

 

(c)              
Record Holder of Underlying Securities as of Conversion Date. The Person or Persons entitled to receive the Preferred
Conversion Shares on a Conversion Date shall be treated for all purposes as the record holder(s) of such Preferred Conversion Shares
(including any fractional shares) as of the time of delivery of the applicable Conversion Notice (or, in the case of a Mandatory
Conversion, 8:30 a.m., New York City Time, on the Mandatory Conversion Date). Upon receipt or deemed receipt by the Company of
a copy of a Conversion Notice in respect of any Optional Conversion, the Company shall promptly send, via facsimile or electronic
mail, a confirmation of receipt of such Conversion Notice to the Holder and the Company's designated transfer agent (the “Transfer
Agent”), which confirmation to the Transfer Agent shall constitute an instruction to the Transfer Agent to process the
Optional Conversion. In the case of an Optional Conversion, on or before the second (2nd) Business Day (or, if earlier, the end
of the Standard Settlement Period) following the date of receipt or deemed receipt by the Company of the Conversion Notice, the
Company shall, on or before the Optional Conversion Delivery Deadline, issue and deliver to the Holder or its designee certificates,
registered in the name of the Holder or its designee, representing the aggregate number of Preferred Conversion Shares (including
any fractional Preferred Conversion Shares) to which the Holder shall be entitled. In the case of a Mandatory Conversion, on or
before 8:30 a.m., New York City time, on the Conversion Date, the Company shall issue and deliver to the Holder or its designee
certificates, registered in the name of the Holder or its designee, representing the aggregate number of Preferred Conversion Shares
to which the Holder shall be entitled (such delivery deadline or the Optional Delivery Deadline, as applicable, being referred
to as the "Share Delivery Date"). Notwithstanding the foregoing, if as of the applicable Conversion Date, the Transfer
Agent is a "qualified custodian" (as defined in Rule 206(4)-2 (or successor thereto) under the Investment Advisers Act
of 1940, as amended), in lieu of the Company's delivering certificates representing the Preferred Conversion Shares issuable upon
the applicable conversion, the Transfer Agent (acting as the transfer agent for the Series B-1 Preferred Stock) shall, on or before
the Share Delivery Date, electronically credit the aggregate number of shares of Series B-1 Preferred Stock to which the Holder
shall be entitled by book-entry in the name of the Holder or its designee on the books and records of the Transfer Agent and deliver
a statement thereof to the Holder.

 

(d)              
No Adjustment. No adjustment to shares of Series B-2 Preferred Stock being converted on a Conversion Date or to
the shares of Series B-1 Preferred Stock deliverable to the Holders upon the conversion thereof shall be made in respect of dividends
or other distributions payable to holders of the Class A Common Stock as of any date prior to the close of business on such Conversion
Date (it being understood that the foregoing shall not limit any Holder’s right to receive Participating Dividends payable
prior to such time or the operation of Section 10(a) in respect of events occurring prior to such time). Until the Conversion
Date with respect to any share of Series B-2 Preferred Stock has occurred, such share of Series B-2 Preferred Stock will remain
outstanding and will be entitled to all of the powers, designations, preferences and other rights provided herein.

 

    12

     

    

 

(e)              
Fractional Shares. In the event that the conversion of Series B-2 Preferred Stock into Preferred Conversion Shares
would result in the issuance of fractional shares, the Company shall issue such fractional Preferred Conversion Shares to the applicable
Holder.

 

(f)               
Restriction on Conversions.

 

(i)                
Limitation on Conversion. Notwithstanding anything in this Certificate of Designations to the contrary, unless and
until the Requisite Stockholder Approval (to the extent and only to the extent required under the listing rules of NASDAQ) is obtained,
the Holders shall not have the right to acquire shares of Series B-1 Preferred Stock issuable upon conversion of the Series B-2
Preferred Stock, and the Company shall not be required to issue shares of Series B-1 Preferred Stock issuable upon conversion of
the Series B-2 Preferred Stock, in excess of the Share Cap (the “Conversion Restriction”). Any purported delivery
of shares of Series B-1 Preferred Stock upon conversion of any Series B-2 Preferred Stock will be void and have no effect to the
extent, and only to the extent, that such delivery would result in issuance of shares of Series B-1 Preferred in excess of the
Share Cap in violation of the listing rules of Nasdaq. Notwithstanding the foregoing, for any conversion following the six-month
anniversary of the Original Issuance Date, in the case of a conversion pursuant to Section 6, Section 7 or this Section 8, the
Holder or the Company, as applicable, may request a conversion of a number of shares of Series B-2 Preferred Stock that would result
in the issuance of shares that, but for the Conversion Restriction, would exceed the Share Cap; provided, that, in lieu
of any shares of Series B-1 Preferred Stock otherwise deliverable upon conversion that would, but for the Conversion Restriction,
exceed the Share Cap, the Company shall instead deliver to the requisite Holder an amount of cash per share of such Series B-1
Preferred Stock equal to the product of (x) the VWAP per share of Class A Common Stock on the Trading Day immediately preceding
the Conversion Date, multiplied by (y) the Series B-1 Preferred Conversion Rate as in effect on such Trading Day (such payment,
a “Cash Payment”), payable within not more than thirty (30) days following the applicable Conversion Date (such
date, the “Cash Payment Deadline”); provided, however, that the Holder may not request the conversion
of shares in excess of the Share Cap prior to the earlier to occur of (A) the Restricted Period Termination Date (as such term
is defined in the Investment Agreement) and (B) if any, a Restricted Period Early Termination Event (as such term is defined in
the Investment Agreement) following which the transfer restrictions in Section 5.3(a) of the Investment Agreement are not applicable
to 100% of the Prohibited Shares (as such term is defined in the Investment Agreement) (following which the Holder may request
conversion of shares that would, but for the Conversion Restriction, exceed the Share Cap, which shall be treated in accordance
with the forgoing proviso); provided, further, that, for any conversion that would, but for the Conversion Restriction,
exceed the Share Cap that is in connection with a Change of Control, in lieu of the price per share payable in accordance with
the foregoing, the Company shall instead deliver to the requisite Holder, at the same time as such consideration is delivered to
the holders of Class A Common Stock, the consideration received by the holders of Class A Common Stock in respect of each share
of Class A Common Stock issuable upon conversion of all of the Preferred Conversion Shares in excess of the Share Cap, and if such
payment is in violation of the Nasdaq listing rules applicable to the Company, the Company shall instead deliver to the Holder
converting shares in excess of the Share Cap that would be in violation of the Nasdaq listing rules cash in an amount equal to
the Fair Market Value of such consideration.

 

    13

     

    

 

(ii)             
Covenant to Seek the Requisite Stockholder Approval. The Company will use its reasonable best efforts to obtain the
Requisite Stockholder Approval, including by seeking such approval, if not previously obtained, at each regular annual meeting
of its stockholders occurring after the first Company Stockholders’ Meeting (as such term is defined in the Investment Agreement)
and endorsing its approval in the related proxy materials. The Company will promptly notify the Holders if the Requisite Stockholder
Approval is obtained.

 

(iii)           
Cash Dividends Upon Default of Cash Payment Obligations. If the Company fails to make any required Cash Payment by
the required Cash Payment Deadline on any share of Series B-2 Preferred Stock, then the Holder thereof will be entitled to receive
cumulative cash dividends on each such share at a rate per annum of 4.00% on the Original Issuance Price (such dividends, “Default
Cash Dividends”). Default Cash Dividends, if any, shall accumulate on a daily basis from, and including, the Cash Payment
Deadline to, but excluding, the date upon which the required Cash Payment is made (whether or not there shall be earnings
or funds of the Company legally available for the payment of Default Cash Dividends or the Company declares the payment of Default
Cash Dividends). Default Cash Dividends, if any, shall be payable quarterly in arrears on March 31, June 30, September 31 and December
31 of each year to the applicable Holder as it appears on the Company’s Register at the close of business on the March 15,
June 15, September 15 and December 15 preceding the applicable payment date. Default Cash Dividends, if any, payable for any period
less than a full quarterly dividend period (based upon the number of days elapsed during the period) shall be computed on the basis
of a 360-day year consisting of twelve 30-day months.

 

(g)              
Legends.

 

(i)                
Restrictive Legend. The Holder understands that, except as otherwise specified pursuant to Section 6(g)(ii), the
certificates representing shares of Series B-2 Preferred Stock shall bear a restrictive legend in substantially the following form
(and a stop-transfer order consistent therewith may be placed against transfer of such certificates):

 

“THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES REPRESENTED HEREBY AND THE SHARES ISSUABLE UPON CONVERSION HEREOF MAY NOT BE SOLD, TRANSFERRED
OR AS-SIGNED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT, INCLUDING PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OR PURSUANT TO A PRIVATE SALE EFFECTED
UNDER SECTION 4(A)(7) OF THE SECURITIES ACT OR APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED
 “4[a](1) AND A HALF” SALE SUBJECT TO THE COMPANY’S AND THE TRANSFER AGENT’S RIGHT PRIOR TO ANY SUCH OFFER,
SALE, TRANSFER, ENCUMBRANCE, ASSIGNMENT OR OTHER DISPOSITION TO REQUIRE THE DELIVERY OF REASONABLE AND CUSTOMARY CERTIFICATIONS,
OPINIONS OF COUNSEL AND/OR OTHER INFORMATION REASONABLY SATISFACTORY TO EACH OF THEM.”

 

    14

     

    

 

(ii)             
Removal of Restrictive Legend. Notwithstanding the foregoing, the certificates evidencing the shares of Series B-2
Preferred Stock shall not contain any legend restricting the transfer thereof (including the legend set forth above in subsection
6(g)(i)): (A) while a registration statement covering the sale or resale of such shares is effective under the Securities Act,
subject to the Holder’s delivery to the Company of an undertaking that such Holder will only sell or otherwise transfer such
shares pursuant to either registration under the Securities Act or an exemption therefrom, and that if such securities are sold
pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein (an “Undertaking”),
or (B) if the Holder provides customary paperwork to the effect that it has sold such shares pursuant to Rule 144, or (C) if such
shares are eligible for sale under Rule 144(b)(1) (without the application of Rule 144(c)(1)) as set forth in customary non-affiliate
paperwork provided by the Holder, or (D) if at any time on or after the date that is three months after the Closing Date (as defined
in the Investment Agreement) (the “Non-affiliation Date”) the Holder certifies that it is not an Affiliate of
the Company and that the Holder’s holding period for the purposes of Rule 144 is at least six (6) months, subject to the
Holder’s delivery to the Company of an Undertaking; provided, that each Holder shall be deemed to have given such certification
upon each delivery of a Notice of Conversion, unless such Holder otherwise advises the Company in writing, or (E) if such legend
is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued
by the staff of the SEC) as determined in good faith by counsel to the Company or set forth in a legal opinion delivered by Katten
Muchin Rosenman LLP or other nationally recognized counsel to the Holder (collectively, the “Unrestricted Conditions”).
Subject to the terms and conditions hereof, upon the reasonable request of the Holder, the Company shall cause its counsel to issue
a legal opinion to the Transfer Agent promptly after the Non-affiliation Date, or at such other time as any of the Unrestricted
Conditions have been satisfied, if required by the Company’s Transfer Agent, to effect the issuance of the shares of Series
B-2 Preferred Stock without a restrictive legend or removal of the legend hereunder. If any of the Unrestricted Conditions is met
at the time of issuance of any shares of Series B-2 Preferred Stock, then such shares shall be issued free of all legends. The
Company agrees that following the Non-affiliation Date or at such time as any of the Unrestricted Conditions are met or such legend
is otherwise no longer required under this Section 6(d)(ii), it will, no later than two (2) Trading Days (or, if less, the number
of days comprising the Standard Settlement Period) following the delivery by the Holder to the Company or the Transfer Agent of
a certificate representing Series B-2 Preferred Stock issued with a restrictive legend, deliver or cause to be delivered to such
Holder a certificate (or electronic transfer) representing such shares that is free from all restrictive and other legends.

 

(iii)           
Sale of Unlegended Shares. The removal of any restrictive legends from any securities as set forth in this Section
6 is predicated upon, and the Company’s reliance on, the applicable Holder delivering an Undertaking to the Company; provided
that no Holder shall be required to give more than one Undertaking covering the same shares while an Undertaking with respect to
such shares remains in effect.

 

(iv)            
Underlying Shares. For the avoidance of doubt, the provisions of this Section 8(g) shall not apply to any Preferred
Conversion Shares or any shares of Class A Common Stock issuable upon the conversion of any Preferred Conversion Shares.

 

    15

     

    

 

Section
9.      Change of Control.

 

(a)              
Change of Control Notice. If the Company delivers notice to the holders of Class A Common Stock, or makes a public
announcement or public disclosure, with respect to a Change of Control, the Company shall deliver a copy of such notice, disclosure
or announcement (as applicable) to each Holder at its last address as it shall appear in the Register, at the same time as such
notice is delivered to the holders of Class A Common Stock or, in the case of a public announcement or public disclosure, on the
same date as such announcement or disclosure

 

(b)              
Conversion Right. Prior to the consummation of any Change of Control, each Holder shall be entitled, subject to Section
8(f), to exercise an Optional Conversion in respect of any and all of its Series B-2 Preferred Stock prior to or conditioned upon
such Change of Control.

 

Section
10.  Anti-Dilution Adjustments. (a) Adjustments. The Conversion Rate will be subject to adjustment,
without duplication, upon the occurrence of the following events, except that the Company shall not make any adjustment to the
Conversion Rate if Holders of the Series B-2 Preferred Stock participate, at the same time and upon the same terms as holders
of Class A Common Stock and solely as a result of holding shares of Series B-2 Preferred Stock, in any transaction described in
this Section 10, without having to convert their Series B-2 Preferred Stock, as if they held a number of shares of Class
A Common Stock equal to the Conversion Rate multiplied by the number of shares of Series B-2 Preferred Stock held by such
Holders:

 

(i)                
The issuance of Class A Common Stock as a dividend or distribution to all or substantially all holders of Class A Common
Stock, or a subdivision or combination (including, without limitation, a stock split or a reverse stock split) of Class A Common
Stock or a reclassification of Class A Common Stock into a greater or lesser number of shares of Class A Common Stock, in which
event the Conversion Rate shall be adjusted based on the following formula:

 

CR1 = CR0 x (OS1
/ OS0)

 

where,

 

CR0        =        the Conversion Rate in effect
immediately prior to (i) the close of business on (i) the Record Date for such dividend or distribution or (ii) the effective date
of such subdivision, combination or reclassification;

 

CR1        =        the new Conversion Rate in effect
immediately after (i) the close of business on (i) the Record Date for such dividend or distribution or (ii) the effective date
of such subdivision, combination or reclassification;

 

OS0        =        the number of shares of Class
A Common Stock outstanding immediately prior to the close of business on (i) the Record Date for such dividend or distribution
or (ii) the effective date of such subdivision, combination or reclassification; and

 

    16

     

    

 

OS1        =        the number of shares of Class
A Common Stock that would be outstanding immediately after, and solely as a result of, the completion of such dividend, distribution,
subdivision, combination or reclassification.

 

Any adjustment made pursuant to this clause
(i) shall be effective immediately after the close of business on (i) the Record Date for such dividend or distribution or (ii)
the effective date of such subdivision, combination or reclassification. If any such dividend, distribution, subdivision, combination
or reclassification is announced or declared but does not occur, the Conversion Rate shall be readjusted, effective as of the date
the Board announces that such dividend, distribution, subdivision, combination or reclassification shall not occur to the Conversion
Rate that would then be in effect if such dividend, distribution, subdivision, combination or reclassification had not been declared.

 

(ii)             
The dividend, distribution or other issuance to all or substantially all holders of Class A Common Stock of rights (other
than rights, options or warrants distributed in connection with a stockholder rights plan (in which event the provisions of Section
10(a)(v) shall apply)), options or warrants entitling them to subscribe for or purchase shares of Class A Common Stock for
a period expiring forty-five (45) days or less from the date of issuance thereof, at a price per share that is less than the Current
Market Price as of the Record Date for such issuance, in which event the Conversion Rate will be increased based on the following
formula:

 

CR1 = CR0 x [(OS0+X)]
/ (OS0+Y)

 

where,

 

CR0 = the Conversion Rate in effect immediately
prior to the close of business on the Record Date for such dividend, distribution or other issuance;

 

CR1 = the new Conversion Rate in effect immediately
after the close of business on the Record Date for such dividend, distribution or other issuance;

 

OS0 = the number of shares of Class A Common
Stock outstanding immediately prior to the close of business on the Record Date for such dividend, distribution or other issuance;

 

X = the total number of shares of Class A Common Stock
issuable pursuant to such rights, options or warrants; and

 

Y = the number of shares of Class A Common Stock equal
to the aggregate price payable to exercise such rights, options or warrants divided by the Current Market Price as of the Record
Date for such dividend, distribution or other issuance.

 

For purposes of this clause (ii),
in determining whether any rights, options or warrants entitle the holders to purchase the Class A Common Stock at a price per
share that is less than the Current Market Price as of the Record Date for such dividend, distribution or issuance, there shall
be taken into account any consideration the Company receives for such rights, options or warrants, and any amount payable on exercise
thereof, with the value of such consideration, if other than cash, to be the Fair Market Value thereof.

 

    17

     

    

 

Any adjustment made pursuant to this clause
(ii) shall become effective immediately following the close of business on the Record Date for such dividend, distribution or other
issuance. In the event that such rights, options or warrants are not so issued, the Conversion Rate shall be readjusted, effective
as of the date the Board publicly announced its decision not to issue such rights, options or warrants to the Conversion Rate that
would then be in effect if such dividend, distribution or issuance had not been declared. To the extent that such rights, options
or warrants are not exercised prior to their expiration or shares of Class A Common Stock are otherwise not delivered pursuant
to such rights, options or warrants upon the exercise of such rights, options or warrants, the Conversion Rate shall be readjusted
to the Conversion Rate that would then be in effect had the adjustments made upon the dividend, distribution or other issuance
of such rights, options or warrants been made on the basis of the delivery of only the number of shares of Class A Common Stock
actually delivered.

 

(iii)           
The Company shall, by dividend or otherwise, distribute to all or substantially all holders of its Class A Common Stock
(other than for cash in lieu of fractional shares), shares of any class of its Capital Stock, evidences of its indebtedness, assets,
other property or securities, but excluding (A) dividends or distributions referred to in Section 10(a)(i) or Section
10(a)(ii) hereof; (B) Distribution Transactions as to which Section 10(a)(iv) shall apply; (C) dividends or distributions
paid exclusively in cash; and (D) rights, options or warrants distributed in connection with a stockholder rights plan as to which
Section 10(a)(v) shall apply (any of such shares of its Capital Stock, indebtedness, assets or property that are not so
excluded are hereinafter called the “Distributed Property”), then,
in each such case the Conversion Rate shall be adjusted based on the following formula:

 

CR1 = CR0 x [SP0
/ (SP0 - FMV)]

 

where,

 

CR0        =        the Conversion Rate in effect
immediately prior to the close of business on the Record Date for such dividend or distribution;

 

CR1        =        the new Conversion Rate in effect
immediately after the close of business on the Record Date for such dividend or distribution;

 

SP0        =        the Current Market Price as of
the Record Date for such dividend or distribution; and

 

FMV      =         the Fair Market Value of the portion of
Distributed Property distributed with respect to each outstanding share of Class A Common Stock on the Record Date for such dividend
or distribution; provided, however, that, if FMV is equal or greater than SP0, then in lieu of the foregoing
adjustment, the Company shall distribute to each holder of Series B-2 Preferred Stock on the date the applicable Distributed Property
is distributed to holders of Class A Common Stock, but without requiring such holder to convert its shares of Series B-2 Preferred
Stock, in respect of each share of Series B-2 Preferred Stock held by such holder, the amount of Distributed Property such holder
would have received had such holder owned a number of shares of Class A Common Stock equal to the Conversion Rate on the Record
Date for such dividend or distribution

 

    18

     

    

 

Any adjustment made pursuant to this clause
(iii) shall be effective immediately after the close of business on the Record Date for such dividend or distribution. If any such
dividend or distribution is declared but does not occur, the Conversion Rate shall be readjusted, effective as of the date the
Board announces that such dividend or distribution shall not occur to the Conversion Rate that would then be in effect if such
dividend or distribution had not been declared.

 

(iv)            
The Company effects a Distribution Transaction, in which case the Conversion Rate in effect immediately prior to the effective
date of the Distribution Transaction shall be increased based on the following formula:

 

CR1 = CR0 x [(FMV
+ MP0) / MP0]

 

where,

 

CR0        =        the Conversion Rate in effect
immediately prior to the close of business on the effective date of the Distribution Transaction;

 

CR1        =        the new Conversion Rate in effect
immediately after the close of business on the effective date of the Distribution Transaction;

 

FMV      =        the arithmetic average of the volume-weighted
average prices for a share of the capital stock or other interest distributed to holders of Class A Common Stock on the principal
United States securities exchange or automated quotation system on which such capital stock or other interest trades, as reported
by Bloomberg (or, if Bloomberg ceases to publish such price, any successor service chosen by the Company) in respect of the period
from the open of trading on the relevant Trading Day until the close of trading on such Trading Day (or if such volume-weighted
average price is unavailable, the market price of one (1) share of such capital stock or other interest on such Trading Day determined,
using a volume-weighted average method, as mutually agreed between the Company and the Holders of a majority of the Series B-2
Preferred Stock or, in the absence of such agreement, as determined by an Independent Financial Advisor retained for such purpose
by the Company), for each of the ten (10) consecutive full Trading Days commencing with, and including, the effective date of the
Distribution Transaction; and

 

MP0       =         the arithmetic average of the
VWAP per share of Class A Common Stock for each of the ten (10) consecutive full Trading Days commencing on, and including, the
effective date of the Distribution Transaction

 

Such adjustment
shall become effective immediately following the close of business on the effective date of the Distribution Transaction. If an
adjustment to the Conversion Rate is required under this Section 10(a)(iv), delivery of any additional shares of
Series B-1 Preferred Stock that may be deliverable upon conversion as a result of an adjustment required under this Section
10(a)(iv) shall be delayed only to the extent necessary in order to complete the calculations provided for in this Section
10(a)(iv).

 

    19

     

    

 

(v)              
If the Company has a stockholder rights plan in effect with respect to the Class A Common Stock on any Conversion Date,
upon conversion of any shares of the Series B-2 Preferred Stock, Holders of such shares will receive, in addition to the applicable
number of shares of Class A Common Stock, the rights under such rights plan relating to such Class A Common Stock, unless, prior
to such Conversion Date, the rights have (i) become exercisable or (ii) separated from the shares of Class A Common Stock (the
first of such events to occur, a “Trigger Event”), in which case,
the Conversion Rate will be adjusted, effective automatically at the time of such Trigger Event, as if the Company had made a
distribution of such rights to all holders of the Class A Common Stock as described in Section 10(a)(ii) (without giving
effect to the forty-five (45)-day limit on the exercisability of rights, options or warrants ordinarily subject to such Section
10(a)(ii)), subject to appropriate readjustment in the event of the expiration, termination or redemption of such rights prior
to the exercise, deemed exercise or exchange thereof. Notwithstanding the foregoing, to the extent any such stockholder rights
are exchanged by the Company for shares of Class A Common Stock or other property or securities, the Conversion Rate shall be
appropriately readjusted as if such stockholder rights had not been issued, but the Company had instead issued such shares of
Class A Common Stock or other property or securities as a dividend or distribution of shares of Class A Common Stock pursuant
to Section 10(a)(i) or Section 10(a)(iii), as applicable.

 

To the extent that such rights are not exercised
prior to their expiration, termination or redemption, the Conversion Rate shall be readjusted to the Conversion Rate that would
then be in effect had the adjustments made upon the occurrence of the Trigger Event been made on the basis of the issuance of,
and the receipt of the exercise price with respect to, only the number of shares of Class A Common Stock actually issued pursuant
to such rights.

 

Notwithstanding
anything to the contrary in this Section 10(a)(v), no adjustment shall be required to be made to the Conversion
Rate with respect to any Holder which is, or is an “affiliate” or “associate” of, an “acquiring
person” under such stockholder rights plan or with respect to any direct or indirect transferee of such Holder who receives
Series B-2 Preferred Stock in such transfer after the time such Holder becomes, or its affiliate or associate becomes, such an
 “acquiring person.”

 

(b)              
Calculation of Adjustments. All adjustments to the Conversion Rate shall be calculated by the Company to the nearest
1/10,000th of one (1) share of Class A Common Stock (or if there is not a nearest 1/10,000th of a share, to the next lower 1/10,000th
of a share). No adjustment to the Conversion Rate will be required, unless such adjustment would require an increase or decrease
of at least one percent (1%) of the Conversion Rate; provided, however, that any such adjustment that is not required
to be made will be carried forward and taken into account in any subsequent adjustment; provided, further, that any
such adjustment of less than one percent (1%) that has not been made will be made upon any Conversion Date.

 

(c)              
When No Adjustment Required. (i) Except as otherwise provided in this Section 10, the Conversion Rate will
not be adjusted for the issuance of Class A Common Stock or any securities convertible into or exchangeable for Class A Common
Stock or carrying the right to purchase any of the foregoing, or for the repurchase of Class A Common Stock.

 

    20

     

    

 

(ii)            
Except as otherwise provided in this Section 10, the Conversion Rate will not be adjusted as a result of the issuance
of, the distribution of separate certificates representing, the exercise or redemption of, or the termination or invalidation
of, rights pursuant to any stockholder rights plans.

 

(iii)           
No adjustment to the Conversion Rate will be made:

 

(A)            
upon the issuance of any shares of Class A Common Stock pursuant to any present or future plan providing for the reinvestment
of dividends or interest payable on securities of the Company and the investment of additional optional amounts in Class A Common
Stock under any plan in which purchases are made at market prices on the date or dates of purchase, without discount, and whether
or not the Company bears the ordinary costs of administration and operation of the plan, including brokerage commissions;

 

(B)             
upon the issuance of any shares of Class A Common Stock or options or rights to purchase such shares pursuant to any present
or future employee, director or consultant benefit plan or program of or assumed by the Company or any of its Subsidiaries or of
any employee agreements or arrangements or programs;

 

(C)             
upon the issuance of any shares of Class A Common Stock pursuant to any option, warrant, right, or exercisable, exchangeable
or convertible security;

 

(D)            
for dividends or distributions declared or paid to holders of Class A Common Stock in which Holders participate pursuant
to Section 4(b); or

 

(E)             
for a change solely in the par value of the Class A Common Stock.

 

(d)              
Successive Adjustments. After an adjustment to the Conversion Rate under this Section 10, any subsequent
event requiring an adjustment under this Section 10 shall cause an adjustment to each such Conversion Rate as so adjusted.

 

(e)              
Multiple Adjustments. For the avoidance of doubt, if an event occurs that would trigger an adjustment to the Conversion
Rate pursuant to this Section 10 under more than one subsection hereof, such event, to the extent fully taken into account
in a single adjustment, shall not result in multiple adjustments hereunder; provided, however, that if more than
one subsection of this Section 10 is applicable to a single event, the subsection shall be applied that produces the largest
adjustment.

 

(f)               
Tax Adjustments. The Company may, but shall not be required to, make such increases in the Conversion Rate and,
if applicable, the Preferred Conversion Rate, in addition to those required by this Section 10, as the Board considers
to be advisable in order to avoid or diminish any income tax to any holders of shares of Company stock resulting from any dividend
or distribution of stock or issuance of rights or warrants to purchase or subscribe for stock or from any event treated as such
for income tax purposes or for any other reason.

 

    21

     

    

 

(g)              
Notice of Adjustments. Subject to Section 5.3(c) of the Investment Agreement, whenever the Conversion Rate or, if
applicable, the Preferred Conversion Rate is adjusted as provided under this Section 10, the Company shall as soon as reasonably
practicable following the occurrence of an event that requires such adjustment (or if the Company is not aware of such occurrence,
as soon as reasonably practicable after becoming so aware) or the date the Company makes an adjustment pursuant to Section
10(f):

 

(i)              
compute the adjusted applicable Conversion Rate in accordance with this Section 10; and

 

(ii)             
in the event that the Company shall give notice to the holders of Class A Common Stock of, or publicly announces or publicly
discloses, any action of the type described in Section 10 (but only if the action of the type described in Section 10
would result in an adjustment to the Conversion Price or a change in the type of securities or property to be delivered upon
conversion of the Series B-2 Preferred Stock), the Company shall, at the time of such notice, announcement or disclosure, and
in the case of any action that would require the fixing of a record date, at least ten (10) days prior to such record date, give
notice to each Holder by mail, first-class postage prepaid, at the address appearing in the Register, which notice shall specify
the record date, if any, with respect to any such action, the approximate date on which such action is to take place and the facts
with respect to such action as shall be reasonably necessary to indicate the effect on the Conversion Price and the number, kind
or class of shares or other securities or property, which shall be deliverable upon conversion or redemption of the Series B-2
Preferred Stock and the Conversion Shares; and

 

(iii)            
whenever the Conversion Price shall be adjusted pursuant to one or more provisions of Section 10, the Company shall,
as soon as practicable following the determination of the revised Conversion Price (and the resulting Preferred Stock Conversion
Price), (A) file at the principal office of the Company, a statement showing in reasonable detail the facts requiring such adjustment,
the Conversion Price (and the Preferred Stock Conversion Price) that shall be in effect after such adjustment and the method by
which the adjustment to the Conversion Price (and Preferred Stock Conversion Price) was determined and (B) cause a copy of such
statement to be sent in the manner set forth in clause (ii) to each Holder.

 

(h)              
Notwithstanding anything herein to the contrary, if an event occurs that would trigger an adjustment to the Conversion
Rate pursuant to this Section 10 also triggers an adjustment to the Series B-1 Conversion Rate, such event, to the extent
fully taken into account in the adjustment to the Series B-1 Conversion Rate, shall not result in an adjustment hereunder.

 

Section
11.  Adjustment for Reorganization Events.

 

(a)              
Reorganization Events. In the event of:

 

(i)              
any reclassification, statutory exchange, merger, consolidation or other similar business combination of the Company with
or into another Person, in each case, pursuant to which at least a majority of the Class A Common Stock is changed or converted
into, or exchanged for, cash, securities or other property of the Company or another Person;

 

    22

     

    

 

(ii)             
any sale, transfer, lease or conveyance to another Person of all or substantially all the property and assets of the Company,
in each case pursuant to which the Class A Common Stock is converted into cash, securities or other property; or

 

(iii)            
any statutory exchange of securities of the Company with another Person (other than in connection with a merger or acquisition)
or reclassification, recapitalization or reorganization of the Class A Common Stock into other securities;

 

(each of which
is referred to as a “Reorganization Event” and the cash, securities
or other property into which the Class A Common Stock is changed, converted or exchanged, the “Exchange Property”
and the amount and kind of Exchange Property that a holder of one (1) share of Class A Common Stock would be entitled to receive
on account of such Reorganization Event (without giving effect to any arrangement not to issue or deliver a fractional portion
of any security or other property), an “Exchange Property Unit”), then, notwithstanding anything to the contrary
in this Certificate of Designations, from and after the effective time of such Reorganization Event, without the consent of the
Holders, each share of Series B-2 Preferred Stock will remain outstanding (unless converted in accordance with Section 11(d))
and (I) the consideration due upon conversion of any Series B-2 Preferred Stock will be determined in the same manner as if each
reference to any number of shares of Class A Common Stock in Section 10 or in this Section 11, or in any related
definitions, were instead a reference to the same number of Exchange Property Units; (II) for purposes of Sections 6 and
7, each reference to any number of shares of Class A Common Stock in such Sections (or in any related definitions) will
instead be deemed to be a reference to the same number of Exchange Property Units (and the terms of any conversion shall be based
upon the Original Issue Price at the time of such subsequent conversion); and (III) other references to “Class A Common Stock”
shall refer to the Exchange Property with appropriate adjustment to preserve, to the greatest extent possible (so long as there
is no detrimental effect to the Company), the economic and other rights in respect of the Series B-2 Preferred Stock granted by
this Certificate of Designations and the Investment Agreement; provided, however, that the foregoing shall not apply
if such Holder is a Person with which the Company consolidated or into which the Company merged or which merged into the Company
or to which such sale or transfer was made, as the case may be (any such Person, a “Constituent
Person”), or an Affiliate of a Constituent Person, to the extent such Reorganization Event provides for different
treatment of Class A Common Stock held by such Persons. If the kind or amount of securities, cash and other property receivable
upon such Reorganization Event is not the same for each share of Class A Common Stock held immediately prior to such Reorganization
Event by a Person (other than a Constituent Person or an Affiliate thereof), then for the purpose of this Section 11(a),
the kind and amount of securities, cash and other property receivable upon conversion following such Reorganization Event will
be deemed to be the weighted average of the types and amounts of consideration received by the holders of Class A Common Stock.

 

(b)              
Successive Reorganization Events. The above provisions of this Section 11 shall similarly apply to successive
Reorganization Events.

 

(c)              
Reorganization Event Notice. Subject to Section 5.3(c) of the Investment Agreement, if the Company (or any successor)
delivers notice to the holders of Class A Common Stock, or makes a public announcement or public disclosure, with respect to a
Reorganization Event, then, at the same time as such notice is delivered to the holders of Class A Common Stock or, in the case
of a public announcement or public disclosure, on the same date as such announcement, the Company shall provide written notice
to the Holders of such event and of the kind and amount of the cash, securities or other property that constitutes the Exchange
Property. Failure to deliver such notice shall not affect the operation of this Section 11.

 

    23

     

    

 

(d)              
Reorganization Event Agreements. The Company shall not enter into any agreement for a transaction constituting a
Reorganization Event, unless (i) such agreement provides for or does not interfere with or prevent (as applicable) conversion
of the Series B-2 Preferred Stock into the Exchange Property in a manner that is consistent with and gives effect to this Section
11, and (ii) to the extent that the Company is not the surviving corporation in such Reorganization Event or will be dissolved
in connection with such Reorganization Event, proper provision shall be made in the agreements governing such Reorganization Event
for the conversion of the Series B-2 Preferred Stock into stock of the Person surviving such Reorganization Event or such other
continuing entity in such Reorganization Event.

 

(e)              
Change of Control. For the sake of clarity, if a Reorganization Event constitutes a Change of Control, then Section
9 shall take precedence over this Section 11 to the extent there is any inconsistency between such sections.

 

Section
12.  Adverse Changes; Voting Rights.

 

(a)              
So long as any shares of Series B-2 Preferred Stock are outstanding, in addition to any other vote required by applicable
law, the Company may not take any of the following actions (including by means of merger, consolidation, reorganization, recapitalization
or otherwise) without the prior affirmative vote or written consent from the Holders of at least a majority of the then-issued
and outstanding shares of Series B-2 Preferred Stock, voting as a separate class: amend, alter, repeal or otherwise modify (whether
by merger, consolidation or otherwise) any provision of the Certificate of Incorporation (including this Certificate of Designations)
in a manner that would adversely affect the powers, preferences, rights or privileges of the Series B-2 Preferred Stock or otherwise
alter or amend this Certificate of Designations.

 

(b)              
Each Holder of Series B-2 Preferred Stock will have one (1) vote per share on any matter on which Holders of Series B-2
Preferred Stock are entitled to vote separately as a class, whether at a meeting or by written consent.

 

(c)              
For the avoidance of doubt and notwithstanding anything to the contrary in the Certificate of Incorporation or By-Laws,
the Holders shall have the exclusive consent and voting rights set forth in Section 12(a) and may take action or consent
to any action with respect to such rights without a meeting by delivering a consent in writing or by electronic transmission of
the Holders of the Series B-2 Preferred Stock entitled to cast not less than the minimum number of votes that would be necessary
to authorize, take or consent to such action at a meeting of stockholders.

 

(d)              
Except as otherwise provided herein or as otherwise required by Delaware General Corporation Law, the Series B-2 Preferred
Stock shall have no voting rights.

 

    24

     

    

 

Section
13.  Status of Shares. Shares of Series B-2 Preferred Stock that have been issued and reacquired in any manner,
whether by redemption, repurchase or otherwise or upon any conversion of shares of Series B-2 Preferred Stock to Class A Common
Stock, shall thereupon be retired and shall have the status of authorized and unissued shares of preferred stock of the Company
undesignated as to series, and may be redesignated as any series of preferred stock of the Company and reissued.

 

Section
14.  Term. Except as expressly provided in this Certificate of Designations, the shares of Series B-2 Preferred
Stock shall not be redeemable or otherwise mature and the term of the Series B-2 Preferred Stock shall be perpetual.

 

Section
15.  Creation of Capital Stock. The Board, without the vote of the Holders, may authorize and issue additional
shares of Capital Stock of the Company.

 

Section
16.  No Sinking Fund. Shares of Series B-2 Preferred Stock shall not be subject to or entitled to the operation
of a retirement or sinking fund.

 

Section
17.  Taxes. (a) Transfer Taxes. The Company shall pay any and all stock transfer, documentary, stamp
and similar taxes that may be payable in respect of any issuance or delivery of shares of Series B-2 Preferred Stock or Preferred
Conversion Shares or other securities issued on account of Series B-2 Preferred Stock pursuant hereto or certificates representing
such shares or securities. The Company shall not, however, be required to pay any such tax that may be payable in respect of any
transfer involved in the issuance or delivery of shares of Series B-2 Preferred Stock, Preferred Conversion Shares or other securities
in a name other than the name in which the shares of Series B-2 Preferred Stock with respect to which such shares or other securities
are issued or delivered were registered, or in respect of any payment to any Person other than a payment to the registered holder
thereof, and shall not be required to make any such issuance, delivery or payment, unless and until the Person otherwise entitled
to such issuance, delivery or payment has paid to the Company the amount of any such tax or has established, to the satisfaction
of the Company, that such tax has been paid or is not payable.

 

(b)              
Withholding. All payments and distributions (or deemed distributions) on the shares of Series B-2 Preferred Stock
(and on the shares of Series B-1 Preferred Stock received upon their conversion) shall be subject to withholding and backup withholding
of taxes to the extent required by law, subject to applicable exemptions, and amounts withheld, if any, shall be treated as received
by the Holders. The Company shall use commercially reasonably efforts to notify the Holders of any amounts expected to be deducted
and withheld pursuant to the preceding sentence reasonably prior to the relevant payment date and the basis for such deduction
and withholding and shall reasonably cooperate with the applicable Holders to reduce or eliminate any such deductions and withholdings
to the extent permitted under applicable law.

 

(c)              
Tax Treatment. The Series B-2 Preferred Stock is intended to be treated as common stock that does not constitute
 “preferred stock” within the meaning of Section 305 of the Internal Revenue Code of 1986, as amended, and the Company
shall apply the provisions of this Certificate of Designations consistent with such intention.

 

    25

     

    

 

Section
18.  Notices. All notices referred to herein shall be in writing and, unless otherwise specified herein, all
notices hereunder shall be deemed to have been given upon the earlier of receipt thereof or three (3) Business Days after the mailing
thereof if sent by registered or certified mail (unless first-class mail shall be specifically permitted for such notice under
the terms of this Certificate of Designations) with postage prepaid, addressed, (i) if to the Company, to its office at 220 West
Germantown Pike, Suite 250, Plymouth Meeting, PA 19462 (Attention: General Counsel), or to any transfer or other agent of the Company
designated to receive such notice as permitted by this Certificate of Designations; (ii) if to any Holder, to such Holder at the
address of such Holder as listed in the Register; or (iii) to such other address as the Company or any such Holder, as the case
may be, shall have designated by notice similarly given.

 

Section
19.  Facts Ascertainable. When the terms of this Certificate of Designations refer to a specific agreement or
other document to determine the meaning or operation of a provision hereof, the Secretary of the Company shall maintain a copy
of such agreement or document at the principal executive offices of the Company and a copy thereof shall be provided free of charge
to any Holder who makes a request therefor. The Secretary of the Company shall also maintain a written record of the Issuance Date,
the number of shares of Series B-2 Preferred Stock issued to a Holder and the date of each such issuance, and shall furnish such
written record free of charge to any Holder who makes a request therefor.

 

Section
20.  Waiver. Notwithstanding any provision in this Certificate of Designations to the contrary, any provision
contained herein and any right of the Holders of Series B-2 Preferred Stock granted hereunder may be waived as to all shares of
Series B-2 Preferred Stock (and the Holders thereof) upon the written consent of the Holders of a majority of the shares of Series
B-2 Preferred Stock then outstanding.

 

Section
21.  Severability. If any term of the Series B-2 Preferred Stock set forth herein is invalid, unlawful or incapable
of being enforced by reason of any rule of law or public policy, all other terms set forth herein, which can be given effect without
the invalid, unlawful or unenforceable term will, nevertheless, remain in full force and effect, and no term herein set forth will
be deemed dependent upon any other such term, unless so expressed herein.

 

Section
22.  No Other Rights. Except as expressly provided in any agreement between a Holder and the Company, the Series
B-2 Convertible Preferred Stock will have no rights, preferences or voting powers, except as provided in this Certificate of Designations
or the Certificate of Incorporation or as provided by applicable law.

 

[Signature Page Follows]

 

    26

     

    

 

This Certificate of Designations has been
approved by the Board in the manner and by the vote required by law.

 

The undersigned acknowledges this Certificate
of Designations to be the corporate act of the Company and, as to all matters or facts required to be verified under oath, the
undersigned acknowledges that, to the best of his or her knowledge, information and belief, these matters and facts are true in
all material respects and that this statement is made under the penalties for perjury.

 

IN WITNESS WHEREOF, the Company has caused
this Certificate of Designations to be signed in its name and on its behalf by its _____________ and attested to by its ____________
on this _____ day of [●], 2020.

 

 

	ATTEST:	 	ADAPTHEALTH CORP.
	 	 	 	 
	 	 	 	 
	 	 	By:	 
	Name: 	 	 	Name:
	Title:	 	 	Title:

 

    27

     

    

 

Exhibit I

ADAPTHEALTH
CORP.CONVERSION NOTICE

 

Reference is made to
the Certificate of Designation, Preferences and Rights of the Series B-2 Convertible Preferred Stock of AdaptHealth Corp. (the
 “Certificate of Designations”). In accordance with and pursuant to the Certificate of Designations, the undersigned
hereby elects to convert the number of shares of Series B-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series
B-2 Preferred Stock”), of AdaptHealth Corp., a Delaware corporation (the “Company”), indicated below into shares
of Series B-1 Preferred Stock, par value $0.0001 per share, of the Company (the “Series B-1 Preferred Stock”), [as
of the date specified below][[upon/immediately prior to], and subject to the occurrence of, [●]].

 

Date of Conversion (if applicable): ___________________________________________

Number of shares of Series B-2 Preferred
Stock to be converted: _____________________

 

Please
confirm the following information:

 

Conversion Price: ________________________________________________________

Number of shares of Series B-1 Preferred
Stock to be issued:________________________

 

Please issue the shares of Series B-1 Preferred
Stock into which the shares of Series B-2 Preferred Stock are being converted in the following name and to the following address:

 

Issue to: _________________________________________

Address: _________________________________________

Telephone Number: _________________________________

Email: ____________________________________________

Dated: ___________________________________________

Account Number (if electronic book entry
transfer): _____________________________

 

     

     

    

 

Annex II

 

Form of Amended and Restated Registration Rights Agreement

 

     

     

    

 

AMENDED AND RESTATED REGISTRATION RIGHTS
AGREEMENT

 

This AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is dated as of [●], 2020, by and among (i) AdaptHealth
Holdings LLC, a Delaware limited liability company (the “Company”), (ii) AdaptHealth Corp., a Delaware
corporation (“Pubco”), (iii) each of the Persons listed on the Schedule of Investors attached hereto as
of the date hereof, and (iv) each of the other Persons set forth from time to time on the Schedule of Investors who, at any
time, own securities of the Company or Pubco and enter into a Joinder to this Agreement agreeing to be bound by the terms hereof
(each Person identified in the foregoing (iii) and (iv), an “Investor” and, collectively, the “Investors”).
This Agreement shall become effective as of the Closing pursuant to the OEP Investment Agreement (as defined below). Unless otherwise
provided in this Agreement, capitalized terms used herein shall have the meanings set forth in Section 12 hereof.

 

WHEREAS, Pubco and certain
of the Investors are parties to that certain Registration Rights Agreement, dated as of November 8, 2019, as amended (the
 “Prior Agreement”);

 

WHEREAS, Pubco and OEP
AHCO Investment Holdings, LLC (“OEP”) entered into an Investment Agreement, dated as of May 25, 2020 (the
 “OEP Investment Agreement”), pursuant to which, OEP agreed to purchase and Pubco agreed to sell shares of Series A
Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), of Pubco;

 

WHEREAS, Pubco, Deerfield
Partners, L.P. (“Deerfield Partners”) (together with Deerfield Private Design Fund IV, the “Deerfield
Investors”) entered into an Investment Agreement, dated as of [●], 2020 (the “Deerfield Investment Agreement”),
pursuant to which, Deerfield Partners agreed to purchase and Pubco agreed to sell shares of Series B-2 Convertible Preferred
Stock, par value $0.0001 per share (the “Series B-2 Preferred Stock”), of Pubco;

 

WHEREAS, Section 13(d) of
the Prior Agreement provides that an amendment may occur with the prior written consent of Pubco and the holders of a majority
of the Registrable Securities (as such term is used therein) then outstanding (the “Requisite Holders”); and

 

WHEREAS, Pubco and the
Requisite Holders desire to amend and restate the terms and conditions of the Prior Agreement and to provide for the terms and
conditions included herein and to include the recipients of the other Registrable Securities identified herein.

 

NOW, THEREFORE, in consideration
of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties to this Agreement hereby agree as follows:

 

     

     

    

 

1.            Resale
Shelf Registration Rights.

 

(a)            Registration
Statement Covering Resale of Registrable Securities. Pubco filed with the Commission a Registration Statement on Form S-1
(“Form S-1”) for an offering to be made on a delayed or continuous basis pursuant to Rule 415 of the
Securities Act registering the resale from time to time by the Investors of all of the Registrable Securities held by the Investors
(other than OEP) (the “Existing Resale Shelf Registration Statement”). Pubco shall use reasonable best efforts
to keep the Existing Resale Shelf Registration Statement continuously effective to be supplemented and amended to the extent necessary
to ensure that such Existing Resale Shelf Registration Statement is available or, if not available, to ensure that another Registration
Statement is available (which replacement Registration Statement shall be deemed an Existing Resale Shelf Registration Statement),
under the Securities Act at all times until such date as all Registrable Securities covered by the Existing Resale Shelf Registration
Statement, including the Registrable Securities held by the OEP Parties to be added to the Existing Resale Shelf Registration Statement
in accordance with Section 1(b), have been disposed of in accordance with the intended method(s) of distribution set
forth in such Registration Statement or such securities have been withdrawn (the “Effectiveness Period”); provided,
that Pubco may amend the Existing Resale Shelf Registration Statement in accordance with Section 1(b) and Section 1(c).
Without limiting the foregoing or any of Pubco’s obligations under this Agreement, the Company will take such actions, including
filing supplements to the prospectus included in such Registration Statement, as shall be necessary to ensure that the Existing
Resale Shelf Registration Statement remains effective and available for the resale of all of the shares of Common Stock issuable
upon conversion or otherwise in respect of any Series B-1 Preferred Stock (in addition to all of the other Registrable Securities
covered by the Existing Resale Shelf Registration Statement) in accordance with the plan of distribution set forth therein. The
Existing Resale Shelf Registration Statement shall contain a Prospectus in such form as to permit any Investor to sell such Registrable
Securities pursuant to Rule 415 under the Securities Act (or any successor or similar provision adopted by the Commission
then in effect) at any time beginning on the effective date for such Registration Statement (subject to lock-up restrictions provided
in this Agreement and in the Lock-Up Agreements), and shall provide that such Registrable Securities may be sold pursuant to any
method or combination of methods legally available to, and requested by, the Investors; provided, that Pubco may amend the Existing
Resale Shelf Registration Statement in accordance with Section 1(b), Section 1(c), Section 1(d) or Section 1(e).

 

    - 2 -

     

    

 

(b)            Pubco
shall use its reasonable best efforts to prepare and file or cause to be prepared and filed with the SEC no later than the
date that is sixty (60) days prior to the Restricted Period Termination Date (as defined in the OEP Investment Agreement),
either, at the sole discretion of Pubco, (x) a Registration Statement for an offering to be made on a continuous basis
pursuant to Rule 415 of the Securities Act (provided, that such Registration Statement replaces and becomes the Existing
Resale Shelf Registration Statement) or (y) an amendment or prospectus supplement to the Existing Resale Shelf
Registration Statement registering the resale from time to time by the OEP Parties of all of the Registrable Securities held
by the OEP Parties (such Registration Statement, as amended, the “OEP Resale Shelf Registration
Statement”). The OEP Resale Shelf Registration Statement shall be on Form S-3 or, if Form S-3 is not then
available to Pubco, on Form S-1 or such other appropriate form permitting Registration of the Registrable
Securities for resale by the OEP Parties. The OEP Resale Shelf Registration Statement shall contain a Prospectus in such form
as to permit the OEP Parties to sell the Registrable Securities pursuant to Rule 415 under the Securities Act (or any
successor or similar provision adopted by the SEC then in effect) at any time beginning on the effective date for the OEP
Resale Shelf Registration Statement (subject to lock-up or transfer restrictions pursuant to Section [5.3] of the OEP
Investment Agreement and in this Agreement), and shall provide that the Registrable Securities held by the OEP Parties may be
sold pursuant to any method or combination of methods legally available to, and requested by, the OEP Parties. Pubco shall
use its reasonable best efforts to cause the OEP Resale Shelf Registration Statement to be declared effective as soon as
possible after filing, but in no event later than the Restricted Period Termination Date. Once effective, Pubco shall use its
reasonable best efforts to keep the OEP Resale Shelf Registration Statement continuously effective and in compliance with the
Securities Act and useable for the resale of the Registrable Securities covered by the OEP Resale Shelf Registration
Statement, including by filing successive replacement or renewal OEP Resale Shelf Registration Statements upon the expiration
of the OEP Resale Shelf Registration Statement, until such time as the OEP Parties no longer hold Registrable Securities. The
OEP Parties shall be entitled, at any time and from time to time when the OEP Resale Shelf Registration Statement is
effective (subject to lock-up or transfer restrictions provided the OEP Investment Agreement and in this Agreement), to sell
any or all of the Registrable Securities covered by the OEP Resale Shelf Registration Statement. Notwithstanding the first
sentence of this Section 1(b), in the event of the occurrence of a Restricted
Period Early Termination Event (as defined in the OEP Investment Agreement) prior to the date that is sixty (60) days prior
to the Restricted Period Termination Date, Pubco shall use reasonable best efforts to file and cause to be declared effective
the OEP Resale Shelf Registration Statement for the Registrable Securities with respect to which the lockup period has
terminated within thirty (30) days following such termination. Pubco shall pay all Registration Expenses in connection with
the filing of the OEP Resale Shelf Registration Statement.

 

(c)            If
any OEP Party becomes a holder of Registrable Securities after the OEP Resale Shelf Registration Statement is declared effective
in accordance with Section 1(b), and such OEP Party has executed a Joinder entitling it to the benefits of this Agreement,
then Pubco shall, as promptly as is reasonably practicable following delivery of written notice to Pubco of such OEP Party becoming
a holder of Registrable Securities and requesting for its name to be included as a selling securityholder in the Prospectus related
to the OEP Resale Shelf Registration Statement:

 

(i)            if
required and permitted by applicable law, file with the Commission a supplement to the related Prospectus or a post-effective
amendment to the OEP Resale Shelf Registration Statement so that such OEP Party is named as a selling securityholder
in the OEP Resale Shelf Registration Statement and the related Prospectus in such a manner as to permit such OEP Party to
deliver a prospectus to purchasers of the Registrable Securities in accordance with applicable law; provided, however, that
Pubco shall not be required to file more than one post-effective amendment or a supplement to the related prospectus for such
purpose in any 45-day period;

 

(ii)           if,
pursuant to Section 1(c)(i), Pubco shall have filed a post-effective amendment to the OEP Resale Shelf Registration
Statement that is not automatically effective, use its reasonable best efforts to cause such post-effective amendment to become
effective under the Securities Act as promptly as is reasonably practicable; and

 

(iii)          notify
such OEP Party as promptly as is reasonably practicable after the effectiveness of any post-effective amendment filed pursuant
to Section 1(c)(i).

 

    - 3 -

     

    

 

(d)            Pubco
shall use its reasonable best efforts to prepare and file or cause to be prepared and filed with the SEC, as soon as reasonably
possible following the date hereof, but in no event later than the fifteenth (15th) day following the date hereof, either,
at the sole discretion of Pubco, (x) a Registration Statement for an offering to be made on a continuous basis pursuant to
Rule 415 of the Securities Act (provided, that such Registration Statement replaces and becomes the Existing Resale Shelf
Registration Statement) or (y) to the extent permitted under applicable Law, an amendment or prospectus supplement to the
Existing Resale Shelf Registration Statement registering the resale from time to time by each Deerfield Party of all of the Registrable
Securities held by it (such Registration Statement, as amended, the “Deerfield Resale Shelf Registration Statement”).
The Deerfield Resale Shelf Registration Statement shall be on Form S-3 or, if Form S-3 is not then available to Pubco,
on Form S-1 or such other appropriate form permitting Registration of Registrable Securities for resale by the Deerfield Parties.
The Deerfield Resale Shelf Registration Statement shall contain a Prospectus in such form as to permit each Deerfield Party to
sell the Registrable Securities pursuant to Rule 415 under the Securities Act (or any successor or similar provision adopted
by the SEC then in effect) at any time beginning on the effective date for the Deerfield Resale Shelf Registration Statement (subject
to lock-up or transfer restrictions pursuant to Section [5.3] of the Deerfield Investment Agreement and Section 4(a) hereof),
and shall provide that the Registrable Securities held by each Deerfield Party may be sold pursuant to any method or combination
of methods legally available to, and requested by, such Deerfield Party and in accordance with a plan of distribution approved
by such Deerfield Party. Pubco shall use its reasonable best efforts to cause the Deerfield Resale Shelf Registration Statement
to be declared effective as soon as possible after filing, but in no event later than the ninetieth (90th) day following the Closing
Date. Without limiting the foregoing, as soon as practicable, but in no event later than five (5) business days, following
the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such Registration
Statement or any amendment thereto will not be subject to review, Pubco shall file a request for acceleration of effectiveness
of such Registration Statement (to the extent required, by declaration or ordering of effective, of such Registration Statement
or amendment by the SEC) to a time and date not later than two (2) business days after the submission of such request. No
later than two (2) business days after the Registration Statement becomes effective, Pubco shall file with the SEC the final
prospectus included in the Registration Statement pursuant to Rule 424 (or successor thereto) under the Securities Act. Once
effective, Pubco shall use its reasonable best efforts to

    - 4 -

     

    

keep the Deerfield Resale Shelf Registration
Statement continuously effective and in compliance with the Securities Act and useable for the resale of the Registrable Securities
covered by the Deerfield Resale Shelf Registration Statement, including by filing successive replacement or renewal Deerfield Resale
Shelf Registration Statements upon the expiration of the Deerfield Resale Shelf Registration Statement, until such time as no Deerfield
Party holds any Registrable Securities. Each Deerfield Party shall be entitled, at any time and from time to time when the Deerfield
Resale Shelf Registration Statement is effective, to sell any or all of the Registrable Securities held by it and covered by the
Deerfield Resale Shelf Registration Statement. Pubco shall pay all Registration Expenses in connection with the filing of the Deerfield
Resale Shelf Registration Statement.

 

(e)            If
any Deerfield Party becomes a holder of Registrable Securities after the Deerfield Resale Shelf Registration Statement is declared
effective in accordance with Section 1(d), and such Deerfield Party has executed a Joinder entitling it to the benefits
of this Agreement, then Pubco shall, as promptly as is reasonably practicable following delivery of written notice to Pubco of
such Deerfield Party becoming a holder of Registrable Securities and requesting for its name to be included as a selling securityholder
in the Prospectus related to the Deerfield Resale Shelf Registration Statement:

 

    - 5 -

     

    

 

(i)            if
required and permitted by applicable law, file with the Commission a supplement to the related Prospectus or a post-effective amendment
to the Deerfield Resale Shelf Registration Statement so that such Deerfield Party is named as a selling securityholder in the Deerfield
Resale Shelf Registration Statement and the related Prospectus in such a manner as to permit such Deerfield Party to deliver a
prospectus to purchasers of the Registrable Securities in accordance with applicable law; provided, however, that Pubco shall not
be required to file more than one post-effective amendment or a supplement to the related prospectus for such purpose in any 45-day
period;

 

(ii)           if,
pursuant to Section 1(e)(i), Pubco shall have filed a post-effective amendment to the Deerfield Resale Shelf
Registration Statement that is not automatically effective, use its reasonable best efforts to cause such post-effective amendment
to become effective under the Securities Act as promptly as is reasonably practicable; and

 

(iii)          notify
such Deerfield Party as promptly as is reasonably practicable after the effectiveness of any post-effective amendment filed pursuant
to Section 1(e)(i).

 

(f)            Registrations
effected pursuant to this Section 1 shall not be counted as Demand Registrations effected pursuant to Section 2.

 

2.            Demand
Registrations.

 

(a)            Requests
for Registration. Subject to the terms and conditions of this Agreement and of the Lock-Up Agreements, at any time or from
time to time, the holders of Registrable Securities may request registration under the Securities Act of all or any portion of
their Registrable Securities on Form S-1 or any similar long-form registration statement (“Long-Form Registrations”)
or, if available, on Form S-3 (including a shelf registration pursuant to Rule 415 under the Securities Act) or any similar
short-form registration statement, including an automatic shelf registration statement (as defined in Rule 405) (an “Automatic
Shelf Registration Statement”), if available to Pubco (“Short-Form Registrations”) in accordance
with Section 2(b) and Section 2(c) below (such holders being referred to herein as the “Initiating
Investors” and all registrations requested by the Initiating Investors being referred to herein as “Demand Registrations”).
Each request for a Demand Registration shall specify the approximate number of Registrable Securities requested to be registered
and the intended method of distribution. Within five (5) Business Days after receipt of any such request, Pubco shall give
written notice of such requested registration to all other holders of Registrable Securities and, subject to the terms and conditions
set forth herein, shall include in such registration (and in all related registrations and qualifications under state blue sky
laws or in compliance with other registration requirements and in any related underwriting) all such Registrable Securities with
respect to which Pubco has received written requests for inclusion therein within five (5) Business Days after the receipt
of Pubco’s notice. Each holder of Registrable Securities agrees that such holder shall treat as confidential the receipt
of the notice of Demand Registration and shall not disclose or use the information contained in such notice of Demand Registration
without the prior written consent of Pubco until such time as the information contained therein is or becomes available to the
public generally, other than as a result of disclosure by the holder in breach of the terms of this Agreement.

 

    - 6 -

     

    

 

(b)            Long-Form Registrations.
(i) The OEP Parties may request an aggregate of three (3), (ii) the Deerfield Parties may request an aggregate of
one (1) and (iii) the Investors (other than any OEP Party) holding a majority of the Registrable Securities (other
than those held by the OEP Parties) may request an aggregate of one (1) Long-Form Registration in which
Pubco shall pay all Registration Expenses whether or not any such Long-Form Registration has become effective; provided
that, Pubco shall not be obligated to effect, or to take any action to effect, any Long-Form Registration unless the
aggregate market price of the Registrable Securities requested to be registered in such Long-Form Registration exceeds
$20,000,000 at the time of request; provided, further, that Pubco shall only be obligated to effect, or take any action to
effect, three (3) Long-Form Registrations in the case of any request therefor by any of the OEP Parties, one
(1) Long-Form Registrations in the case of any request therefor by any of the Deerfield Parties and one
(1) Long-Form Registration in the case of any request therefor by Investors (other than any OEP Party) holding a
majority of the Registrable Securities (other than those held by the OEP Parties). A registration shall not count as a
permitted Long-Form Registration until it has become effective and unless the holders of Registrable Securities are able
to register and sell at least 90% of the Registrable Securities requested to be included in such registration; provided that
in any event Pubco shall pay all Registration Expenses in connection with any registration initiated as a
Long-Form Registration whether or not it has become effective and whether or not such registration has counted as one of
the permitted Long-Form Registrations hereunder.

 

(c)            Short-Form Registrations.
In addition to the Long-Form Registration provided pursuant to Section 2(b), each of (i) the Investors
holding a majority of the Common Units not held by Pubco, (ii) the Investors holding a majority of the Founder Shares,
(iii) the Investors holding a majority of the PIPE Shares (including any Common Stock issuable in respect of any
Series B-1 Preferred Stock that was exchanged for PIPE Shares), (iv) the Deerfield Parties and (v) the OEP
Parties, in each case, shall be entitled to request an unlimited number of Short-Form Registrations in which Pubco shall
pay all Registration Expenses whether or not any such Short-Form Registration has become effective; provided, however,
that Pubco shall not be obligated to effect any such Short-Form Registration: (i) if the holders of Registrable
Securities, together with the holders of any other securities of Pubco entitled to inclusion in such
Short-Form Registration, propose to sell Registrable Securities with an aggregate market price at the time of request of
less than $5,000,000, or (ii) if Pubco has, within the twelve (12) month period preceding the date of such request,
already effected three (3) Short-Form Registrations for the holders of Registrable Securities requesting a
Short-Form Registration pursuant to this Section 2(c). Demand Registrations shall be
Short-Form Registrations whenever Pubco is permitted to use any applicable short form registration and if the managing
underwriters (if any) agree to the use of a Short-Form Registration. For so long as Pubco is subject to the reporting
requirements of the Exchange Act, Pubco shall use its reasonable best efforts to make Short-Form Registrations available
for the offer and sale of Registrable Securities. If Pubco is qualified to and, pursuant to the request of the holders of a
majority of the Registrable Securities, has filed with the Commission a registration statement under the Securities Act on
Form S-3 pursuant to Rule 415 (a “Shelf Registration”), then Pubco shall use its reasonable best
efforts to cause the Shelf Registration to be declared effective under the Securities Act as soon as practicable after
filing, and, if Pubco is a WKSI at the time of any such request, to cause such Shelf Registration to be an Automatic Shelf
Registration Statement, and once effective, Pubco shall cause such Shelf Registration to remain effective (including by
filing a new Shelf Registration, if necessary) for a period ending on the earlier of (i) the date on which all
Registrable Securities included in such registration have been sold or distributed pursuant to the Shelf Registration or
(ii) the date as of which all of the Registrable Securities included in such registration are able to be sold within a
90-day period in compliance with Rule 144 under the Securities Act. If for any reason Pubco ceases to be a WKSI
or becomes ineligible to utilize Form S-3, Pubco shall prepare and file with the Commission a registration statement or
registration statements on such form that is available for the sale of Registrable Securities.

 

    - 7 -

     

    

 

(d)            Shelf
Takedowns. At any time when the Existing Resale Shelf Registration Statement, OEP Resale Shelf Registration Statement, the
Deerfield Resale Shelf Registration Statement or a Shelf Registration for the sale or distribution by holders of Registrable Securities
on a delayed or continuous basis pursuant to Rule 415, including by way of an underwritten offering, block sale or other distribution
plan (each, a “Resale Shelf Registration”) is effective and its use has not been otherwise suspended by Pubco
in accordance with the terms of Section 2(f) below, upon a written demand (a “Takedown Demand”)
by any Investor that is, in either case, a Shelf Participant holding Registrable Securities at such time (the “Initiating
Holder”), Pubco will facilitate in the manner described in this Agreement a “takedown” of Registrable Securities
off of such Resale Shelf Registration (a “takedown offering”) and Pubco shall pay all Registration Expenses
in connection therewith; provided that Pubco will provide (x) in connection with any non-marketed underwritten takedown offering
(other than a Block Trade), at least two (2) Business Days’ notice of such Takedown Demand to each holder of Registrable
Securities (other than the Initiating Holder) that is a Shelf Participant, (y) in connection with any Block Trade initiated
prior to November 8, 2022, notice of such Takedown Demand to each holder of Registrable Securities (other than the Initiating
Holder) that is a Shelf Participant no later than noon Eastern time on the Business Day prior to the requested Takedown Demand
and (z) in connection with any marketed underwritten takedown offering, at least five (5) Business Days’ notice
of such Takedown Demand to each holder of Registrable Securities (other than the Initiating Holder) that is a Shelf Participant.
In connection with (x) any non-marketed underwritten takedown offering initiated prior to November 8, 2022 and (y) any
marketed underwritten takedown offering, if any Shelf Participants entitled to receive a notice pursuant to the preceding sentence
request inclusion of their Registrable Securities (by notice to Pubco, which notice must be received by Pubco no later than (A) in
the case of a non-marketed underwritten takedown offering (other than a Block Trade), the Business Day following the date notice
is given to such participant, (B) in the case of a Block Trade, by 10:00 p.m. Eastern time on the date notice is given
to such participant and (C) in the case of a marketed underwritten takedown offering, three (3) Business Days following
the date notice is given to such participant), the Initiating Holder and the other Shelf Participants that request inclusion of
their Registrable Securities shall be entitled to sell their Registrable Securities in such offering. Each holder of Registrable
Securities that is a Shelf Participant agrees that such holder shall treat as confidential the receipt of the notice of a Takedown
Demand and shall not disclose or use the information contained in such notice without the prior written consent of Pubco until
such time as the information contained therein is or becomes available to the public generally, other than as a result of disclosure
by the holder in breach of the terms of this Agreement.

 

    - 8 -

     

    

 

(e)            Priority
on Demand Registrations and Takedown Offerings. Pubco shall not include in any Demand Registration that is an underwritten
offering any securities that are not Registrable Securities without the prior written consent of the managing underwriters and
the holders of a majority of the Registrable Securities then outstanding. If a Demand Registration or a takedown offering is an
underwritten offering and the managing underwriters advise Pubco in writing that in their opinion the number of Registrable Securities
and, if permitted hereunder, other securities requested to be included in such offering exceeds the number of Registrable Securities
and other securities, if any, which can be sold in an orderly manner in such offering within a price range acceptable to the holders
of a majority of the Registrable Securities held by Initiating Investors, Pubco shall include in such offering prior to the inclusion
of any securities which are not Registrable Securities the Registrable Securities requested to be included in such registration
(pro rata among the holders of such Registrable Securities on the basis of the number of Registrable Securities owned by each such
holder).

 

(f)            Restrictions
on Demand Registrations and Takedown Offerings. Any demand for the filing of a registration statement or for a registered offering
(including a takedown offering) hereunder will be subject to the constraints of any applicable lock-up arrangements to which any
demanding Investor is party, and any such demand must be deferred until such lock-up arrangements no longer apply.

 

(i)            Pubco
shall not be obligated to effect any Demand Registration within 30 days prior to Pubco’s good faith estimate of the
date of filing of an underwritten Public Offering of Pubco’s securities and for such a period of time after such a
filing as the managing underwriters request, provided that such period shall not exceed 90 days from the effective date of
any such underwritten Public Offering. Pubco may postpone, for up to 60 days from the date of the request (the
 “Suspension Period”), the filing or the effectiveness of a registration statement for a Demand
Registration or suspend the use of a prospectus that is part of any Resale Shelf Registration (and therefore suspend sales of
the Registrable Securities included therein) by providing written notice to the holders of Registrable Securities if the
board of directors of Pubco reasonably determines in good faith that the offer or sale of Registrable Securities would be
expected to have a material adverse effect on any proposal or plan by Pubco or any subsidiary thereof to engage in any
material acquisition or disposition of assets or stock (other than in the ordinary course of business) or any material
merger, consolidation, tender offer, recapitalization, reorganization or similar transaction or would require Pubco to
disclose any material nonpublic information which would reasonably be likely to be detrimental to Pubco and its subsidiaries;
provided that in such event, the holders of Registrable Securities initially requesting such Demand Registration or Takedown
Demand shall be entitled to withdraw such request. Pubco may delay or suspend the effectiveness of a Demand
Registration or takedown offering pursuant to this Section 2(f)(i) only once in any consecutive twelve-month
period; provided that, for the avoidance of doubt, Pubco may in any event delay or suspend the effectiveness of Demand
Registration or takedown offering in the case of an event described under Section 5(g) to enable it to
comply with its obligations set forth in Section 5(f). Pubco may extend the Suspension Period for an additional
consecutive 60 days with the consent of the Applicable Approving Party.

 

    - 9 -

     

    

 

(ii)           In
the case of an event that causes Pubco to suspend the use of any Resale Shelf Registration as set forth in Section 2(f)(i) or
pursuant to Section 5(g) (a “Suspension Event”), Pubco shall give a notice to the holders of
Registrable Securities registered pursuant to such Shelf Registration (a “Suspension Notice”) to suspend sales
of the Registrable Securities and such notice shall state generally the basis for the notice and that such suspension shall continue
only for so long as the Suspension Event or its effect is continuing. A holder of Registrable Securities shall not effect any sales
of the Registrable Securities pursuant to such Resale Shelf Registration (or such filings) at any time after it has received a
Suspension Notice from Pubco and prior to receipt of an End of Suspension Notice (as defined below). Each holder of Registrable
Securities agrees that such holder shall treat as confidential the receipt of the Suspension Notice and shall not disclose or use
the information contained in such Suspension Notice without the prior written consent of Pubco until such time as the information
contained therein is or becomes available to the public generally, other than as a result of disclosure by such holder in breach
of the terms of this Agreement. The holders of Registrable Securities may recommence effecting sales of the Registrable Securities
pursuant to the Resale Shelf Registration (or such filings) following further written notice to such effect (an “End of
Suspension Notice”) from Pubco, which End of Suspension Notice shall be given by Pubco to the holders of Registrable
Securities and to such holders’ counsel, if any, promptly following the conclusion of any Suspension Event.

 

(iii)          Notwithstanding
any provision herein to the contrary, if Pubco shall give a Suspension Notice with respect to any Resale Shelf Registration pursuant
to this Section 2(f), Pubco agrees that it shall extend the period of time during which such Resale Shelf Registration
shall be maintained effective pursuant to this Agreement by the number of days during the period from the date of receipt by the
holders of the Suspension Notice to and including the date of receipt by the holders of the End of Suspension Notice and provide
copies of the supplemented or amended prospectus necessary to resume sales, with respect to each Suspension Event; provided that
such period of time shall not be extended beyond the date that Common Stock covered by such Resale Shelf Registration are no longer
Registrable Securities.

 

(g)            Selection
of Underwriters. In connection with any Demand Registration, the Applicable Approving Party shall have the right to select
the investment banker(s) and manager(s) to administer the offering; provided that such selection shall be subject to
the written consent of Pubco, which consent will not be unreasonably withheld, conditioned or delayed. If any takedown offering
is an underwritten offering, the Applicable Approving Party shall have the right to select the investment banker(s) and manager(s) to
administer such takedown offering. In each case, the Applicable Approving Party shall have the right to approve the underwriting
arrangements with such investment banker(s) and manager(s) on behalf of all holders of Registrable Securities participating
in such offering. All Investors proposing to distribute their securities through underwriting shall (together with Pubco and the
Company) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting.

 

    - 10 -

     

    

 

(h)            Other
Registration Rights. Pubco represents and warrants to each holder of Registrable Securities that the registration rights granted
in this Agreement do not conflict with any other registration rights granted by Pubco. Except as provided in this Agreement, Pubco
shall not grant to any Persons the right to request Pubco to register any equity securities of Pubco, or any securities, options
or rights convertible or exchangeable into or exercisable for such securities, without the prior written consent of the holders
of a majority of the Registrable Securities then outstanding.

 

(i)             Revocation
of Demand Notice or Takedown Notice. At any time prior to the effective date of the registration statement relating to a Demand
Registration or the “pricing” of any offering relating to a Takedown Demand, the holders of Registrable Securities
that requested such Demand Registration or takedown offering may revoke such request for a Demand Registration or takedown offering
on behalf of all holders of Registrable Securities participating in such Demand Registration or takedown offering without liability
to such holders of Registrable Securities, in each case by providing written notice to Pubco.

 

3.            Piggyback
Registrations.

 

(a)            Right
to Piggyback. Whenever Pubco proposes to register an offering of any of its securities under the Securities Act (other
than (i) pursuant to the Existing Resale Shelf Registration Statement, OEP Resale Shelf Registration Statement or
Deerfield Resale Shelf Registration Statement), (ii) pursuant to a Demand Registration, (iii) pursuant to a
Takedown Demand, (iv) in connection with registrations on Form S-4 or S-8 promulgated by the Commission or any
successor forms, (v) a registration relating solely to employment benefit plans, (vi) in connection with a
registration the primary purpose of which is to register debt securities, or (vii) a registration on any form that does
not include substantially the same information as would be required to be included in a registration statement
covering the sale of Registrable Securities) and the registration form to be used may be used for the registration of
Registrable Securities (a “Piggyback Registration”), Pubco shall give prompt written notice to all holders
of Registrable Securities of its intention to effect such a Piggyback Registration and, subject to the terms of Sections
3(c) and 3(d) hereof, shall include in such Piggyback Registration (and in all related registrations or
qualifications under blue sky laws or in compliance with other registration requirements and in any related underwriting) all
Registrable Securities with respect to which Pubco has received written requests for inclusion therein within 10 business
days after the delivery of Pubco’s notice; provided that any such other holder may withdraw its request for inclusion
at any time prior to executing the underwriting agreement or, if none, prior to the applicable registration statement
becoming effective.

 

(b)            Piggyback
Expenses. The Registration Expenses of the holders of Registrable Securities shall be paid by Pubco in all Piggyback Registrations,
whether or not any such registration became effective.

 

(c)            Priority
on Primary Registrations. If a Piggyback Registration is an underwritten primary registration on behalf of Pubco, and the managing
underwriters advise Pubco in writing that in their opinion the number of securities requested to be included in such registration
exceeds the number of securities which can be sold in such offering without adversely affecting the marketability, proposed offering
price, timing or method of distribution of the offering, Pubco shall include in such registration (i) first, the securities
Pubco proposes to sell, (ii) second, the Registrable Securities requested to be included in such registration by the Investors
which, in the opinion of such underwriters, can be sold, without any such adverse effect (pro rata among the holders of such Registrable
Securities on the basis of the number of Registrable Securities owned by each such holder), and (iii) third, other securities
requested to be included in such registration which, in the opinion of such underwriters, can be sold, without any such adverse
effect.

 

    - 11 -

     

    

 

(d)            Priority
on Secondary Registrations. If a Piggyback Registration is an underwritten secondary registration on behalf of holders of
Pubco’s securities other than holders of Registrable Securities, and the managing underwriters advise Pubco in writing
that in their opinion the number of securities requested to be included in such registration exceeds the number of securities
which can be sold in such offering without adversely affecting the marketability, proposed offering price, timing or method
of distribution of the offering, Pubco shall include in such registration (i) first, the securities requested to be
included therein by the holders initially requesting such registration, (ii) second, the Registrable Securities
requested to be included in such registration by the Investors which, in the opinion of such underwriters, can be sold,
without any such adverse effect (pro rata among the holders of such Registrable Securities on the basis of the number of
Registrable Securities owned by each such holder), and (iii) third, other securities requested to be included in
such registration which, in the opinion of such underwriters, can be sold, without any such adverse effect.

 

(e)            Other
Registrations. If Pubco has previously filed a Registration Statement with respect to Registrable Securities pursuant to Section 2
or pursuant to this Section 3, and if such previous registration has not been withdrawn or abandoned, then Pubco shall
not be required to file or cause to be effected any other registration of any of its equity securities or securities convertible
or exchangeable into or exercisable for its equity securities under the Securities Act (except on Form S-8 or any successor
form) at the request of any holder or holders of such securities until a period of at least 90 days has elapsed from the effective
date of such previous registration; provided, however, that Pubco shall at all times remain obligated to file or amend, as applicable,
(i) any OEP Resale Shelf Registration Statement in accordance with Section 1(b) and/or Section 1(c) in
the time periods specified therein and (ii) any Deerfield Resale Shelf Registration Statement in accordance with Section 1(c) and/or
Section 1(d) in the time periods specified therein.

 

(f)            Right
to Terminate Registration. Pubco shall have the right to terminate or withdraw any registration initiated by it under this
Section 3 whether or not any holder of Registrable Securities has elected to include securities in such registration.
The Registration Expenses of such withdrawn registration shall be borne by Pubco in accordance with Section 7.

 

4.            Agreements
of Holders.

 

(a)            If
required by the managing underwriter(s), in connection with any underwritten Public Offering on or after the date hereof, each
holder that beneficially owns 1% or more of the outstanding Common Stock shall enter into lock-up agreements with the managing
underwriter(s) of such underwritten Public Offering in such form as agreed to by such managing underwriter(s); provided, however,
that:

 

    - 12 -

     

    

 

(i)            the
Deerfield Parties shall not be required to enter into lock-up agreements pursuant to this Section 4(a) on more than [two
(2) occasions]1,

 

(ii)            any
lock-up agreements to which the Deerfield Parties enter into pursuant to this Section 4(a) shall be for a period of not
more than sixty (60) days,

 

(iii)          the
obligation of the Deerfield Parties to enter into lock-up agreements pursuant to this Section 4(a) shall terminate on
November 8, 2021, and

 

(iv)          the
Deerfield Parties shall not be required to enter into a lock-up agreement pursuant to this Section 4(a) within six (6) months
following the expiration of a previous lock-up agreement entered into by the Deerfield Parties pursuant to this Section 4(a).

 

(b)            The
holders of Registrable Securities shall use reasonable best efforts to provide such information as may reasonably be requested
by Pubco, or the managing underwriter, if any, in connection with the preparation of any Registration Statement, including amendments
and supplements thereto, in order to effect the Registration Statement, including amendments and supplements thereto, in order
to effect the Registration of any Registrable Securities under the Securities Act pursuant to Section 3 and in connection
with Pubco’s obligation to comply with federal and applicable state securities laws.

 

5.            Registration
Procedures. In connection with the Registration to be effected pursuant to the Existing Resale Shelf Registration Statement,
OEP Resale Shelf Registration Statement or Deerfield Resale Shelf Registration Statement, and whenever the holders of Registrable
Securities have requested that any Registrable Securities be registered pursuant to this Agreement or have initiated a takedown
offering, Pubco shall use its reasonable best efforts to effect the registration and the sale of such Registrable Securities in
accordance with the intended method of disposition thereof, and pursuant thereto Pubco shall as expeditiously as reasonably possible:

 

(a)            prepare
in accordance with the Securities Act and all applicable rules and regulations promulgated thereunder and file with the Commission
a registration statement, and all amendments and supplements thereto and related prospectuses as may be necessary to comply with
applicable securities laws, with respect to such Registrable Securities and use its reasonable best efforts to cause such registration
statement to become effective (provided that at least five (5) Business Days before filing a registration statement or prospectus
or any amendments or supplements thereto, Pubco shall furnish to counsel selected by the Applicable Approving Party copies of all
such documents proposed to be filed, which documents shall be subject to the review and comment of such counsel);

 

 

1 Note to Draft: To be reduced to one (1) occasion
if a lock-up agreement is entered into pursuant to Section 4(a) by Deerfield prior to execution.

 

    - 13 -

     

    

 

(b)            notify
each holder of Registrable Securities of (A) the issuance by the Commission of any stop order suspending the effectiveness
of any registration statement or the initiation of any proceedings for that purpose, (B) the receipt by Pubco or its counsel
of any notification with respect to the suspension of the qualification of the Registrable Securities for sale in any jurisdiction
or the initiation or threatening of any proceeding for such purpose, and (C) the effectiveness of each registration statement
filed hereunder;

 

(c)            prepare
and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
therewith as may be necessary to keep such registration statement effective for a period ending when all of the securities covered
by such registration statement have been disposed of in accordance with the intended methods of distribution by the sellers thereof
set forth in such registration statement (but not in any event before the expiration of any longer period required under the Securities
Act or, if such registration statement relates to an underwritten Public Offering, such longer period as in the opinion of counsel
for the underwriters a prospectus is required by law to be delivered in connection with sale of Registrable Securities by an underwriter
or dealer) and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such
registration statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth
in such registration statement;

 

(d)            furnish
to each seller of Registrable Securities thereunder such number of copies of such registration statement, each amendment and supplement
thereto, the prospectus included in such registration statement (including each preliminary prospectus), each Free-Writing Prospectus
and such other documents as such seller may reasonably request in order to facilitate the disposition of the Registrable Securities
owned by such seller;

 

(e)            during
any period in which a prospectus is required to be delivered under the Securities Act, promptly file all documents required to
be filed with the Commission, including pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Act;

 

(f)             use
its reasonable best efforts to register or qualify such Registrable Securities under such other securities or blue sky laws of
such jurisdictions as the lead underwriter or the Applicable Approving Party reasonably requests and do any and all other acts
and things which may be reasonably necessary or advisable to enable such seller to consummate the disposition in such jurisdictions
of the Registrable Securities owned by such seller (provided that Pubco shall not be required to (i) qualify generally to
do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 5(f), (ii) consent
to general service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction);

 

(g)            promptly
notify in writing each seller of such Registrable Securities (i) after it receives notice thereof, of the date and time
when such registration statement and each post-effective amendment thereto has become effective or a prospectus or supplement
to any prospectus relating to a registration statement has been filed and when any registration or qualification has become
effective under a state securities or blue sky law or any exemption thereunder has been obtained, (ii) after receipt
thereof, of any request by the Commission for the amendment or supplementing of such registration statement or prospectus or
for additional information, and (iii) at any time when a prospectus relating thereto is required to be delivered under
the Securities Act, of the happening of any event as a result of which the prospectus included in such registration statement
contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading,
and, at the request of any such seller, Pubco promptly shall prepare, file with the Commission and furnish to each such
seller a reasonable number of copies of a supplement or amendment to such prospectus so that, as thereafter delivered to the
purchasers of such Registrable Securities, such prospectus shall not contain an untrue statement of a material fact or
omit to state any fact necessary to make the statements therein not misleading;

 

    - 14 -

     

    

 

(h)            cause
all such Registrable Securities to be listed on each securities exchange on which similar securities issued by Pubco are then listed
and, if not so listed, to be listed on a securities exchange and, without limiting the generality of the foregoing, to arrange
for at least two market makers to register as such with respect to such Registrable Securities with FINRA;

 

(i)            provide
a transfer agent and registrar for all such Registrable Securities not later than the effective date of such registration statement;

 

(j)            enter
into and perform such customary agreements (including underwriting agreements in customary form) and take all such other actions
as the Applicable Approving Party or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition
of such Registrable Securities (including, without limitation, effecting a stock split or a combination of shares and preparing
for and participating in such number of “road shows”, investor presentations and marketing events as the underwriters
managing such offering may reasonably request);

 

(k)            make
available for inspection by any seller of Registrable Securities, any underwriter participating in any disposition pursuant to
such registration statement and any attorney, accountant or other agent retained by any such seller or underwriter, all financial
and other records, pertinent corporate and business documents and properties of Pubco as shall be necessary to enable them to exercise
their due diligence responsibility, and cause Pubco’s officers, managers, directors, employees, agents, representatives and
independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or
agent in connection with such registration statement;

 

(l)             take
all reasonable actions to ensure that any Free-Writing Prospectus utilized in connection with any Demand Registration (including
any Shelf Registration), takedown offering or Piggyback Registration hereunder complies in all material respects with the Securities
Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities
Act to the extent required thereby and, when taken together with the related prospectus, shall not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading;

 

(m)           otherwise
use its reasonable best efforts to comply with all applicable rules and regulations of the Commission;

 

    - 15 -

     

    

 

(n)            permit
any holder of Registrable Securities who, in its good faith judgment (based on the advice of counsel), could reasonably be expected
to be deemed to be an underwriter or a controlling Person of Pubco to participate in the preparation of such registration or comparable
statement and to require the insertion therein of material furnished to Pubco in writing, which in the reasonable judgment of such
holder and its counsel should be included;

 

(o)            in
the event of the issuance of any stop order suspending the effectiveness of a registration statement, or of any order suspending
or preventing the use of any related prospectus or suspending the qualification of any Common Stock included in such registration
statement for sale in any jurisdiction, use its reasonable best efforts promptly to obtain the withdrawal of such order;

 

(p)            use
its reasonable best efforts to cause such Registrable Securities covered by such registration statement to be registered with or
approved by such other governmental agencies or authorities as may be necessary to enable the sellers thereof to consummate the
disposition of such Registrable Securities;

 

(q)            cooperate
with the holders of Registrable Securities covered by the registration statement and the managing underwriter or agent, if any,
to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legends) representing securities
to be sold under the registration statement and enable such securities to be in such denominations and registered in such names
as the managing underwriter, or agent, if any, or such holders may request;

 

(r)            cooperate
with each holder of Registrable Securities covered by the registration statement and each underwriter or agent participating in
the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made
with FINRA;

 

(s)            if
such registration includes an underwritten Public Offering, use its reasonable best efforts to obtain a cold comfort letter from
Pubco’s independent public accountants and addressed to the underwriters, in customary form and covering such matters of
the type customarily covered by cold comfort letters as the underwriters in such registration reasonably request;

 

(t)            provide
a legal opinion of Pubco’s outside counsel, dated the effective date of such registration statement (and, if such
registration includes an underwritten Public Offering, dated the date of the closing under the underwriting agreement), with
respect to the registration statement, each amendment and supplement thereto, the prospectus included therein (including
the preliminary prospectus) and such other documents relating thereto in customary form and covering such matters of the type
customarily covered by legal opinions of such nature, which opinion shall be addressed to the underwriters;

 

(u)            if
Pubco files an Automatic Shelf Registration Statement covering any Registrable Securities, use its reasonable best efforts to remain
a WKSI (and not become an ineligible issuer (as defined in Rule 405)) during the period during which such Automatic Shelf
Registration Statement is required to remain effective;

 

    - 16 -

     

    

 

(v)            if
Pubco does not pay the filing fee covering the Registrable Securities at the time an Automatic Shelf Registration Statement is
filed, pay such fee at such time or times as the Registrable Securities are to be sold; and

 

(w)            subject
to the terms of Section 2(c) and Section 2(d), if an Automatic Shelf Registration Statement has been
outstanding for at least three (3) years, at the end of the third year, refile a new Automatic Shelf Registration Statement
covering the Registrable Securities, and, if at any time when Pubco is required to re-evaluate its WKSI status Pubco determines
that it is not a WKSI, use its reasonable best efforts to refile the registration statement on Form S-3 and keep such registration
statement effective (including by filing a new Resale Shelf Registration or Shelf Registration, if necessary) during the period
throughout which such registration statement is required to be kept effective.

 

6.            Termination
of Rights. Notwithstanding anything contained herein to the contrary, the right of any Investor to include Registrable Securities
in any Demand Registration or any Piggyback Registration shall terminate on such date that such Investor (together with its Affiliates)
beneficially owns less than 1% of the outstanding Common Stock on an as-converted basis and may sell all of the Registrable Securities
owned by such Investor pursuant to Rule 144 of the Securities Act without any restrictions as to volume or the manner of sale
or otherwise; provided, however, that with respect to any Investor whose rights have terminated pursuant to this Section 6,
if following such a termination, such Investor loses the ability to sell all of its Registrable Securities pursuant to Rule 144
of the Securities Act without any restrictions as to volume or the manner of sale or otherwise due to a change in interpretive
guidance by the Commission, then such Investor’s right to include Registrable Securities in any Demand Registration or any
Piggyback Registration shall be reinstated until such time as the Investor is once again able to sell all of its Registrable Securities
pursuant to Rule 144 of the Securities Act without any restrictions as to volume or the manner of sale or otherwise.

 

7.            Registration
Expenses.

 

(a)            All
expenses incident to Pubco’s performance of or compliance with this Agreement, including, without limitation, all registration,
qualification and filing fees, listing fees, fees and expenses of compliance with securities or blue sky laws, stock exchange rules and
filings, printing expenses, messenger and delivery expenses, fees and disbursements of custodians, and fees and disbursements of
counsel for Pubco and all independent certified public accountants, underwriters (excluding underwriting discounts and commissions)
and other Persons retained by Pubco (all such expenses being herein called “Registration Expenses”), shall be
borne by Pubco as provided in this Agreement and, for the avoidance of doubt, Pubco also shall pay all of its internal expenses
(including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties),
the expense of any annual audit or quarterly review, the expense of any liability insurance and the expenses and fees for listing
the securities to be registered on each securities exchange on which similar securities issued by Pubco are then listed. Each Person
that sells securities pursuant to a Demand Registration, a Takedown Demand or Piggyback Registration hereunder shall bear and pay
all underwriting discounts and commissions and transfer taxes applicable to the securities sold for such Person’s account.

 

    - 17 -

     

    

 

(b)            Pubco
shall reimburse the holders of Registrable Securities included in such registration for the reasonable fees and disbursements of
one counsel chosen by the Applicable Approving Party and one local counsel (if necessary) for each applicable jurisdiction and
chosen by the applicable holder of Registrable Securities, in each case, for the purpose of rendering a legal opinion on behalf
of such holders in connection with any underwritten Demand Registration, takedown offering or Piggyback Registration.

 

8.            Additional
Payments Under Certain Circumstances.

 

(a)            Payments
(“Additional Payments”) with respect to the shares of Common Stock included in the Registrable Securities shall
be assessed as follows if the following event occurs (such event being herein called a “Registration Default”):
the Existing Resale Shelf Registration Statement ceases to be effective prior to the expiration of the Effectiveness Period (unless
and except to the extent that another Registration Statement covering the applicable Registrable Securities is effective during
the Effectiveness Period).

 

(b)            Additional
Payments shall accrue on the applicable Registrable Securities for each such day from and including the date on which any
such Registration Default occurs to but excluding the date on which all such Registration Defaults have been cured at a rate
of $0.05 per share (subject to proportionate adjustment in the event of any stock split, reverse stock split or other
recapitalization) per month or portion thereof (on a 30/360 basis); provided, however, that the Company’s obligation to
pay Additional Payments extends only to any shares of Common Stock included in the Registrable Securities that are affected
by the Registration Default; and provided further that Additional Payments shall in no event accrue on account of any
Registrable Securities during any period that such Registrable Securities may not be sold pursuant to the terms of the
Lock-Up Agreements or any other applicable lock-up arrangements to which the applicable Investor is party; provided, however,
that notwithstanding anything to the contrary herein, no Additional Payments were accrued or are payable for any Registration
Default in the 180 day period following November 8, 2019, and each Investor waives any entitlement thereto. Other than
the obligation of payment of any Additional Payments in accordance with the terms hereof, the Company will have no other
liabilities for monetary damages with respect to its registration obligations. With respect to each Investor, the
Company’s obligations to pay Additional Payments remain in effect only so long as the applicable shares of Common Stock
held by the Investor are Registrable Securities. Notwithstanding anything to the contrary contained herein, (i) in no
event shall the aggregate of all Additional Payments payable by the Company hereunder on account of any share of Common Stock
exceed $0.50 per share (subject to proportionate adjustment in the event of any stock split, reverse stock split or other
recapitalization), (ii) no Additional Payments shall accrue during any Suspension Period, (iii) a Registration
Default shall be deemed not to have occurred and be continuing, and no Additional Payments shall accrue as a result thereof,
if the Registration Default (x) relates to any information supplied or failed to be supplied by an Investor in
relation to any Registration Statement or the related Prospectus or (y) arises due to the filing by Pubco of any
post-effective amendment to the Existing Resale Shelf Registration Statement in connection with Pubco’s obligation to
comply with Section 1(b) or Section 1(c) (but only until such post-effective amendment is
declared effective by the Commission), (iv) no Additional Payments shall accrue or be payable to any OEP Party or in
respect of the Registrable Securities issued pursuant to the OEP Investment Agreement and (v) no Additional Payments
shall accrue or be payable to any Deerfield Party or in respect of the Registrable Securities issued pursuant to the
Deerfield Investment Agreement. No Additional Payments shall be payable (i) if as of the relevant Registration Default,
the Registrable Securities may be sold by the Investors without volume or manner of sale restrictions under Rule 144, as
determined by counsel to the Company pursuant to a written opinion letter to such effect, addressed and reasonably acceptable
to the Company’s transfer agent or (ii) with respect to any period after the expiration of the Effectiveness
Period (it being understood that this clause shall not relieve the Company of any Additional Payments accruing prior to the
expiration of the Effectiveness Period).

 

    - 18 -

     

    

 

(c)            Any
amounts of Additional Payments pursuant to this Section 8 will be payable in cash in arrears on the last day of each
month following the date on which a Registration Default occurs. The amount of Additional Payments will be determined on the basis
of a 360-day year comprised of twelve 30-day months, and the actual number of days on which Additional Payments accrued
during such period.

 

9.            Indemnification.

 

(a)            Pubco
agrees to (i) indemnify and hold harmless, to the fullest extent permitted by law, each Investor and their respective officers,
directors, members, partners, agents, affiliates and employees and each Person who controls such Investor (within the meaning of
the Securities Act or the Exchange Act) against all losses, claims, actions, damages, liabilities and expenses caused by (A) any
untrue or alleged untrue statement of material fact contained in any registration statement, prospectus or preliminary prospectus
or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein
or necessary to make the statements therein not misleading, or (B) any violation or alleged violation by Pubco of the Securities
Act or any other similar federal or state securities laws or any rule or regulation promulgated thereunder applicable to Pubco
and relating to action or inaction required of Pubco in connection with any such registration, qualification or compliance, and
(ii) pay to each Investor and their respective officers, directors, members, partners, agents, affiliates and employees and
each Person who controls such Investor (within the meaning of the Securities Act or the Exchange Act), as incurred, any legal and
any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage, liability
or action, except insofar as the same are caused by or contained in any information furnished in writing to Pubco or any managing
underwriter by such Investor expressly for use therein; provided, however, that the indemnity agreement contained in this Section 9
shall not apply to amounts paid in settlement of any such claim, loss, damage, liability or action if such settlement is effected
without the consent of Pubco (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall Pubco be liable
in any such case for any such claim, loss, damage, liability or action to the extent that it solely arises out of or is based upon
an untrue statement of any material fact contained in the registration statement or omission to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading, in each case to the extent that such untrue statement
or alleged untrue statement or omission or alleged omission was made in the registration statement, in reliance upon and in conformity
with written information furnished by such Investor expressly for use in connection with such registration statement. In connection
with an underwritten offering, Pubco shall indemnify any underwriters or deemed underwriters, their officers and directors and
each Person who controls such underwriters (within the meaning of the Securities Act or the Exchange Act) to the same extent as
provided above with respect to the indemnification of the holders of Registrable Securities.

 

    - 19 -

     

    

 

(b)            In
connection with any registration statement in which a holder of Registrable Securities is participating, each such holder
shall furnish to Pubco in writing such information relating to such holder as Pubco reasonably requests for use in connection
with any such registration statement or prospectus and, to the extent permitted by law, shall indemnify Pubco, its officers,
directors, employees, agents and representatives and each Person who controls Pubco (within the meaning of the
Securities Act) against any losses, claims, damages, liabilities and expenses resulting from any untrue or alleged untrue
statement of material fact contained in the registration statement, prospectus or preliminary prospectus or any amendment
thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission is
contained in any information so furnished in writing by such holder; provided that the obligation to indemnify shall be
individual, not joint and several, for each holder and shall be limited to the net amount of proceeds actually received by
such holder from the sale of Registrable Securities pursuant to such registration statement.

 

(c)            Any
Person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with
respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any Person’s
right to indemnification hereunder to the extent such failure has not materially prejudiced the indemnifying party) and (ii) unless
in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties
may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability
for any settlement made by the indemnified party without its consent (but such consent shall not be unreasonably withheld, conditioned
or delayed). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated
to pay the fees and expenses of more than one counsel (as well as one local counsel for each applicable jurisdiction) for all parties
indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a
conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim.
In such instance, the conflicted indemnified parties shall have a right to retain one separate counsel, chosen by the holders of
a majority of the Registrable Securities included in the registration, at the expense of the indemnifying party. No indemnifying
party, in the defense of such claim or litigation, shall, except with the consent of each indemnified party, consent to the entry
of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.

 

    - 20 -

     

    

 

(d)            Each
party hereto agrees that, if for any reason the indemnification provisions contemplated by Sections 9(a) or 9(b) are
unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities
or expenses (or actions in respect thereof) referred to therein, then each indemnifying party, in lieu of indemnifying such
indemnified party, shall contribute to the amount paid or payable by such indemnified party as a result of such losses,
claims, damages, liabilities or expenses (or actions in respect thereof) in such proportion as is appropriate to reflect the
relative fault of the indemnifying party and the indemnified party in connection with the actions which resulted in such
losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative fault
of such indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action
in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a
material fact, relates to information supplied by such indemnifying party or indemnified party, and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The
parties hereto agree that it would not be just or equitable if contribution pursuant to this Section 9(d) were
determined by pro rata allocation (even if the holders or any underwriters or all of them were treated as one entity for such
purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section 9(d).
The amount paid or payable by an indemnified party as a result of the losses, claims, damages, liabilities or expenses (or
actions in respect thereof) referred to above shall be deemed to include any legal or other fees or expenses reasonably
incurred by such indemnified party in connection with investigating or, except as provided in Section 9(c),
defending any such action or claim. No Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation. The sellers’ obligations in this Section 9(d) to contribute shall be
several in proportion to the amount of securities registered by them and not joint and shall be limited to an amount equal to
the net proceeds actually received by such seller from the sale of Registrable Securities effected pursuant to such
registration.

 

(e)            The
indemnification and contribution provided for under this Agreement shall remain in full force and effect regardless of any investigation
made by or on behalf of the indemnified party or any officer, director or controlling Person of such indemnified party and shall
survive the transfer of Registrable Securities and the termination or expiration of this Agreement.

 

10.          Participation
in Underwritten Registrations. No Person may participate in any registration hereunder which is underwritten unless such
Person (a) agrees to sell such Person’s securities on the basis provided in any underwriting arrangements approved
by the Person or Persons entitled hereunder to approve such arrangements (including, without limitation, pursuant to any
over-allotment or “green shoe” option requested by the underwriters; provided that no holder of Registrable
Securities shall be required to sell more than the number of Registrable Securities such holder has requested to include) and
(b) completes and executes all questionnaires, powers of attorney, custody agreements, stock powers, indemnities,
underwriting agreements and other documents required under the terms of such underwriting arrangements; provided that no
holder of Registrable Securities included in any underwritten registration shall be required to make any representations or
warranties to Pubco or the underwriters (other than representations and warranties regarding such holder, such holder’s
title to the securities, such Person’s authority to sell such securities and such holder’s intended method of
distribution) or to undertake any indemnification obligations to Pubco or the underwriters with respect thereto that are
materially more burdensome than those provided in Section 9. Each holder of Registrable Securities shall execute
and deliver such other agreements as may be reasonably requested by Pubco and the lead managing underwriter(s) that are
consistent with such holder’s obligations under Section 4, Section 5 and this Section 10
or that are necessary to give further effect thereto. To the extent that any such agreement is entered into pursuant to, and
consistent with, Section 4 and this Section 10, the respective rights and obligations created
under such agreement shall supersede the respective rights and obligations of the holders, Pubco and the underwriters created
pursuant to this Section 10.

 

    - 21 -

     

    

 

11.            Other
Agreements. Pubco shall file all reports required to be filed by it under the Securities Act and the Exchange Act and the rules and
regulations adopted by the Commission thereunder and shall take such further action as the Investors may reasonably request, all
to the extent required to enable such Persons to sell securities pursuant to (a) Rule 144 adopted by the Commission under
the Securities Act (as such rule may be amended from time to time) or any similar rule or regulation hereafter adopted
by the Commission or (b) a registration statement on Form S-1 or any similar registration form hereafter adopted by the
Commission. Upon request, Pubco shall deliver to the Investors a written statement as to whether it has complied with such requirements.
Pubco shall at all times use its reasonable best efforts to cause the securities so registered to continue to be listed on one
or more of the New York Stock Exchange, the American Stock Exchange and the Nasdaq Stock Market. Pubco shall use its best efforts
to facilitate and expedite transfers of Registrable Securities pursuant to Rule 144, which efforts shall include timely notice
to its transfer agent to expedite such transfers of Registrable Securities.

 

12.            Definitions.

 

(a)            “Affiliate”
means, with respect to any specified Person, any other Person that, at the time of determination, directly or indirectly through
one or more intermediaries, controls, is controlled by or is under common control with such specified Person.

 

(b)            “Applicable
Approving Party” means the holders of a majority of the Registrable Securities participating in the applicable offering
or, in the case of a Short-Form Registration effected pursuant to Section 2(c), the holders of a majority of the
type of Registrable Securities that initiated such Short-Form Registration.

 

(c)            “as-converted
basis” means, for purposes of computing beneficial ownership, such number of shares of Common Stock calculated on a basis
assuming all shares of Series A Preferred Stock, Series B-2 Preferred Stock or Series B-1 Preferred Stock, as applicable,
had been converted by the holders thereof in accordance with their terms, but disregarding any restrictions or limitations upon
the conversion of such Series A Preferred Stock, Series B-2 Preferred Stock or Series B-1 Preferred Stock, as applicable.

 

(d)            “Block
Trade” means any non-marketed underwritten takedown offering taking the form of a bought deal or block sale to a financial
institution.

 

(e)            “Business
Day” means any day that is not a Saturday or Sunday or a legal holiday in the state in which Pubco’s chief executive
office is located or in New York, NY.

 

    - 22 -

     

    

 

 

(f)            “Closing”
means the closing of the sale of Series A Preferred Stock to OEP pursuant to Section [1.2] of the OEP Investment Agreement.

 

(g)            “Commission”
means the U.S. Securities and Exchange Commission.

 

(h)            “Common
Stock” means the Class A Common Stock of Pubco, par value $0.0001 per share.

 

(i)            “Common
Unit” has the meaning set forth in the LLC Agreement.

 

(j)            “Deerfield
Party” or “Deerfield Parties” means the Deerfield Investors, any Related Deerfield Fund that becomes
a party to this Agreement following the date hereof by execution of a joinder hereto or other written agreement between such Related
Deerfield Fund and the Company, and any of their respective Affiliates.

 

(k)            “Exchange
Act” means the Securities Exchange Act of 1934, as amended from time to time, or any successor federal law then in force,
together with all rules and regulations promulgated thereunder.

 

(l)            “FINRA”
means the Financial Industry Regulatory Authority.

 

(m)            “Founder
Shares” means the 6,250,000 shares of Common Stock issued to the Original Holders prior to Pubco’s initial public
offering.

 

(n)            “Free-Writing
Prospectus” means a free-writing prospectus, as defined in Rule 405 of the Securities Act.

 

(o)            “LLC
Agreement” means the Fifth Amended and Restated Limited Liability Company Agreement of the Company, dated as of [__],
by and among the Company, Pubco and the other members of the Company (as the same may be amended, supplemented or modified from
time to time in accordance with the terms thereof).

 

(p)            “Lock-Up
Agreements” means those certain Lock-Up Agreements, dated as of July 8, 2019, by and among Pubco, the Company, and
certain of the Persons listed on the Schedule of Investors attached hereto.

 

(q)            “Merger
Agreement” means the Agreement and Plan of Merger, dated as of July 8, 2019, by and between Pubco, the Company and
certain other parties, as amended.

 

(r)            “Person”
means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust,
a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

 

(s)            “PIPE
Shares” means the 12,500,000 shares of Common Stock issued to the one of the Investors pursuant to that certain Subscription
Agreement, dated as of July 8, 2019, by and between Pubco and such Investor.

 

(t)            “Prospectus”
means the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended
by any and all post-effective amendments and including all material incorporated by reference in such prospectus.

 

    - 23 -

     

    

 

(u)            “Public
Offering” means any sale or distribution by Pubco and/or holders of Registrable Securities to the public of Common Stock
pursuant to an offering registered under the Securities Act.

 

(v)            “OEP
Party” or “OEP Parties” means OEP and each Affiliate of OEP to whom shares of Series A Preferred
Stock or shares of Common Stock issued in respect of the conversion of any such Series A Preferred Stock are transferred pursuant
to Section [5.3] of the OEP Investment Agreement.

 

(w)            “Original
Holders” shall mean each of Chris Wolfe, Steven Hochberg, Dr. Mohit Kaushal, Dr. Gregory Sorensen and Dr. Susan
Weaver.

 

(x)            “Register,”
 “Registered” and “Registration” mean a registration effected by preparing and filing a Registration
Statement or similar document in compliance with the requirements of the Securities Act, and the applicable rules and regulations
promulgated thereunder, and such Registration Statement becoming effective.

 

(y)            “Registrable
Securities” means (i) any Common Stock issued with respect to or in exchange for any Common Units held by the
Investors, (ii) any Founder Shares held by the Investors (including any Common Stock issued or issuable in respect of
any Series B-1 Preferred Stock issued to Deerfield Private Design Fund IV, L.P. (“Deerfield Private Design Fund
IV”) in exchange for such Common Stock pursuant to the Exchange Agreement, dated as of the date hereof, between the
Company and Deerfield Private Design Fund IV (the “Exchange Agreement”)), (iii) any Private Placement
Warrants (or underlying securities) held by the Investors, (iv) any PIPE Shares held by the Investors (including any
Common Stock issued or issuable in respect of any Series B-1 Preferred Stock issued to Deerfield Private Design Fund IV in
exchange for such PIPE Shares pursuant to the Exchange Agreement), (v) any Common Stock issued to an Investor pursuant
to the terms of the Merger Agreement, (vi) any Common Stock issued to OEP pursuant to the
OEP Investment Agreement (whether or not such shares of Series A Preferred Stock or Common Stock are subsequently
transferred to any OEP Party) held by any OEP Party, (vii) any Common Stock issued or issuable upon conversion of the
Series A Preferred Stock issued to OEP pursuant to the OEP Investment Agreement (whether or not such shares of
Series A Preferred Stock or Common Stock are subsequently transferred to any OEP Party) held by any OEP Party,
(viii) any Common Stock issued or issuable, directly or indirectly, upon conversion of the Series B-2 Preferred
Stock (or upon conversion of the Series B-1 Preferred Stock into which the Series B-2 Preferred Stock is converted)
to Deerfield Partners pursuant to the Deerfield Investment Agreement (whether or not such shares of Series B-2 Preferred
Stock, Series B-1 Preferred Stock or Common Stock are subsequently transferred to any Deerfield Party) held by any
Deerfield Party or (ix) any Common Stock issued or issuable with respect to the securities referred to in the preceding
clauses (i) through (viii) by way of a stock dividend or stock split or in connection with a combination of shares,
recapitalization, merger, consolidation or other reorganization. For purposes of this definition, the shares of Common Stock
issuable upon conversion or exercise of any security shall be determined without regard to any limitation on the conversion
or exercise thereof. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities
when they have been sold or distributed to the public pursuant to an offering registered under the Securities Act or sold to
the public through a broker, dealer or market maker in compliance with Rule 144 following November 8, 2019 or
repurchased by Pubco or any of its subsidiaries. For purposes of this Agreement, a Person shall be deemed to be a holder of
Registrable Securities, and the Registrable Securities shall be deemed to be in existence, whenever such Person has the right
to acquire directly or indirectly such Registrable Securities (upon conversion or exercise in connection with a transfer of
securities or otherwise, but disregarding any restrictions or limitations upon the conversion or exercise of such right),
whether or not such acquisition has actually been effected, and such Person shall be entitled to exercise the rights of a
holder of Registrable Securities hereunder; provided a holder of Registrable Securities may only request that Registrable
Securities in the form of Common Stock be registered pursuant to this Agreement.

 

    - 24 -

     

    

 

(z)            “Registration
Statement” means any registration statement filed by Pubco with the Commission in compliance with the Securities Act
and the rules and regulations promulgated thereunder for a public offering and sale of Common Stock or Registrable Securities,
including the Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements
to such registration statement, and all exhibits to and all material incorporated by reference in such registration statement
(other than a registration statement on Form S-4 or Form S-8, or their successors).

 

(aa)            “Related
Deerfield Fund” means any investment fund or managed account that is managed on a discretionary basis by the same investment
manager as a Deerfield Party.

 

(bb)            “Rule 144”,
 “Rule 158”, “Rule 405”, “Rule 415” and “Rule 430B”
mean, in each case, such rule promulgated under the Securities Act (or any successor provision) by the Commission, as the
same shall be amended from time to time, or any successor rule then in force.

 

(cc)            “Securities
Act” means the Securities Act of 1933, as amended from time to time, or any successor federal law then in force, together
with all rules and regulations promulgated thereunder.

 

(dd)            “Shelf
Participant” means any holder of Registrable Securities listed as a potential selling stockholder in connection with
the Existing Resale Shelf Registration Statement, OEP Resale Shelf Registration Statement, Deerfield Resale Shelf Registration
Statement or the Shelf Registration, as applicable, or any such holder that could be added to such Existing Resale Shelf Registration
Statement, OEP Resale Shelf Registration Statement, Deerfield Resale Shelf Registration Statement or Shelf Registration without
the need for a post-effective amendment thereto or added by means of an automatic post-effective amendment thereto.

 

(ee)            “WKSI”
means a “well-known seasoned issuer” as defined under Rule 405.

 

13.            Miscellaneous.

 

(a)            No
Inconsistent Agreements. Neither the Company nor Pubco shall not hereafter enter into any agreement with respect to its securities
which is inconsistent with or violates or in any way impairs the rights granted to the Investors in this Agreement.

 

(b)            Entire
Agreement; Effectiveness. This Agreement constitutes the entire agreement of the parties hereto with respect to the subject
matter hereof and supersedes all prior agreements, understandings, negotiations and discussions among the parties hereto, written
or oral, with respect to the subject matter hereof, including without limitation, but subject to the remainder of this Section 13(b),
the Prior Agreement. This Agreement shall be automatically effective as of the Closing (as defined in the OEP Investment Agreement),
without further action by any party hereto. Prior to the Closing, the Prior Agreement shall remain in effect. If the Investment
Agreement is terminated for any reason, then this amendment shall be void and of no force and effect.

 

(c)            Remedies.
Any Person having rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting
a bond or other security), to recover damages caused by reason of any breach of any provision of this Agreement and to exercise
all other rights granted by law. The parties hereto agree and acknowledge that money damages would not be an adequate remedy for
any breach of the provisions of this Agreement and that, in addition to any other rights and remedies existing in its favor, any
party shall be entitled to specific performance and/or other injunctive relief from any court of law or equity of competent jurisdiction
(without posting any bond or other security) in order to enforce or prevent violation of the provisions of this Agreement.

 

    - 25 -

     

    

 

(d)            Amendments
and Waivers. Except as otherwise provided herein, the provisions of this Agreement may be amended or waived only with the prior
written consent of Pubco and the holders of a majority of the Registrable Securities then outstanding; provided, that no
amendment may materially and disproportionately adversely affect the rights of any holder of Registrable Securities compared to
other holders of Registrable Securities without the consent of such adversely affected holder; and provided further, that
the definition of “Effectiveness Period”, “Deerfield Investors”, “Deerfield Parties”,
 “Registrable Securities”, “Related Deerfield Fund”, Section 1(d), Section 1(e), Section 4(a) (Agreements
of Holders), Section 8 (Additional Payments Under Certain Circumstances), any other provision of this Agreement that
expressly relates to any Deerfield Investor, any Deerfield Party, any Deerfield Related Fund, the Deerfield Shelf Registration
Statement or the Series B-1 Preferred Stock and this Section 13(d) may not be amended in a manner adverse to any
Deerfield Party without the prior written consent of the Deerfield Parties. Any amendment or waiver effected in accordance with
this Section 13(d) shall be binding upon each Investor, Pubco and the Company. The failure of any party to enforce
any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right
of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms.

 

(e)            Successors
and Assigns. All covenants and agreements in this Agreement by or on behalf of any of the parties hereto shall bind and inure
to the benefit of the respective successors and assigns of the parties hereto whether so expressed or not. In addition, whether
or not any express assignment has been made, the provisions of this Agreement which are for the benefit of purchasers or holders
of Registrable Securities are also for the benefit of, and enforceable by, any subsequent holder of Registrable Securities.

 

(f)            Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be prohibited by or invalid, illegal or unenforceable in
any respect under any applicable law, such provision shall be ineffective only to the extent of such prohibition,
invalidity, illegality or unenforceability, without invalidating the remainder of this Agreement.

 

(g)            Counterparts.
This Agreement may be executed simultaneously in counterparts (including by means of telecopied, facsimile or portable data format
(PDF) signature pages), any one of which need not contain the signatures of more than one party, but all such counterparts taken
together shall constitute one and the same Agreement.

 

(h)            Descriptive
Headings; Interpretation. The descriptive headings of this Agreement are inserted for convenience only and do not constitute
a part of this Agreement. The use of the word “including” herein shall mean “including without limitation.”

 

(i)            Governing
Law; Jurisdiction. All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement
and the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the State of Delaware,
without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any
other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. The parties
hereto agree that any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or
in connection with, this Agreement or the transactions contemplated hereby shall be brought in any Delaware Chancery Court, or
if such court does not have subject matter jurisdiction, any court of the United States located in the State of Delaware. Each
of the parties hereby irrevocably consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom)
in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection that it may
now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit,
action or proceeding brought in any such court has been brought in an inconvenient forum. Process in any such suit, action or proceeding
may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court.

 

    - 26 -

     

    

 

(j)            Notices.
All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall
be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by or email
or by registered or certified mail (postage prepaid, return receipt requested) to each Investor at the address indicated on the
Schedule of Investors attached hereto and to Pubco and the Company at the addresses indicated below (or at such other address for
a party as shall be specified in a notice given in accordance with this Section 13(j)):

 

if to Pubco:

 

AdaptHealth
Corp.

220 West Germantown
Pike Suite 250

Plymouth Meeting,
PA 19462

Attention:
General Counsel

E-mail: cjoyce@adapthealth.com

 

with a copy
to:

 

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019

Attention: Steven J. Gartner; Michael E. Brandt;
and Danielle Scalzo

Facsimile: (212) 728-8111

Email:     sgartner@willkie.com;
mbrandt@willkie.com; and DScalzo@willkie.com

 

if to the Company:

 

AdaptHealth Holdings, LLC

122 Mill Road, Suite A130

Phoenixville, Pennsylvania 19460

Attention: Luke McGee

Email: luke.mcgee@adapthealth.com

 

with a copy
to:

 

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019

Attention: Steven J. Gartner; Michael E. Brandt;
and Danielle Scalzo

Facsimile: (212) 728-8111

Email:     sgartner@willkie.com;
mbrandt@willkie.com; and DScalzo@willkie.com

 

(k)            Mutual
Waiver of Jury Trial. As a specifically bargained inducement for each of the parties to enter into this Agreement (with each
party having had opportunity to consult counsel), each party hereto expressly and irrevocably waives the right to trial by jury
in any lawsuit or legal proceeding relating to or arising in any way from this Agreement or the transactions contemplated herein,
and any lawsuit or legal proceeding relating to or arising in any way to this Agreement or the transactions contemplated herein
shall be tried in a court of competent jurisdiction by a judge sitting without a jury.

 

(l)            No
Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any of the provisions of this Agreement.

 

* * * * *

 

    - 27 -

     

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Registration Rights Agreement as of the date first written above.

 

 

	 	COMPANY:
	 	 
	 	ADAPTHEALTH HOLDINGS LLC
	 	 
	 	By:	             
	 	Name:
	 	Title:

 

[Signature Page to
Registration Rights Agreement]

 

    

     

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Registration Rights Agreement as of the date first written above.

 

	 	PUBCO:
	 	 
	 	ADAPTHEALTH CORP.
	 	 
	 	By:	             
	 	Name: 
	 	Title:

 

[Signature Page to
Registration Rights Agreement]

 

    

     

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Registration Rights Agreement as of the date first written above.

 

	 	INVESTORS:
	 	 
	 	[ONE EQUITY PARTNERS VII, L.P.]
	 	 
	 	By:	             
	 	Name:
	 	Title:

 

[Signature Page to
Registration Rights Agreement]

 

    

     

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Registration Rights Agreement as of the date first written above.

 

	 	INVESTORS:
	 	 
	 	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
	 	By: Deerfield Mgmt IV, L.P., General Partner
	 	By: J.E. Flynn Capital IV, LLC, General Partner
	 	 
	 	By:	                 
	 	Name:
	 	Title: Authorized Signatory
	 	 
	 	DEERFIELD PARTNERS, L.P.
	 	By: Deerfield Mgmt, L.P., General Partner
	 	By: J.E. Flynn Capital, LLC, General Partner
	 	 
	 	By:	 
	 	Name:
	 	Title: Authorized Signatory
	 	 
	 	2321 CAPITAL LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	AMPEV LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	BLUEMOUNTAIN SUMMIT OPPORTUNITIES FUND II (US) L.P.
	 	 
	 	By:	 
	 	Name:
	 	Title:

 

[Signature Page to
Registration Rights Agreement]

 

    

     

    

 

	 	BLUE RIVER NJ LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	CFCP LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	FRESH POND INVESTMENT LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	JEDI ENTERPRISES, LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	LBM DME HOLDINGS LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	MAYAID2001 LLC
	 	 
	 	By:	          
	 	Name:
	 	Title:

 

[Signature Page to
Registration Rights Agreement]

 

    

     

    

 

	 	MCLARTY CAPITAL PARTNERS SBIC, L.P.
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	OCEAN ROCK NJ LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	PLAINS CAPITAL LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	QUAD CAPITAL, LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	QUADRANT MANAGEMENT, INC.
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	VERUS EQUITY HOLDING COMPANY LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	VERUS NOTE HOLDING COMPANY LLC
	 	 
	 	By:	                    
	 	Name:
	 	Title:

 

[Signature Page to
Registration Rights Agreement]

 

    

     

    

 

	 	WHEATFIELD LLC
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	CLIFTON BAY OFFSHORE INVESTMENTS L.P.
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	BLUEMOUNTAIN FOINAVEN MASTER FUND L.P.
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	BMSB L.P.
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	BLUEMOUNTAIN FURSAN FUND L.P.
	 	 
	 	By:	                
	 	Name:
	 	Title:

 

[Signature Page to
Registration Rights Agreement]

 

    

     

    

 

REGISTRATION RIGHTS AGREEMENT JOINDER

 

The undersigned is executing
and delivering this Joinder pursuant to the Registration Rights Agreement dated as of [___] (as the same may hereafter be amended,
the “Registration Rights Agreement”), among AdaptHealth Holdings Corporation, a Delaware corporation, AdaptHealth Holdings
LLC, a Delaware limited liability company (the “Company”), and the other persons named as parties therein.

 

By executing and delivering
this Joinder to Pubco, the undersigned hereby agrees to become a party to, to be bound by, and to comply with the provisions of
the Registration Rights Agreement as a holder of Registrable Securities in the same manner as if the undersigned were an original
signatory to the Registration Rights Agreement.

 

Accordingly, the undersigned
has executed and delivered this Joinder as of the ___ day of _____________, 20__.

 

	 	INVESTOR:
	 	 
	 	[•]
	 	 
	 	By:	           
	 	Its:
	 	 
	 	Address for Notices:
	 	 
	 	[•]
	 	[•]
	 	[•]
	 	[•]
	 	 
	 	Agreed and Accepted as of
	 	 
	 	ADAPTHEALTH HOLDINGS LLC
	 	 
	 	By:	 
	 	Its:

  

     

     

    

 

	 	Agreed and Accepted as of
	 	 
	 	ADAPTHEALTH HOLDINGS LLC
	 	 
	 	By:	           
	 	 
	 	Its:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]